<SEC-DOCUMENT>0001193125-20-287356.txt : 20201106
<SEC-HEADER>0001193125-20-287356.hdr.sgml : 20201106
<ACCEPTANCE-DATETIME>20201106070123
ACCESSION NUMBER:		0001193125-20-287356
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201106
DATE AS OF CHANGE:		20201106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		201292365

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d44327d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:md="http://www.mednax.com/20200930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
 <div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2020To09_30_2020">false</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="hidden15530513" contextRef="PAsOn09_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden15530515" contextRef="PAsOn09_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2020To09_30_2020">Q3</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2020To09_30_2020">0000893949</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2020To09_30_2020">--12-31</ix:nonNumeric><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="hidden15530485" contextRef="PAsOn11_02_2020" unitRef="Unit_shares" decimals="INF">85598299</ix:nonFraction><ix:footnote id="FN_57535" xml:lang="en-US">Due to a loss from continuing operations for the three months and nine months ended September 30, 2020, no incremental shares are included because the effect would be antidilutive.</ix:footnote ><ix:footnote id="FN_57539" xml:lang="en-US">Presented within retained (deficit) earnings as the balance is immaterial.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20200930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_02_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >md:TaxYearTwoThousandAndTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyPartnersIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyPartnersIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_NonqualifiedstockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >md:NonqualifiedstockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyPartnersIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:DivestitureOfMeddataMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_DeferredTaxAssetsGoodwillMemberMDDeferredTaxAssetsAxis_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis" >md:DeferredTaxAssetsGoodwillMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:RadiologyPartnersIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis" >md:RuralAreaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-06</xbrli:startDate> <xbrli:endDate>2020-05-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2020_CorporateJointVentureMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >us-gaap:CorporateJointVentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><ix:relationship fromRefs="Fact_15530393" toRefs="FN_57535"/><ix:relationship fromRefs="Fact_15530394" toRefs="FN_57535"/><ix:relationship fromRefs="Fact_15530395" toRefs="FN_57535"/><ix:relationship fromRefs="Fact_15530396" toRefs="FN_57535"/><ix:relationship fromRefs="Fact_15530683" toRefs="FN_57539"/><ix:relationship fromRefs="Fact_15530684" toRefs="FN_57539"/><ix:relationship fromRefs="Fact_15530706" toRefs="FN_57539"/><ix:relationship fromRefs="Fact_15530707" toRefs="FN_57539"/><ix:relationship fromRefs="Fact_15530731" toRefs="FN_57539"/><ix:relationship fromRefs="Fact_15530732" toRefs="FN_57539"/><ix:relationship fromRefs="Fact_15532133" toRefs="FN_57539"/><ix:relationship fromRefs="Fact_15532134" toRefs="FN_57539"/></ix:resources></ix:header></div><div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em; line-height: 12pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: normal; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2020To09_30_2020">10-Q</ix:nonNumeric></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P01_01_2020To09_30_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div> </td> </tr> </table> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2020To09_30_2020" format="ixt:datemonthdayyearen">September 30, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2020To09_30_2020">2020</ix:nonNumeric></ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2020To09_30_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission File Number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2020To09_30_2020">001-12111</ix:nonNumeric></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2020To09_30_2020">MEDNAX, INC.</ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2020To09_30_2020" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2020To09_30_2020">26-3667538</ix:nonNumeric></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporation or organization)</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div> </td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2020To09_30_2020">1301 Concord Terrace</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2020To09_30_2020">Sunrise</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2020To09_30_2020" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2020To09_30_2020">33323</ix:nonNumeric></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip Code)</div></div></td> </tr> </table> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2020To09_30_2020">954</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2020To09_30_2020">384-0175</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div></div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 24pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not Applicable </div></div></div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Former name, former address and former fiscal year, if changed since last report) </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="width: 32%; font-family: 'Times New Roman';"></td>
<td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="width: 32%; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Symbol</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">on which registered</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2020To09_30_2020">Common Stock</ix:nonNumeric>, par value $.01 per share</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2020To09_30_2020">MD</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2020To09_30_2020" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2020To09_30_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2020To09_30_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 58%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 20%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2020To09_30_2020" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2020To09_30_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Emerging growth company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2020To09_30_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2020To09_30_2020" format="ixt:booleanfalse">&#9746;</ix:nonNumeric></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;2, 2020, the registrant had outstanding&#160;<span style="-sec-ix-hidden:hidden15530485">85,598,299</span> shares of Common Stock, par value $.01 per share. </div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div></div></div> <div id="toc" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PART <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">I&#160;-&#160;FINANCIAL</div> INFORMATION</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 1.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial Statements</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_3">Consolidated Balance Sheets as of September&#160;30, 2020 and December&#160;31, 2019 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_4">Consolidated Statements of Income for the Three and Nine Months Ended September&#160;30, 2020 and 2019 (Unaudited) </a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_5">Consolidated Statements of Equity for the Three and Nine Months Ended September&#160;30, 2020 and 2019 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_6">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_7">Notes to Consolidated Financial Statements (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 2.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_8">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 3.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_9">Quantitative and Qualitative Disclosures About Market Risk</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 4.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_10">Controls and Procedures</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 12pt;">&#160;</td>
<td colspan="4" style="height: 12pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_11">PART II&#160;-&#160;OTHER INFORMATION </a></div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 1.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_12">Legal Proceedings</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 1A.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_13">Risk Factors</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 2.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_14">Unregistered Sales of Equity Securities and Use of Proceeds</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 6.</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_15">Exhibits</a></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx44327_16">SIGNATURES </a></div></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div><div id="tx44327_3" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">294,512</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">81,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">267,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">434,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,317</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income taxes receivable</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,287</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets held for sale</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">951,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,651,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">731,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,480,668</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,641,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,424,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LIABILITIES AND EQUITY</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable and accrued expenses</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">388,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">410,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of finance lease liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of operating lease liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income taxes payable</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities held for sale</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">106,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">488,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">541,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term debt and finance lease liabilities, net</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,742,263</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,730,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term professional liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">242,366</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">204,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities held for sale</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,619,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,646,905</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shareholders&#8217; equity:</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock; $<span style="-sec-ix-hidden:hidden15530513">.01</span> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction> issued</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock; $<span style="-sec-ix-hidden:hidden15530515">.01</span> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">85,504</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,023,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive income</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retained (deficit) earnings</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">222,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total MEDNAX, Inc. shareholders&#8217; equity</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">804,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Noncontrolling<div style="display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">i</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">nterest</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total equity</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">805,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and equity</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,424,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="tx44327_4" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except per share data) </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">460,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">454,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,317,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,321,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">309,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">301,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">909,168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">880,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">66,455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">72,688</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">66,346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">194,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">185,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">440,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">406,345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,251,494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,189,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income from operations</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,827</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">131,612</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other income</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,534</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">83,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,081</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">86,741</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income (loss) from continuing operations before income taxes</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,871</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,859</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Loss) income from continuing operations</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,652</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,887</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from discontinued operations, net of tax</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">38,392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,268,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">718,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,539,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,255,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">732,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,507,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">18.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">18.26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">15.15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">17.88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,302</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr> </table> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="tx44327_5" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF EQUITY </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Additional</div> <div style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><div style="white-space:nowrap;display:inline;">Paid-in</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Retained</div> <div style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Deficit)</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Total</div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Amount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Capital</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Earnings</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight:bold;display:inline;">Equity</div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding loss on investments, net of tax <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_15530683">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_15530684">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock and conversion of deferred stock to common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">995,257</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">491,287</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,487,396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on investments, net of tax<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530706">2,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530707">2,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,004,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">179,071</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">826,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contribution from noncontrolling Interests<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15532133">245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15532134">245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on investments, net of tax<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> (1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530731">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530732">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock and conversion of deferred stock to common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">311</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,452</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,023,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">219,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">805,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Presented within retained (deficit) earnings as the balance is immaterial. </div></div> </td> </tr> </table> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF EQUITY (continued) </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="line-height: normal;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained</div></div></div> <div style="line-height: normal;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(Deficit)</div></div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnings</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January&#160;1, 2019</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">87,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">992,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,094,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,087,884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding loss on investments, net of tax <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock swaps</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodSharesStockSwaps" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,525</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,217</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">977,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,801,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,779,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on investments, net of tax <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,080</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,080</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,527</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2019</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">967,429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,756,757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,725,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2019To09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,255,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,255,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on investments, net of tax <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2019To09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2019</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">977,709</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Presented within retained (deficit) earnings as the balance is immaterial. </div></div> </td> </tr> </table> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="tx44327_6" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">732,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,507,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">718,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,539,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income to net cash from operating activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of premiums, discounts and issuance costs</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,512</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,484</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,545</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term assets</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,825</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable / receivable</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,838</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities&#8212;discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">216,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">222,414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition payments, net of cash acquired</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of investments</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from maturities or sales of investments</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,865</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of business, net of cash sold</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,080</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,179</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,729</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities&#8212;discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,079</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,793</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">54,522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings on credit agreement</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,225,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on credit agreement</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,755,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of senior notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments for credit facility amendment and financing costs</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on finance lease obligations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contribution from noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromMinorityShareholders" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromMinorityShareholders" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchases of common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">174,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities&#8212;discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="white-space: nowrap; background-color: rgb(255, 255, 255); width: 7%; height: 15px; padding: 0pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">183,571</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase (decrease) in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at beginning of period</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,774</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 83%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at end of period</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">294,512</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 83%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="tx44327_7" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30, 2020 </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation and New Accounting Pronouncements: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>esults of the interim periods presented. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#8220;MDX&#8221;) together with the accounts of MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#8220;MEDNAX&#8221; and the &#8220;Company&#8221; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn09_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction>% economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the Company entered into a joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn08_31_2020_CorporateJointVentureMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction>% economic interest and for which it is deemed the primary beneficiary. The equity interests of the outside investor in the equity of this consolidated entity is accounted for and presented as noncontrolling interests on the Company&#8217;s Consolidated Balance Sheets. Although </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the<div style="display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">joint</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"> venture was <div style="letter-spacing: 0px; top: 0px;;display:inline;">formed</div> during the third quarter of 2020, it has not yet begun operations. Any future results of operations attributable to <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>noncontrolling interests<div style="letter-spacing: 0px; top: 0px;;display:inline;"> will be accounted for and presented as such</div> on the Company&#8217;s Consolidated Statements of Income. </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">Report on Form 10-K (the &#8220;Form<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>10-K&#8221;). </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2019.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, the Company divested its anesthesiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">9,</div>&#160;2020, the Company </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">entered into</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a definitive agreement to divest its radiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for additional information. </div></div> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures.</div></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <ix:nonNumeric name="md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true" continuedAt="TextSelection_15633185">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;):</div> </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. &#160;&#160;&#160;&#160;Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesiology services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_15633185"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for information regarding the divestment of the Company&#8217;s anesthesiology services medical group and the planned divestment of the Company&#8217;s radiology services medical group. The Company&#8217;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Overall, the Company&#8217;s operating results were significantly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#8217;s response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including <ix:nonFraction name="md:PercentageIncreaseDecreaseInSalaryAndWage" contextRef="P01_01_2020To09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) the Company enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. The Company also divested its anesthesiology services medical group in May 2020, where operating results were significantly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In response to the anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the Company&#8217;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $<ix:nonFraction name="md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">139.2</ix:nonFraction>&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</ix:nonNumeric> to <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</ix:nonNumeric> for the second and third quarters of 2020 and <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</ix:nonNumeric> for the fourth quarter of <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</ix:nonNumeric>, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction>&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction>&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At September&#160;30, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To09_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.25</ix:nonFraction>% senior unsecured notes due 2023 and its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To09_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.25</ix:nonFraction>% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months. At September&#160;30, 2020, the Company had no outstanding&#160;principal balance on its Credit Agreement. The Company had outstanding letters of credit of $<ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn09_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million which reduced the amount available on its Credit Agreement to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">899.8</ix:nonFraction>&#160;million at September&#160;30, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction>&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The remaining $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds in April 2020, of which the Company&#8217;s affiliated physician practices <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">within continuing operations </div></div>received an aggregate of approximately $<ix:nonFraction name="md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue" contextRef="PAsOn09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million during the nine months ended September&#160;30, 2020. The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the deferred amount due December&#160;31, 2021 and the remaining <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020. </div></div> <div style="margin: 6pt 0in 18pt 23.8pt; text-indent: 24.5pt; font-family: &quot;Times New Roman&quot;, serif; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The COVID-19 <div style="letter-spacing: 0px; top: 0px;;display:inline;">pandemic has</div> materially <div style="letter-spacing: 0px; top: 0px;;display:inline;">impacted the Company&#8217;s</div> financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. </div></div></div></div> </ix:continuation><ix:nonNumeric name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true" continuedAt="TextSelection_15530512">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Equivalents and Investments: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents consisted entirely of money market funds totaling $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn09_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction>&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_15530512"><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at September&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn09_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,680</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn09_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn09_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,529</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn09_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 64%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">81,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuati<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>n inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div> <div style="text-align: center;"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 8%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 8%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div></div></div> </div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,775</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn09_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">81,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,446</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">759,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">766,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn09_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn09_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,035,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,025,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 18pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#8217;s line of credit approximates fair value. If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level&#160;2 in the fair value hierarchy. </div></div></ix:nonNumeric><ix:nonNumeric name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true" continuedAt="TextSelection_15530517">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable and Net Revenue: </div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,119,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,750,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">852,046</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,315,998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 65%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">267,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">434,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_15530517" continuedAt="TextSelectionAppend_15530517_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient <div style="letter-spacing: 0px; top: 0px;;display:inline;">service </div>revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. </div></div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_15530517_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">382,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">400,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,133,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,159,363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">154,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">149,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,389</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 60%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">460,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">454,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,317,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,321,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="md:BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true" continuedAt="TextSelection_15535513">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combinations, Assets Held for Sale and Discontinued Operations: </div></div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">During the nine months ended September&#160;30, 2020, the Company completed the acquisition of <ix:nonFraction name="md:NumberOfPediatricSubspecialtyPracticesAcquired" contextRef="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> pediatric subspecialty practice for total consideration of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction>&#160;million, of which $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction>&#160;million was paid in cash and $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million was recorded as a contingent consideration liability. This acquisition expanded the Company&#8217;s national network of physician practices. In connection with this acquisition, the Company recorded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> goodwill of $<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction>&#160;million and other intangible assets consisting primarily of physician and hospital agreements of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction>&#160;million.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of <div style="display:inline;">the </div>Radiology Services Medical Group </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div></div>&#160;2020, the Company entered into a </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">securities purchase</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement with Radiology Partners, Inc., pursuant to which Radiology Partners, Inc. will acquire the Company&#8217;s radiology services medical group for $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">885</ix:nonFraction>&#160;million </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cash, subject to certain customary adjustments.</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;This divestiture will allow the Company to focus solely on its Pediatrix and Obstetrix medical groups. The Company determined that the criterion to classify the radiology services medical group as assets held for sale within the Company&#8217;s Consolidated Balance Sheets effective September&#160;30, 2020 were met. Accordingly, the assets and liabilities of the radiology services medical group were classified as current assets and current liabilities held for sale at September&#160;30, 2020 as the Company expects to divest of the radiology services medical group within the next twelve months. The classification to assets held for sale impacted the net book value of the assets and liabilities expected to be transferred upon sale. The estimated fair value of the radiology services medical group was determined using the purchase price in the </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">purchase</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement along with estimated broker, accounting, legal and </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">selling</div></div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> expenses.</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;The Company deemed the carrying amount of </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>assets</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> within the medical group, specifically accounts receivable and property and equipment, to represent fair value and therefore recorded a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge of&#160;$<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2020To09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">43.0</ix:nonFraction>&#160;million against goodwill, which represented the difference between the estimated fair value of the radiology services medical group and the carrying amount of the net assets held for sale. Recognition of the charge against goodwill resulted in a tax benefit which </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_15535513" continuedAt="TextSelectionAppend_15535513_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">generated an additional $<ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>&#160;million deferred tax asset that increased the fair value of the medical group. An incremental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge is then required to reduce the <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">radiology services </div></div>medical group&#8217;s net assets to its previously determined fair value. Accordingly, the Company recorded the incremental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge of $4.0&#160;million for a total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge of $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2020To09_30_2020_DeferredTaxAssetsGoodwillMemberMDDeferredTaxAssetsAxis_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction>&#160;million, reducing the goodwill balance of the radiology services medical group. Upon completion of the divestiture, the Company could record an additional gain or loss on disposal at the time final net proceeds are determined.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in accordance with accounting guidance for discontinued operations, the expected divestiture of the radiology services medical group was deemed to represent a fundamental strategic shift that will have a major effect on the Company&#8217;s operations, and accordingly, the operating results of the radiology services medical group were reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 with prior periods recast to conform with the current period presentation. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the major classes of assets and liabilities of the radiology services medical group that are included as assets and liabilities held for sale in the accompanying Consolidated Balance Sheets as of September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other <div style="letter-spacing: 0px; top: 0px;;display:inline;">current&#160;</div>assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating leases <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">640,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">685,170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,059</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">180,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">951,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,033,614</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,505</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and finance leases</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the radiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">125,765</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">125,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">340,133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">366,678</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84,718</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234,169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">238,402</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">160,587</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">228,562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">369,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">443,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">34,822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">102,912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> income, net</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,059</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.59in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax (provision) benefit</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,988</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">96,946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">75,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_15535513_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of </div></div><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anesthesiology Services Medical Group </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest the Company&#8217;s anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $<ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction>&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction> to $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>&#160;million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>&#160;million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology services medical group, which net of various other working capital items, approximated $<ix:nonFraction name="md:AccountsReceivableRetained" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">110.0</ix:nonFraction>&#160;million </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">at March&#160;31, 2020. <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div>The </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> operating results of the anesthesiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A single </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">anesthesiology </div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">practice&#160;was not included in the divestiture of the anesthesiology services medical group, and </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">continues to operate as an affiliate of the Company. Its</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> results of operations are reflected in the three months ended September&#160;30, 2020 while the incremental loss on sale </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the anesthesiology services medical group </div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recorded during the three months ended September&#160;30, 2020 reflects a true up of various divested account balances during the third quarter of 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The total preliminary loss on sale <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the anesthesiology services medical group </div></div>recorded during the nine months ended September&#160;30, 2020 was $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">648.7</ix:nonFraction>&#160;million. Upon completion of a valuation for the contingent economic interest and working capital <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up,</div> final net proceeds will be determined, and the Company will adjust the loss on sale at that time. In addition, as a result of the sale, the Company currently estimates that it will generate an approximately $<ix:nonFraction name="md:CapitalLossCarryForward" contextRef="PAsOn09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.68</ix:nonFraction>&#160;billion capital loss carryforward <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">that will expire</div></div> in 2025. Based on management&#8217;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">419.0</ix:nonFraction>&#160;million valuation allowance against this deferred tax asset as of September&#160;30, 2020.</div> <ix:nonNumeric name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the anesthesiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">309,602</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">377,661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">924,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">250,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">351,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">746,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,179</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,785</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,331,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,331,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on sale, net</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">644,653</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,615,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,067,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,180,343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,798</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,305,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">689,775</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,255,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> (expense) income, net</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,798</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,305,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">689,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,255,512</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">129,241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">115,987</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,698</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,176,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">684,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,139,525</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of MedData </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company divested of <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">its</div></div> management services organization, MedData, in October 2019. During the nine months ended September&#160;30, 2020, the Company recorded a net incremental loss on the sale of MedData of $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To09_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.8</ix:nonFraction>&#160;million, primarily for the finalization of certain transaction related expenses, a working capital <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up</div> and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration. This incremental loss is reflected as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the nine months ended September&#160;30, 2020. The operating results of MedData were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2019.</div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Accrued Expenses: </div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,410</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">158,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">193,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,768</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">388,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">410,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net decrease in accrued salaries and bonuses of $<ix:nonFraction name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">35.1</ix:nonFraction>&#160;million, from December&#160;31, 2019 to September&#160;30, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September&#160;30, 2020. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common and Common Equivalent Shares: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per common share calculation for the three and nine months ended September&#160;30, 2020 and 2019 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common equivalent shares outstanding (a)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530393">83,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530394">82,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530395">83,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_15530396">84,302</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted net income per common share calculation</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">829</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">796</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a)</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the three months and nine months ended September&#160;30, 2020, no incremental shares are included because the effect wou<div style="letter-spacing: 0px; top: 0px;;display:inline;">l</div>d be antidilutive. </div></div></div></div> </td> </tr> </table> </div> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true" continuedAt="TextSelection_15530441">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans and Stock Purchase Plans: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;A&amp;R 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Under the A&amp;R 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock, deferred stock awards&#160;and stock options ratably over the corresponding vesting periods. During the nine months ended September&#160;30, 2020, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>&#160;million shares of restricted stock and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_NonqualifiedstockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> of stock underlying&#160;</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options to its employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under the A&amp;R 2008 Incentive Plan. At September&#160;30, 2020, the Company had <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million shares available for future grants and awards under the A&amp;R 2008 Incentive Plan.</div></ix:nonNumeric></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_15530441" continuedAt="TextSelectionAppend_15530441_1"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;">Under the Company&#8217;s 1996 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To09_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction>% of market value on January 1st, April 1st, July 1st and October 1st of each year.</div> </ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div></div></div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_15530441_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Each of the ESPP and the SPP provide for the issuance of an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers. During the nine months ended September&#160;30, 2020, approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million shares in the aggregate were issued under the ESPP and SPP. At September&#160;30, 2020, the Company had approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>&#160;million shares in the aggregate reserved for issuance under the ESPP and SPP.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three and nine months ended September&#160;30, 2020 and 2019, the Company recognized stock-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">18.2</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">27.6</ix:nonFraction>&#160;million, respectively. </div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="md:CommonStockRepurchasesTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Repurchase Programs: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time-to-time</div></div> based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the nine months ended September&#160;30, 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn08_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $<ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">107.2</ix:nonFraction>&#160;million remained available for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the nine months ended September&#160;30, 2020, the Company withheld approximately <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million shares of its common stock to satisfy minimum statutory withholding obligations of $<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction>&#160;million in connection with the vesting of restricted stock and deferred stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2020To09_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September&#160;30, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx44327_8" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2019, filed with the Securities and Exchange Commission on February&#160;20, 2020 (the &#8220;2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K&#8221;).</div> As used in this Quarterly Report, the terms &#8220;MEDNAX&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to the parent company, MEDNAX, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#8220;MDX&#8221;), together with MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company&#8217;s 2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> including Item 1A, Risk Factors, and Item 1A. Risk Factors below, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see &#8220;Caution Concerning Forward-Looking Statements&#8221; below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX is a leading provider of physician services including newborn, maternal-fetal, pediatric cardiology and other pediatric subspecialty care. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology and pediatric urology services. In addition to our national physician network, we provide services nationwide to healthcare facilities and physicians, including ours, through a consulting services company. MEDNAX divested its anesthesiology services medical group on May&#160;6, 2020 and on September&#160;9, 2020 entered into an agreement to divest of its radiology services medical group, which provides radiology services including diagnostic imaging and interventional radiology, as well as teleradiology services through a network of affiliated radiologists. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by our affiliated clinicians. &#160;&#160;&#160;&#160;Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, we experienced a significant decline in the number of elective surgeries at the facilities where&#160;our affiliated clinicians provided anesthesia services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within our radiology service line, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. Our affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. At this time, we have not experienced, nor do we currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Overall, our operating results since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020 have been significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but volumes did begin to normalize in May 2020 and substantially recovered during the month of June 2020. We divested our anesthesiology services medical group in May 2020, where operating results were significantly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> We have also entered into an agreement to divest our radiology services medical group, where operating results were meaningfully impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We implemented a number of actions to preserve financial flexibility and partially mitigate the significant impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to our transformational and restructuring programs, limiting these expenditures to those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;we temporarily reduced executive and key management base salaries, including 50% reductions in salaries for our named executive officers through June&#160;30, 2020; (ii) our Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) we enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;we enacted significant operational and practice-specific expense reduction plans across our clinical operations.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also implemented a variety of solutions across specialties to support clinicians and patients during this pandemic, including </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinician Shortage Support </div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric clinicians are lending their expertise to help fulfill the need for added adult care. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strengthening of Supply Chain </div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX is helping to address the shortage of personal protective equipment (PPE) by partnering with vendors across industries to source high filtration respirators, surgical masks and other forms of PPE for protective use. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expanded Virtual Care Offerings </div></div> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9%;">Utilizing VSee, an internationally recognized telehealth platform, MEDNAX has deployed a national multi-specialty virtual clinic to expand its telehealth offerings and make virtual care available to its clinical workforce, enabling continued patient consults and clinician collaboration while minimizing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> exposure.</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Early Virus Detection Using Cutting-Edge Imaging Diagnostic Tools </div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">MEDNAX Radiology Solutions is leading early detection efforts through chest imaging. vRad, a MEDNAX company, diagnosed one of the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients in the United States via chest computed tomography (&#8220;CT&#8221;), which showed findings consistent with a severe acute respiratory viral infection. In the absence of laboratory testing kits, chest CT can serve as a diagnostic tool. In addition, MEDNAX Radiology Solutions is refining natural language processing (&#8220;NLP&#8221;) to identify the incidence of viral pneumonia and typical findings of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> virus in the lungs via chest CT across the proprietary MEDNAX Imaging Platform and inference engine, which is connected to more than 2,000 partner facilities across the country. The NLP is run retrospectively to monitor the amount and rate of increase of suspected chest CT findings for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and viral pneumonia, supporting faster treatment. If successful, this cutting-edge diagnostic tool could serve as an effective tracker of the disease&#8217;s progression throughout the country and provide new insights for imaging findings for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients.</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Virtual Forum to Provide Clinician Support </div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">To support frontline clinicians while abiding by social distancing recommendations, MEDNAX has created a virtual doctors&#8217; lounge for clinicians across specialties to connect and socialize in the absence of typical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> lounges, helping to boost morale and preserve a sense of normalcy.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We currently expect that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will continue to materially impact our financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> we are unable to predict the ultimate impact on our business, financial condition, results of operations, cash flows and the trading price of our securities at this time.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act our affiliated physician practices will qualify for and receive. &#160;&#160;&#160;&#160;The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program, and our affiliated physician practices within continuing operations have received an aggregate of approximately $20.0&#160;million in relief payments during the nine months ended September&#160;30, 2020. We have applications pending for certain affiliated physician practices for incremental relief beyond what has been received.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. We intend to utilize this deferral option throughout 2020. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of the Anesthesiology Services Medical Group </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, we entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest our anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, we received a cash payment of $50.0&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250&#160;million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The operating results of the anesthesiology services medical group were reported as discontinued operations in our consolidated statements of income for the three and nine months ended September&#160;30, 2020 and 2019, and the net assets sold were presented as assets and liabilities held for sale in our consolidated balance sheet at December&#160;31, 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of the Radiology Services Medical Group </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;9, 2020, we entered into a securities purchase agreement to divest our radiology services medical group for $885.0&#160;million cash, subject to certain customary adjustments, as the next step in refocusing our business as a dedicated pediatrics and obstetrics organization. The operating results of the radiology services medical group were reported as discontinued operations in our consolidated statements of income for the three and nine months ended September&#160;30, 2020 and 2019, and the net assets to be sold were presented as assets and liabilities held for sale in our consolidated balance sheets at September&#160;30, 2020 and December&#160;31, 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications have been made to certain prior period financial statements and footnote disclosures to conform to the current period presentation, specifically to reflect the impact of the anesthesiology services medical group and radiology services medical group being classified as assets held for sale and discontinued operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Economic Conditions and Other Factors </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our operations and performance depend significantly on economic conditions. During the three months ended September&#160;30, 2020, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) increased as compared to the three months ended September&#160;30, 2019. Economic conditions in the United States (&#8220;U.S.&#8221;) have deteriorated, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and patient volumes have declined. We could experience additional shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients&#8217; inability to pay for certain services.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transformation and Restructuring Initiatives </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and our operational infrastructure. We have broadly classified these workstreams in four broad categories including practice operations, revenue cycle management, information technology and human resources. We have included the expenses, which in certain cases represent estimates, related to such activity on a separate line item in our consolidated statements. In our shared services departments, we were focused on improving processes, using our resources more efficiently and utilizing our scale more effectively to improve cost and service performance across our operations. Within our operational infrastructure, we developed specific operational plans within each of our service lines and affiliated physician practices, with specific milestones and regular reporting, with the goal of generating long-term operational improvements and fostering even greater collaboration across our national medical group. We intended to make a series of information-technology and other investments to improve processes and performance across our enterprise, using both internal and external resources. A significant amount of transformational and restructuring activities were related to our anesthesiology services medical group, which was divested in May 2020. We believed these strategic initiatives, together with our continued plans to invest in focused, targeted and strategic organic and acquisitive growth, positioned us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We originally expected these activities to continue through at least 2020. However, as discussed above, beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they are initiatives that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Various expenses related to our executive management and board restructuring in July 2020 were recorded as transformation and restructuring related expenses during the third quarter of 2020.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare Reform </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA remains subject to continuing legislative and administrative flux and uncertainty. In 2017, Congress unsuccessfully sought to replace substantial parts of the ACA with different mechanisms for facilitating insurance coverage in the commercial and Medicaid markets. Congress may again attempt to enact substantial or target changes to the ACA in the future. Additionally, Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) has administratively revised a number of provisions and may seek to advance additional significant changes through regulation, guidance and enforcement in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of 2017, Congress repealed the part of the ACA that required most individuals to purchase and maintain health insurance or face a tax penalty, known as the individual mandate. In light of these changes, in December 2018, a federal district court in Texas declared that key portions of the ACA were inconsistent with the U.S. Constitution and that the entire ACA is invalid as a result. Several states appealed this decision, and in December 2019, a federal court of appeals upheld the district court&#8217;s conclusion that part of the ACA is unconstitutional but remanded for further evaluation whether in light of this defect the entire ACA must be invalidated. In November 2020, the Supreme Court of the United States is expected to hear this matter and could invalidate portions of, or all of, the ACA. Changes resulting from these proceedings could have a material impact on our business. In the meantime, it also is possible that as a result of these actions, enrollment in healthcare exchanges could decline. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, there will be federal and state elections that could affect which persons and parties occupy the Office of the President of the United States, control one or both chambers of Congress and many states&#8217; governors and legislatures. The candidates running for President of the United States may propose changes to the U.S. healthcare system, including expanding government-funded healthcare insurance options, &#8220;Medicare for All&#8221; or eliminating the ACA in favor of an alternative plan. Any legislative or administrative change to the current healthcare financing system could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the ACA is repealed or further substantially modified by judicial, legislative or administrative action, or if implementation of certain aspects of the ACA are diluted, delayed or replaced with a &#8220;Medicare for All,&#8221; public option or single payor system, such repeal, modification or delay may impact our business, financial condition, results of operations, cash flows and the trading price of our securities. We are unable to predict the impact of any repeal, modification or delay in the implementation of the ACA, including the repeal of the individual mandate or implementation of a single payor system, on us at this time. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the potential impacts to the ACA, there could be changes to other GHC Programs, such as a change to the structure of Medicaid. In the past, Congress and the Administration have sought to convert Medicaid into a block grant or to institute &#8220;per capita spending caps&#8221;, among other things. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, we cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Medicare Access and CHIP Reauthorization Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Access and CHIP Reauthorization Act (&#8220;MACRA&#8221;) requires Medicare providers to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (&#8220;MIPS&#8221;) or Alternative Payment Models (&#8220;APMs&#8221;). Beginning in 2020, MIPS allows eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in an advanced APM, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. MACRA also remains subject to review and potential modification by Congress, as well as shifting regulatory requirements established by CMS. We currently anticipate that our affiliated physicians who are eligible to participate in the MIPS program will continue to be eligible to receive MIPS bonus payments, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medicaid Expansion </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. To date, 38 states and the District of Columbia have expanded Medicaid eligibility to cover this additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-income</div> patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Surprise&#8221; Billing Legislation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">&#8220;Surprise&#8221; medical bills arise when an insured patient receives care from an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> provider resulting in costs that were not expected by the patient. The bill is a &#8220;surprise&#8221; either because the patient did not expect to receive care from an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> provider, or because their cost-sharing responsibility is higher than the patient expected. &#160;&#160;&#160;&#160;For the past several years, state legislatures have been enacting laws that are intended to address the problems associated with surprise billing or balance billing.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">More recently, Congress and President Trump have proposed bipartisan solutions to address this circumstance, either by working in tandem with, or in the absence of, applicable state laws. Several committees of jurisdiction in the U.S. House of Representatives and in the U.S. Senate have proposed solutions to address surprise medical bills, but it is unclear whether any of the proposed solutions will become law. In addition, state legislatures and regulatory bodies continue to address and modify existing laws on the same issue. Any state or federal legislation on the topic of surprise billing may have an unfavorable impact on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> reimbursement that we receive. In addition, actual or prospective legislative changes in this area may impact, and may have impacted, our ability to contract with private payors at favorable reimbursement rates or remain in contract with such payors.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> revenue is currently not material, we cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that future legislation or regulations will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medicare Sequestration </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">across-the-board</div></div> cuts (&#8220;sequestrations&#8221;) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress acts in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. In connection with the CARES Act, the Medicare sequestrations were suspended beginning on May&#160;1, 2020 and are expected to remain suspended through December&#160;31, 2020. Aside from the suspension, the reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Measures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In our analysis of our results of operations, we use certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures. We have incurred and anticipate we will continue to incur certain expenses related to transformational and restructuring related expenses that are expected to be project-based and periodic in nature. Accordingly, beginning with the first quarter of 2019, we began reporting Adjusted earnings before interest, taxes and depreciation and amortization (&#8220;EBITDA&#8221;) from continuing operations, defined as income (loss) from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Adjusted earnings per share (&#8220;Adjusted EPS&#8221;) from continuing operations has also been further adjusted for these items and beginning with the first quarter of 2019 consists of diluted income (loss) from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense and transformational and restructuring related expenses. Adjusted EPS from continuing operations has been further adjusted to reflect the impacts from discrete tax events.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe these measures, in addition to income (loss) from continuing operations, net income (loss) and diluted net income (loss) from continuing operations per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three and nine months ended September&#160;30, 2020 and 2019, refer to the tables below (in thousands, except per share data). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(2,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,887</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(14,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,281</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,909</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,180</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">91,271</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,677</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,360</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,859</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,590</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,195</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,408</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,749</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,830</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">34,291</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,766</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60,846</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,025</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">72,761</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">69,330</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">161,567</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">186,997</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average diluted shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">83,862</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">82,883</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations and diluted (loss) income from continuing operations per share</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(2,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,887</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization (net of tax of $601 and $444)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,802</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.02</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,333</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.02</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation (net of tax of $1,132 and $1,902)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,398</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,706</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.07</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses (net of tax</div></div> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of $8,573 and $3,191)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,718</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.31</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net impact from discrete tax events</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,905</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,784</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.01</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted income and diluted EPS from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">31,171</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">31,285</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our blended statutory tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended September&#160;30, 2020 and 2019. </div></div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average diluted shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">83,260</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">84,302</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations and diluted (loss) income from continuing operations per share</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(14,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(0.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,281</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization (net of tax of $1,632 and $1,289)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,896</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,867</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation (net of tax of $4,550 and $6,893)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,652</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,672</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses (net of tax</div></div> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of $15,211 and $8,006)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">45,635</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.55</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,019</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net impact from discrete tax events</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,849</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted income and diluted EPS from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">57,965</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.70</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">80,834</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.96</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our blended statutory tax rate of 25% was used to calculate the tax effects of the adjustments for the nine months ended September&#160;30, 2020 and 2019. </div></div> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Three Months Ended September&#160;30, 2020 as Compared to Three Months Ended September&#160;30, 2019 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our net revenue attributable to continuing operations was $460.6&#160;million for the three months ended September&#160;30, 2020, as compared to $454.9&#160;million for the same period in 2019. The increase in revenue of $5.7&#160;million, or 1.3%, was primarily attributable to an increase in revenue from acquisitions, partially offset by a decline in same-unit revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue declined by $1.7&#160;million, or 0.4%. The decline in same-unit net revenue was comprised of a decrease of $19.2&#160;million, or 4.3%, related to patient service volumes, partially offset by a net increase of $17.5&#160;million, or 3.9%, from net reimbursement-related factors. The decrease in revenue from patient service volumes was related to a decline across all our services, primarily as a result of the continued impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The net increase in revenue related to net reimbursement-related factors was primarily due to approximately $14.2&#160;million in CARES Act relief and modest improvements in managed care contracting, partially offset by a decrease in revenue caused by an increase in the percentage of our patients enrolled in GHC programs.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits attributable to continuing operations increased $8.6&#160;million, or 2.9%, to $309.9&#160;million for the three months ended September&#160;30, 2020, as compared to $301.3&#160;million for the same period in 2019. Of the $8.6&#160;million increase, $5.6&#160;million was related to benefits and incentive compensation, primarily bonus expense, and $3.0&#160;million was related to salaries. We anticipate that we will experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Practice supplies and other operating expenses attributable to continuing operations decreased $0.2&#160;million, or 0.6%, to $22.4&#160;million for the three months ended September&#160;30, 2020, as compared to $22.6&#160;million for the same period in 2019. The decrease was primarily attributable to decreases in other practice operating expenses as compared to the prior year, primarily related to decreased activity across many expense categories such as travel, office expenses and professional services resulting from the continued impacts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations of our physician practices and services. General and administrative expenses were $66.3&#160;million for the three months ended September&#160;30, 2020, as compared to $63.3&#160;million for the same period in 2019. The increase of $3.0&#160;million is primarily related to legal and professional services fees, partially offset by decreases in compensation from net staffing reductions as well as decreases in general travel expenses. General and administrative expenses as a percentage of net revenue was 14.4% for the three months ended September&#160;30, 2020, as compared to 13.9% for the same period in 2019. Certain general and administrative expenses related to corporate overhead represent various support services provided across the company, including approximately $10&#160;million in costs related to support for the recently divested anesthesiology services medical group through a transition services agreement. Because a portion of such expenses were previously allocated to but not specifically identifiable to, the anesthesiology services medical group, they are required to be presented as continuing operations. Therefore, general and administrative expenses do not reflect potential general and administrative cost savings that may be achieved in future periods.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Transformational and restructuring related expenses attributable to continuing operations were $34.3&#160;million for the three months ended September&#160;30, 2020, as compared to $12.8&#160;million for the same period in 2019. Approximately $26.7&#160;million of the expenses incurred during the three months ended September&#160;30, 2020 were for compensation-related expenses resulting from the restructuring changes in executive management and the board of directors, with the remainder primarily for external consulting costs for various process improvement and restructuring initiatives, position eliminations and contract termination and other fees. Beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they were initiatives critical to our business operations or those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Various activities related to executive management and board of directors restructuring were recorded as transformational and restructuring related expenses during the three months ended September&#160;30, 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense attributable to continuing operations was $7.2&#160;million for the three months ended September&#160;30, 2020, as compared to $6.4&#160;million for the same period in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Income from operations attributable to continuing operations decreased $28.1&#160;million, or 57.9%, to $20.5&#160;million for the three months ended September&#160;30, 2020, as compared to $48.6&#160;million for the same period in 2019. Our operating margin was 4.4% for the three months ended September&#160;30, 2020, as compared to 10.7% for the same period in 2019. The decrease in our operating margin was primarily due to the decrease in revenue related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and an increase in transformation and restructuring related expenses. Excluding transformation and restructuring related expenses, our income from operations attributable to continuing operations for the three months ended September&#160;30, 2020 and 2019 was $54.8&#160;million and $61.3&#160;million, respectively, and our operating margin was 11.9% and 13.5%, respectively. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations; however, this comparison is affected by the impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> during 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses attributable to continuing operations were $16.4&#160;million for the three months ended September&#160;30, 2020, as compared to $28.3&#160;million for the same period in 2019. The decrease in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses was primarily related to an increase in other income related to the transition services being provided to the buyer of our former anesthesiology services medical group and a decrease in interest expense, primarily due to lower average borrowings under our credit agreement (the &#8220;Credit Agreement&#8221;).</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our effective income tax rate attributable to continuing operations is not meaningful as calculated for the three months ended September&#160;30, 2020 due to the decreased level of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income generated. Income taxes for the three months ended September&#160;30, 2020 were calculated by applying the actual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> effective rate to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income. Our effective income tax attributable to continuing operations was 36.4% for the three months ended September&#160;30, 2019. After excluding discrete tax impacts, during the three months ended September&#160;30, 2019, our effective income tax rate was 27.5%. We believe excluding discrete tax impacts on our effective income tax rate provides a more comparable view of our effective income tax rate.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations was $2.7&#160;million for the three months ended September&#160;30, 2020, as compared to income from continuing operations of $12.9&#160;million for the same period in 2019. Adjusted EBITDA from continuing operations was $72.8&#160;million for the three months ended September&#160;30, 2020, as compared to $69.3&#160;million for the same period in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss from continuing operations per common and common equivalent share was $0.03 on weighted average shares outstanding of 83.9&#160;million for the three months ended September&#160;30, 2020, as compared to diluted income from continuing operations per common and common equivalent share of $0.16 on weighted average shares outstanding of 82.9&#160;million for the same period in 2019. Adjusted EPS from continuing operations was $0.37 for the three months ended September&#160;30, 2020, as compared to $0.38 for the same period in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax, was $38.4&#160;million for the three months ended September&#160;30, 2020, as compared to a loss from discontinued operations of $1.27&#160;billion for the same period in 2019. Diluted loss from discontinued operations per common and common equivalent share was $0.46 for the three months ended September&#160;30, 2020, as compared to $15.31 for the same period in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $41.0&#160;million for the three months ended September&#160;30, 2020, as compared to $1.26&#160;billion for the same period in 2019. Diluted net loss per common and common equivalent share was $0.49 for the three months ended September&#160;30, 2020, as compared to $15.15 for the same period in 2019. </div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nine Months Ended September&#160;30, 2020 as Compared to Nine Months Ended September&#160;30, 2019 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our net revenue attributable to continuing operations was $1.32&#160;billion for the nine months ended September&#160;30, 2020 and 2019. The slight decrease in revenue of $3.8&#160;million, or 0.3%, was primarily attributable to the unfavorable impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on same-unit revenue, driven by declines in volume, partially offset by an increase in revenue from acquisitions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue declined by $25.3&#160;million, or 1.9%. The decline in same-unit net revenue was comprised of a decrease of $60.3&#160;million, or 4.6%, related to patient service volumes, partially offset by a net increase of $35.0&#160;million, or 2.7%, from net reimbursement-related factors. The decrease in revenue from patient service volumes was primarily related to a decline across all our services, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The net increase in revenue related to net reimbursement-related factors was primarily due to approximately $20.0&#160;million in CARES Act relief, modest improvements in managed care contracting and an increase in administrative fees received from our hospital partners.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits attributable to continuing operations increased $28.5&#160;million, or 3.2%, to $909.2&#160;million for the nine months ended September&#160;30, 2020, as compared to $880.7&#160;million for the same period in 2019. The increase of $28.5&#160;million was comprised of $22.7&#160;million in benefits and incentive compensation, primarily bonus expense and malpractice expense, and $5.8&#160;million from salaries. We anticipate that we will experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Practice supplies and other operating expenses attributable to continuing operations decreased $6.2&#160;million, or 8.6%, to $66.5&#160;million for the nine months ended September&#160;30, 2020, as compared to $72.7&#160;million for the same period in 2019. The decrease was primarily attributable to decreases in other practice operating expenses as compared to the prior year, primarily related to decreased activity across many expense categories such as travel, office expenses and professional services resulting from impacts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> primarily during the second quarter of 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations of our physician practices and services. General and administrative expenses were $194.3&#160;million for the nine months ended September&#160;30, 2020, as compared to $185.3&#160;million for the same period in 2019. The increase of $9.0&#160;million is primarily related to legal and professional services fees, partially offset by decreases in compensation from net staffing reductions as well as decreases in general travel expenses. General and administrative expenses as a percentage of net revenue was 14.7% for the three months ended September&#160;30, 2020, as compared to 14.0% for the same period in 2019. Certain general and administrative expenses related to corporate overhead represent various support services provided across the company, including approximately $13&#160;million in costs related to support for the recently divested anesthesiology services medical group through a transition services agreement. Because a portion of such expenses were previously allocated to but not specifically identifiable to the anesthesiology services medical group, they are required to be presented as continuing operations. Therefore, general and administrative expenses do not reflect potential general and administrative cost savings that may be achieved in future periods.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses attributable to continuing operations were $60.8&#160;million for the nine months ended September&#160;30, 2020, as compared to $32.0&#160;million for the same period in 2019. Approximately $30.1&#160;million of the expenses incurred during the nine months ended September&#160;30, 2020 were for external consulting costs for various process improvement and restructuring initiatives and approximately $26.7&#160;million were for compensation-related expenses resulting from the restructuring changes in executive management and the board of directors, with the remainder for position eliminations and contract termination and other fees. Beginning in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they were initiatives critical to our business operations or those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Various activities related to executive management and board of directors restructuring were recorded as transformational and restructuring related expenses during the three months ended September&#160;30, 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense attributable to continuing operations was $20.7&#160;million for the nine months ended September&#160;30, 2020, as compared to $18.8&#160;million for the same period in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Income from operations attributable to continuing operations decreased $65.8&#160;million, or 50.0%, to $65.8&#160;million for the nine months ended September&#160;30, 2020, as compared to $131.6&#160;million for the same period in 2019. Our operating margin was 5.0% for the nine months ended September&#160;30, 2020, as compared to 10.0% for the same period in 2019. The decrease in our operating margin was primarily due to an increase in transformation and restructuring related expenses and practice salaries and benefits. Excluding transformation and restructuring expenses, our income from operations attributable to continuing operations for the nine months ended September&#160;30, 2020 and 2019 was $126.7&#160;million and $163.6&#160;million, respectively, and our operating margin was 9.6% and 12.4%, respectively. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations; however, this comparison is affected by the impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> during 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses attributable to continuing operations were $69.0&#160;million for the nine months ended September&#160;30, 2020, as compared to $86.7&#160;million for the same period in 2019. The decrease in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses was primarily related to an increase in other income related to the transition services being provided to the buyer of our former anesthesiology services medical group and a decrease in interest expense, primarily due to lower average borrowings under our Credit Agreement, partially offset by a decrease in equity earnings resulting from the impacts to the underlying joint venture from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the settlement of a litigation matter.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our effective income tax rate attributable to continuing operations is not meaningful as calculated for the nine months ended September&#160;30, 2020 due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss generated, primarily due to the impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Income taxes for the nine months ended September&#160;30, 2020 were calculated by applying the actual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> effective rate to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss. Our effective income tax attributable to continuing operations was 28.1% for the nine months ended September&#160;30, 2019. The net discrete tax impacts during the nine months ended September&#160;30, 2019 were not material.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations was $14.1&#160;million for the nine months ended September&#160;30, 2020, as compared to income from continuing operations of $32.3&#160;million for the same period in 2019. Adjusted EBITDA from continuing operations was $161.6&#160;million for the nine months ended September&#160;30, 2020, as compared to $187.0&#160;million for the same period in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss from continuing operations per common and common equivalent share was $0.17 on weighted average shares outstanding of 83.3&#160;million for the nine months ended September&#160;30, 2020, as compared to diluted income per common and common equivalent share of $0.38 on weighted average shares outstanding of 84.3&#160;million for the same period in 2019. Adjusted EPS from continuing operations was $0.70 for the nine months ended September&#160;30, 2020, as compared to $0.96 for the same period in 2019. The decrease of 1.0&#160;million in our weighted average shares outstanding is primarily due to the exclusion of common stock equivalents from the weighted average shares calculation for the nine months ended September&#160;30, 2020 as the effect would have been antidilutive. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax, was $718.1&#160;million for the nine months ended September&#160;30, 2020, as compared to loss from discontinued operations of $1.54&#160;billion for the same period in 2019. Diluted loss from discontinued operations per common and common equivalent share was $8.62 for the nine months ended September&#160;30, 2020, as compared to a diluted loss from discontinued operations per common and common equivalent share of $18.26 for the same period in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $732.2&#160;million for the nine months ended September&#160;30, 2020, as compared to a net loss of $1.51&#160;billion for the same period in 2019. Diluted net loss per common and common equivalent share was $8.79 for the nine months ended September&#160;30, 2020, as compared to $17.88 for the same period in 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2020, we had $294.5&#160;million of cash and cash equivalents attributable to our continuing operations as compared to $107.9&#160;million at December&#160;31, 2019. Additionally, we had working capital attributable to our continuing operations of $290.0&#160;million at September&#160;30, 2020, an increase of $79.3&#160;million from working capital of $210.7&#160;million at December&#160;31, 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows from Continuing Operations </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash provided by (used in) operating, investing and financing activities from continuing operations is summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">71,645</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">36,237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(28,179</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(33,729</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(174,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities from Continuing Operations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September&#160;30, 2020, our net cash provided by operating activities for continuing operations was $71.6&#160;million, compared to $36.2&#160;million for the same period in 2019. The net increase in cash provided of $35.4&#160;million was primarily due to an increase in cash flow from deferred income taxes and accounts receivable, partially offset by a decrease in cash from lower earnings and changes in accounts payable and accrued expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September&#160;30, 2020, cash flow from accounts receivable for continuing operations was $30.0&#160;million, as compared to $7.5&#160;million for the same period in 2019. The increase in cash flow from accounts receivable for the nine months ended September&#160;30, 2020 was primarily due to decreases in ending accounts receivable balances at existing units and improvements in the timing of cash collections. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Days sales outstanding (&#8220;DSO&#8221;) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 48.2 days at September&#160;30, 2020 as compared to 51.0 days at December&#160;31, 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities from Continuing Operations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September&#160;30, 2020, our net cash used in investing activities for continuing operations of $28.2&#160;million consisted primarily of capital expenditures of $21.8&#160;million and net purchases of investments of $5.2&#160;million. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities from Continuing Operations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September&#160;30, 2020, our net cash used in financing activities for continuing operations of $3.5&#160;million consisted of the repurchase of $8.5&#160;million of our common stock, partially offset by proceeds from the issuance of common stock of $5.7&#160;million. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;25, 2020, we amended and restated our Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by us from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that we maintain minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict our ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Credit Agreement provides for a $1.2&#160;billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $37.5&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-facility</div> for the issuance of letters of credit. The Credit Agreement matures on March&#160;28, 2024 and is guaranteed by substantially all of our subsidiaries and affiliated professional associations and corporations. At our option, borrowings under the Credit Agreement will bear interest at (i)&#160;the alternate base rate (defined as the higher of (a)&#160;the prime rate, (b)&#160;the Federal Funds Rate plus 1/2 of 1.00% and (c)&#160;LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii)&#160;the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2020, we had no outstanding principal balance on our Credit Agreement. We had outstanding letters of credit of $0.2&#160;million which reduced the amount available on our Credit Agreement to $899.8&#160;million at September&#160;30, 2020, after giving effect to the temporary reduction of the capacity of our Credit Agreement described above through September&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2020, we had an outstanding principal balance of $750.0&#160;million on our 5.25% senior unsecured notes due 2023 (the &#8220;2023 Notes&#8221;) and an outstanding principal balance of $1.0&#160;billion on our 6.25% senior unsecured notes due 2027 (the &#8220;2027 Notes&#8221;). Our obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Credit Agreement. Interest on the 2023 Notes accrues at the rate of 5.25% per annum, or $39.4&#160;million, and is payable semi-annually in arrears on June&#160;1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25% per annum, or $62.5&#160;million, and is payable semi-annually in arrears on January&#160;15 and July 15. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The indenture under which the 2023 Notes and the 2027 Notes are issued, among other things, limits our ability to (1)&#160;incur liens and (2)&#160;enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2023 Notes or the 2027 Notes, upon the occurrence of a change in control of MEDNAX, we may be required to repurchase the 2023 Notes and the 2027 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2023 Notes and the 2027 Notes repurchased plus accrued and unpaid interest. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2020, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Credit Agreement and the 2023 Notes and the 2027 Notes. We believe we will be in compliance with these covenants throughout 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks for continuing operations at September&#160;30, 2020 was $297.8&#160;million, of which $55.5&#160;million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheets. In addition, there is a corresponding insurance receivable of $23.6&#160;million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q.</div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Caution Concerning Forward-Looking Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain information included or incorporated by reference in this Quarterly Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> and this Quarterly Report, including the sections entitled &#8220;Risk Factors.&#8221;</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx44327_9" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At September&#160;30, 2020, we had no outstanding principal balance on our Credit Agreement. </div></div> <div id="tx44327_10" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4. Controls and Procedures </div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We maintain disclosure controls and procedures (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i)&#160;recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September&#160;30, 2020. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Controls Over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No changes in our internal control over financial reporting occurred during the three months ended September&#160;30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx44327_11" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II - OTHER INFORMATION </div></div></div> <div id="tx44327_12" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1. Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;10, 2018, a securities class action lawsuit was filed against our company and certain of our officers and a director in the U.S. District Court for the Southern District of Florida (Case No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0:18-cv-61572-WPD)</div></div></div> that purports to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5</div> thereunder, based on statements made by the defendants primarily concerning our former anesthesiology business. The complaint was seeking unspecified damages, interest, attorneys&#8217; fees and other costs. We filed a motion to dismiss in April 2019, which was granted in October 2019; however, the plaintiff filed a second amended complaint on October&#160;25, 2019. On November&#160;25, 2019, we filed a motion to dismiss the second amended complaint, and on February&#160;7, 2020 a final order granting our motion to dismiss the second amended complaint with prejudice was issued.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;20, 2019, a separate derivative action was filed by plaintiff Beverly Jackson on behalf of MEDNAX, Inc. against MEDNAX, Inc. and certain of its officers and directors in the Seventeenth Judicial Circuit in and for Broward County, Florida (Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CACE-19-006253).</div></div> The plaintiff purported to bring suit derivatively on behalf of our company against certain of our officers and directors for breach of fiduciary duties and unjust enrichment. The derivative complaint repeated many of the allegations in the securities class action described above. We filed a motion to dismiss in December 2019, and on March&#160;16, 2020, an order granting our motion to dismiss without prejudice was issued. On April&#160;6, 2020, the plaintiff filed an amended complaint, and on April&#160;30, 2020, we filed a motion to dismiss the amended complaint. On September&#160;24, 2020, our motion to dismiss was granted, but the plaintiff was granted 20 days to amend their complaint, and on October&#160;14, 2020, the plaintiff filed a second amended complaint. We filed our motion to dismiss the second amended complaint on October&#160;26, 2020.</div> <div id="tx44327_13" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A. Risk Factors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Item 1A. Risk Factors in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> includes a discussion of our risk factors. The information presented below updates, and should be read in conjunction with, the risk factors disclosed in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Except as presented below, there have been no material changes to the risk factors disclosed in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div></div> <div style="text-indent: 4%; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our financial condition and results of operations for fiscal year 2020 and beyond may be materially adversely affected by the ongoing coronavirus pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19).</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has evolved into a global pandemic. The coronavirus has spread to most regions of the world, including virtually all of the United States. The full extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will impact our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions to contain it or treat its impact, such as the potential for further shutdown or stay at home orders, and shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our anesthesiology services medical group, which we divested on May&#160;6, 2020, experienced a significant decline in the number of elective surgeries at a number of the facilities where its affiliated clinicians provide anesthesia services as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> A significant portion of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within our radiology services medical group, which in September 2020 we entered into an agreement to divest, orders for radiological studies declined by a meaningful amount from historically normal levels as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. Additionally, our office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, saw a significant elevation of appointment cancellations compared to historical normal levels as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> To date, we have not experienced, nor do we currently anticipate, any significant impact to our NICU patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> however, there is no assurance that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not adversely affect our NICU patient volumes or otherwise adversely affect our NICU and related neonatology business. Overall, our operating results since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020 have been significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but volumes did begin to normalize in May 2020 and substantially recovered during the months of June 2020 through September 2020.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Across these medical groups, we believe that these patient volume declines primarily reflect a deferral of healthcare services utilization to a later period, rather than a permanent reduction in demand for our services. Given the general necessity of the services our affiliated clinicians provide, we anticipate that this deferral of services may create a backlog of demand in the future, in addition to the resumption of historically normal activity, however, there is no assurance that either will occur. We may also require an increased level of working capital if we experience extended billing and collection cycles as a result of displaced employees, payors, revenue cycle management contractors, or otherwise. The foregoing and other continued disruptions to our business as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could result in a material adverse effect on our business, results of operations, financial condition, prospects and the trading prices of our securities in the near-term and beyond 2020.</div> <div id="tx44327_14" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended September&#160;30, 2020, we repurchased 310,589 shares of our common stock that were withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock and deferred stock. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%; font-family: 'Times New Roman';"></td>
<td style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 9%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Period</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Number&#160;of<br/>Shares<br/>Repurchased (a)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/>Price&#160;Paid<br/>per Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Number of<br/>Shares Purchased as<br/>part of the<br/>Repurchase&#160;Programs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate Dollar<br/>Value of Shares that<br/>May&#160;Yet&#160;Be&#160;Purchased<br/>Under the Repurchase<br/>Programs (a)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">July&#160;1 &#8211; July&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">290,716&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">(b)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">17.65</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">August&#160;1 &#8211; August&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;1 &#8211; September&#160;30, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,873&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">(b)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16.14</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">310,589</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">17.55</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. Our August 2018 repurchase program allows us to repurchase up to an additional $500.0&#160;million of shares of our common stock, of which we repurchased $401.3&#160;million as of September&#160;30, 2020. </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents shares withheld to satisfy minimum statutory withholding obligations of an aggregate of $5.5&#160;million in connection with the vesting of restricted stock. </div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx44327_15" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6. Exhibits </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 3%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="width: 89%; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.1</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520245502/d48531dex21.htm">Securities Purchase Agreement, dated as of September&#160;9, 2020, by and between MEDNAX Services, Inc. and Radiology Partners, Inc. (incorporated by reference to Exhibit 2.1 to MEDNAX&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on September&#160;15, 2020).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.1</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520191602/d82405dex101.htm">Agreement, dated as of July&#160;12, 2020, by and among MEDNAX, Inc., Starboard Value LP and certain of its affiliates (incorporated by reference to Exhibit 10.1 to MEDNAX&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on July&#160;13, 2020).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.2</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520191602/d82405dex102.htm">Separation Agreement, dated July&#160;12, 2020, by and between MEDNAX Services, Inc. and Roger J. Medel, M.D. (incorporated by reference to Exhibit 10.2 to MEDNAX&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on July&#160;13, 2020).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.3</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520203325/d919859dex101.htm">Employment Agreement, dated July&#160;12, 2020, by and between MEDNAX Services, Inc. and Mark S. Ordan (incorporated by Reference to Exhibit 10.1 to MEDNAX&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> filed on July&#160;30, 2020).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.4+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d44327dex104.htm">Employment Agreement, effective September&#160;8, 2020, by and between MEDNAX Services, Inc. and C. Marc Richards.</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.5+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d44327dex105.htm">Amended and Restated Employment Agreement, effective September&#160;27, 2020, by and between MEDNAX Services, Inc. and Dominic J. Andreano.</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.1+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d44327dex311.htm">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a),</span> as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.2+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d44327dex312.htm">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a),</span> as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">32.1*</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d44327dex321.htm">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.1+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">Interactive Data File</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Schema Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Calculation Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Definition Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Label Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Presentation Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">+</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith. </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furnished herewith. </div></div> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx44327_16" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 4%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 3%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 45%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="3" style="vertical-align: top;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MEDNAX, INC.</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: November&#160;6, 2020</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Mark S. Ordan</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Mark S. Ordan</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Chief Executive Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">(Principal Executive Officer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: November&#160;6, 2020</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ C. Marc Richards</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">C. Marc Richards</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Chief Financial Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">(Principal Financial Officer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: November&#160;6, 2020</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ John C. Pepia</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">John C. Pepia</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Chief Accounting Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">(Principal Accounting Officer)</td> </tr> </table> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>d44327dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS EMPLOYMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is made and entered into by and between <B>MEDNAX SERVICES, INC.</B>, a
Florida corporation (&#147;<U>Employer</U>&#148;), and C. Marc Richards (&#147;<U>Employee</U>&#148;) on September&nbsp;27, 2020 and effective as of September&nbsp;8, 2020 (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Employer is presently engaged in &#147;Employer&#146;s Business&#148; as defined on <U>Exhibit</U><U></U><U>&nbsp;A</U>
hereto; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employer desires to employ Employee and benefit from Employee&#146;s contributions to Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants and premises set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Employer and Employee hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. Employment. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1 <I>Employment and Term</I>. Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer on the terms and
conditions set forth herein for an &#147;<U>Initial Term</U>&#148; commencing as of the Effective Date and continuing for a period of three (3)&nbsp;years, unless sooner terminated as hereinafter set forth. Thereafter, the employment of Employee
hereunder shall automatically renew for successive one (1)&nbsp;year periods until terminated in accordance herewith. The Initial Term and any automatic renewals shall be referred to as the &#147;<U>Employment Period</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 <I>Duties of Employee</I>. As of the Effective Date and thereafter during the remaining Employment Period, Employee shall serve as
Executive Vice President of Employer and MEDNAX, Inc., a Florida corporation and the parent corporation of Employer (&#147;<U>MEDNAX</U>&#148;), and from October&nbsp;1, 2020 and thereafter during the remaining Employment Period, Employee shall also
serve as Chief Financial Officer of Employer and MEDNAX and perform such duties as are customary to the position Employee holds or as may be assigned to Employee from time to time by the most senior executive officer of MEDNAX
(&#147;<U>Employee&#146;s Supervisor</U>&#148;) or the Board of Directors of MEDNAX (the &#147;<U>Board</U>&#148;) including, but not limited to, also serving as an officer and/or director, or equivalent, of subsidiaries and/or affiliates of MEDNAX;
<I>provided, </I>that such duties as assigned shall be customary to Employee&#146;s role as an executive officer of Employer and MEDNAX. Employee&#146;s employment shall be full-time and, as such, Employee agrees to devote substantially all of
Employee&#146;s attention and professional time to the business and affairs of Employer and MEDNAX. Employee shall perform Employee&#146;s duties honestly, diligently, competently, in good faith and in the best interest of Employer and MEDNAX.
During the Employment Period, Employee agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably withheld), serve as a director on a corporate board of directors or in any other similar
capacity for any institution other than Employer and MEDNAX, and their respective subsidiaries and affiliates in accordance with this <U>Section</U><U></U><U>&nbsp;1.2</U>. During the Employment Period, it shall not be a violation of this Agreement
to (i)&nbsp;serve on civic </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or charitable boards or committees, or (ii)&nbsp;deliver lectures, fulfill speaking engagements or teach at educational institutions, so long as such activities have been approved by
Employee&#146;s Supervisor and do not interfere with the performance of Employee&#146;s responsibilities as an employee of Employer in accordance with this Agreement, including the restrictions of <U>Section</U><U></U><U>&nbsp;8</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 <I>Place of Performance</I>. Employee shall be based at Employee&#146;s home office located in the Washington, DC metropolitan area,
except for required travel relating to Employer&#146;s Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. Base Salary and Performance Bonus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <I>Base Salary</I>. Employer shall pay Employee during the Employment Period an annual salary of Five Hundred Thousand Dollars ($500,000)
(the &#147;<U>Base Salary</U>&#148;), payable in accordance with Employer&#146;s normal business practices for senior executives (including tax withholding), but in no event less frequently than monthly. Employee&#146;s Base Salary shall be reviewed
at least annually by the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;) and may be increased in its discretion. After any such increase in Base Salary, the term &#147;<U>Base Salary</U>&#148; shall refer to the
increased amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <I>Performance Bonus</I>. Employee shall be eligible to receive a cash bonus (the &#147;<U>Performance
Bonus</U>&#148;) for each year (or prorated with respect to any partial years of employment) during the Employment Period, provided that, except as otherwise provided herein, Employee has remained employed by Employer as of the end of the applicable
year (or as of the end of the Employment Period for the final calendar year of the Employment Period). Employee&#146;s target bonus opportunity for any particular year (&#147;<U>Target Bonus</U>&#148;) shall be one hundred percent (100%) of Base
Salary. The amount of bonus payable to Employee for any particular year will be determined by the Compensation Committee, in its sole discretion, taking into account the performance of Employer and Employee for that particular year (or portion
thereof). All such bonuses shall be paid no later than March 15th of the calendar year immediately following the calendar year in which it is earned. Notwithstanding the foregoing, the Performance Bonus with respect to the 2020 calendar year shall
be paid at one hundred percent (100%) of Base Salary and shall be prorated (on a daily basis relative to 366) based on the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Benefits. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1
<I>Expense Reimbursement</I>. Employer shall promptly reimburse Employee for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred by Employee during the Employment Period on
behalf of or in connection with Employer&#146;s Business pursuant to the reimbursement standards and guidelines of Employer in effect from time to time, including reimbursement for appropriate professional organizations. Employee shall account for
such expenses and submit reasonable supporting documentation in accordance with Employer&#146;s policies in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2
<I>Employee Benefits</I>. During the Employment Period, Employee shall be entitled to participate in such health, welfare, disability, retirement savings and other fringe benefit plans and programs (subject to the terms and conditions of such plans
and programs) as may be provided from time to time to employees of Employer and to the extent that such plans and programs are applicable to other similarly situated employees of Employer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <I>Leave Time</I>. During the Employment Period, Employee shall be entitled to paid
vacation and leave days each calendar year in accordance with the leave policies established by Employer from time to time. Any leave time not used during each fiscal year of Employer may be carried over into the next year to the extent permitted by
Employer policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <I>Equity Plans. </I>During the Employment Period, the Chief Executive Officer of MEDNAX shall recommend to the
Compensation Committee that Employee receive, on an annual basis following the Effective Date, and at the same time as other executive officers of Employer, grants of awards (each an &#147;<U>Equity Award</U>&#148;) pursuant to MEDNAX&#146;s Amended
and Restated 2008 Incentive Compensation Plan, as amended (the &#147;<U>2008 Plan</U>&#148;), or any other similar plan adopted by MEDNAX (together with the 2008 Plan, each an &#147;<U>Equity Plan</U>&#148;), with a grant value determined by the
Compensation Committee in the same manner as for other executive officers of Employer. Every Equity Award made to Employee shall be subject to the terms and conditions of this Agreement and the terms of the applicable Equity Plan, and shall be made
subject to an award agreement that is consistent with terms applicable to other executive officers of Employer. Notwithstanding any contrary provision in this Agreement or any Equity Plan then maintained by MEDNAX, if Employee remains continuously
employed with Employer through the date of a Change in Control (as defined in the Equity Plan pursuant to which the Equity Award is issued), then upon such Change in Control (i)&nbsp;all time-based Equity Awards granted to Employee by MEDNAX shall
immediately become fully vested, <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable and (ii)&nbsp;all performance-based Equity Awards for which the applicable performance condition has been met at the time of
such Change in Control shall immediately become fully vested, <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable. For purposes of clarification, the vesting of any performance-based Equity Awards for which the
performance condition has not been met at the time of such Change in Control shall not be accelerated or otherwise modified pursuant to this <U>Section</U><U></U><U>&nbsp;3.4</U> but such Equity Awards may nonetheless be accelerated or otherwise
modified as determined by the Company under the terms of the Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. Termination; Compensation and Benefits Upon Termination.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <I>Termination for Cause</I>. Employer may terminate Employee&#146;s employment under this Agreement for Cause (as defined
below). The termination date for a termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.1</U> shall be the date specified by Employer in a written notice to Employee of finding of Cause. If
Employee&#146;s employment is terminated for Cause, Employer shall pay (i)&nbsp;Employee&#146;s Base Salary through the termination date at the rate in effect at the termination date, (ii)&nbsp;reimbursement for reasonable business expenses incurred
prior to the termination date, subject to Employer policy and the provisions of <U>Section</U><U></U><U>&nbsp;3.1</U> hereof, and (iii)&nbsp;any other benefits that are vested benefits under applicable Employer benefit plans or that are required by
applicable law (the foregoing clauses (i)-(iii), the &#147;<U>Accrued Obligations</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <I>Disability</I>. Employer may terminate Employee&#146;s employment under this
Agreement upon the Disability (as defined below) of Employee. The termination date for a termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U> shall be the date specified by Employer in a notice to Employee. In the
event of Employee&#146;s Disability, (i)&nbsp;Employee shall continue to receive Employee&#146;s Base Salary for ninety (90)&nbsp;days under the Company&#146;s short term disability policy, which may be amended or modified in the Company&#146;s
discretion upon written notice to Employee (the &#147;<U>Initial Disability Period</U>&#148;), and (ii)&nbsp;following such Initial Disability Period, if Employee&#146;s Disability continues, the Company may terminate Employee&#146;s employment
immediately upon written notice. If Employee&#146;s employment is terminated in connection with Employee&#146;s Disability, in addition to the Accrued Obligations and subject to and conditioned on Employee&#146;s compliance with the terms of
<U>Section</U><U></U><U>&nbsp;5</U> hereof, Employee shall be eligible to receive (A)&nbsp;a bonus with respect to Employer&#146;s fiscal year in which the termination date occurs, equal to Employee&#146;s minimum Target Bonus for the year of
termination, multiplied by the number of days in the fiscal year prior to and including the date of termination and divided by three hundred sixty five (365) (a &#147;<U><FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus</U>&#148;) payable
within thirty (30)&nbsp;days of the termination date; and (B)&nbsp;all time-based Equity Awards granted to Employee by MEDNAX prior to termination of Employee&#146;s employment shall immediately become fully vested,
<FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable, and all performance-based shares awards shall remain outstanding and shall vest based upon actual performance determined at the end of the applicable
performance period (the &#147;<U>Equity Acceleration</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <I>Death</I>. Employee&#146;s employment under this Agreement shall
terminate automatically upon the death of Employee, without any requirement of notice by Employer to Employee&#146;s estate. The date of Employee&#146;s death shall be the termination date for a termination of Employee&#146;s employment under this
Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.3</U>. Upon Employee&#146;s death during the Employment Period, Employer shall pay or provide to the person or entity designated by Employee in a notice filed with Employer or, if no person
is designated, to Employee&#146;s estate (i)&nbsp;the Accrued Obligations; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus; and (iii)&nbsp;the Equity Acceleration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <I>Termination by Employer Without Cause</I>. Employer may terminate Employee&#146;s employment under this Agreement without Cause by
giving Employee written notice of such termination. The termination date shall be the date specified by Employer in such notice, which may be up to ninety (90)&nbsp;days from the date of such notice. Upon any termination of Employee&#146;s
employment without Cause pursuant to this <U>Section</U><U></U><U>&nbsp;4.4</U>, in addition to the Accrued Obligations and subject to and conditioned on Employee&#146;s compliance with the terms of <U>Section</U><U></U><U>&nbsp;5</U> hereof,
Employee shall be eligible to receive: (i)&nbsp;a <FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus; (ii)&nbsp;severance payments equivalent to Employee&#146;s monthly Base Salary for a period of twenty-four (24)&nbsp;months after the
termination date (the &#147;<U>Severance Period</U>&#148;), payable in installments in Employer&#146;s normal payroll; (iii)&nbsp;continuation of health, medical, hospitalization and other similar health insurance programs on the same basis as
regular, full-time employees of Employer and their eligible dependents during the Severance Period (or, at Employer&#146;s option, Employer may provide health insurance to Employee and Employee&#146;s eligible dependents through an insurance
carrier(s) selected by Employer in lieu of providing the foregoing coverage, provided the coverage afforded by such insurance is substantially comparable to the foregoing coverage, and Employee shall pay the cost of such insurance up to the amount
that would have been paid by Employee under the foregoing coverage and Employer shall pay the excess cost, if any); and (iv)&nbsp;an amount equal to the greater of (A) 1.5 times Employee&#146;s Average Annual Performance Bonus (as defined below) or
(B) 1.5 times Employee&#146;s Target Bonus amount, payable within thirty (90)&nbsp;days of the termination date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <I>Termination by Employee without Good Reason</I>. Employee may terminate
Employee&#146;s employment under this Agreement without Good Reason (as defined below) upon not less than ninety (90)&nbsp;days prior written notice to Employer. Upon receipt of such notice from Employee, Employer may, at its option, accelerate the
effective date of Employee&#146;s termination of employment at any time in advance of the expiration of such ninety (90)&nbsp;day period (which acceleration shall not constitute Good Reason or a termination by Employer without Cause). The
termination date under this <U>Section</U><U></U><U>&nbsp;4.5</U> shall be the date specified by Employer, but in no event more than ninety (90)&nbsp;days after Employer&#146;s receipt of notice from Employee as contemplated by this
<U>Section</U><U></U><U>&nbsp;4.5</U>. Upon any termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.5</U>, Employee shall be entitled to the Accrued Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <I>Termination by Employee for Good Reason.</I> Employee may terminate Employee&#146;s employment hereunder for Good Reason. If Employee
desires to terminate Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U>, Employee must, within ninety (90)&nbsp;days after the occurrence of events giving rise to the Good Reason, provide Employer
with a written notice describing the Good Reason in reasonable detail. If Employer fails to cure the matter cited within thirty (30)&nbsp;days after the date of Employee&#146;s notice, then this Agreement shall terminate as of the end of such thirty
(30)&nbsp;day cure period, provided, however, that Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30)&nbsp;day cure period. If Employee&#146;s employment under this
Agreement is terminated pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U>, then Employee shall be eligible to receive the same payments and benefits, subject to the same conditions, for a termination without Cause as set forth in
<U>Section</U><U></U><U>&nbsp;4.4</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <I>Continuation of Benefit Plans</I>. Following any termination that results in the
expiration of Employee&#146;s continued benefit plan coverage, Employee and each of Employee&#146;s eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to COBRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <I>Continuing Obligations</I>. The obligations imposed on Employee with respect to
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and assignment of rights to inventions or developments in this
Agreement or any other agreement executed by the parties shall continue, notwithstanding the termination of the employment relationship between the parties and regardless of the reason for such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. Conditions to Severance; Certain Definitions. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <I>Release. </I>Employer shall provide Employee with a general release in the form attached as <U>Exhibit</U><U></U><U>&nbsp;B</U>
(subject to such modifications as Employer may reasonably request) (the &#147;<U>Release</U>&#148;) within seven (7)&nbsp;days after Employee&#146;s termination date. Payments or benefits to which Employee may be entitled pursuant to
<U>Section</U><U></U><U>&nbsp;4</U> hereof (other than the Accrued Obligations) (the &#147;<U>Severance Amounts</U>&#148;) shall be conditioned upon (i)&nbsp;Employee executing the Release within twenty one (21)&nbsp;days after receiving it from
Employer (or such longer period as may be set forth in the Release) and the Release becoming irrevocable upon the expiration of seven (7)&nbsp;days following Employee&#146;s execution of it, (ii)&nbsp;Employee agreeing to submit to a reasonable exit
interview if requested by Employer, and (iii)&nbsp;Employee&#146;s compliance with all post-termination obligations to Employer and its subsidiaries and affiliates and surrendering to Employer all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proprietary or confidential information and articles belonging to Employer or its subsidiaries or affiliates. Payment of the Severance Amounts shall be suspended during the period (the
&#147;<U>Suspension Period</U>&#148;) that begins on Employee&#146;s termination date and ends on the date (&#147;<U>Suspension Termination Date</U>&#148;) that is at least forty-five (45)&nbsp;days after Employee&#146;s termination date; provided,
however, that this suspension shall not apply, and Employer shall be required to provide, any continued health insurance coverage (or COBRA reimbursement) that would be required under <U>Section</U><U></U><U>&nbsp;4</U> hereof during the Suspension
Period. If Employee executes the Release and the Release becomes irrevocable by no later than the Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll
period that follows the Suspension Termination Date, and any Severance Amounts that are payable after the Suspension Termination Date shall be paid at the times provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <I>Certain Definitions</I>. As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Average Annual Performance Bonus</U>&#148; shall mean an amount equal to the average of the percentage of the Performance Bonus
target achieved by Employee for the three (3)&nbsp;full calendar years prior to the termination date (or such lesser period as Employee may have been employed by Employer), and calculated based on Employee&#146;s Base Salary and Target Bonus in
Employee&#146;s current position. For illustration purposes, if Employee earned 40%, 100% and 70% of Employee&#146;s Target Bonus in each of the three full calendar years prior to termination, and Employee&#146;s current Target Bonus was 100% of
Base Salary, and Base Salary was $450,000.00, then Employee&#146;s Average Annual Performance Bonus would equal $315,000.00. ((40%+ 100% + 70%) / 3 x 100% x $450,000.00 = $315,000.00). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Cause</U>&#148; shall mean the occurrence of any of: (i)&nbsp;Employee&#146;s engagement in (A)&nbsp;willful misconduct resulting
in material harm to MEDNAX or Employer, or (B)&nbsp;gross negligence; (ii)&nbsp;Employee&#146;s conviction of, or pleading nolo contendere to, a felony or any other crime involving fraud, financial misconduct, or misappropriation of Employer&#146;s
assets; (iii)&nbsp;Employee&#146;s willful and continual failure, after written notice from Employee&#146;s Supervisor or the Board to (A)&nbsp;perform substantially Employee&#146;s employment duties consistent with Employee&#146;s position and
authority, or (B)&nbsp;follow, consistent with Employee&#146;s position, duties, and authorities, the reasonable lawful mandates of Employee&#146;s Supervisor or the Board; (iv)&nbsp;Employee&#146;s failure or refusal to comply with a reasonable
policy, standard or regulation of Employer in any material respect, including but not limited to Employer&#146;s sexual harassment, other unlawful harassment, workplace discrimination or substance abuse policies; or (v)&nbsp;Employee&#146;s breach
of <U>Section</U><U></U><U>&nbsp;8.4</U> hereof resulting in material harm to MEDNAX or Employer. No act or omission shall be deemed willful or grossly negligent for purposes of this definition if taken or omitted to be taken by Employee in a good
faith belief that such act or omission to act was in the best interests of Employer or MEDNAX or if done at the express direction of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Subject to the requirements of applicable law, &#147;<U>Disability</U>&#148; shall mean (i)&nbsp;Employee&#146;s inability to perform
Employee&#146;s duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii)&nbsp;a determination by an independent qualified physician selected by Employer and acceptable to Employee
(which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an additional ninety (90)&nbsp;or more days in any
one hundred twenty (120)&nbsp;day period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Good Reason</U>&#148; shall mean: (i)&nbsp;a decrease in Employee&#146;s Base
Salary; (ii)&nbsp;a decrease in Employee&#146;s Target Bonus opportunity; (iii)&nbsp;Employee is assigned any position, duties, responsibilities or compensation that is inconsistent with the position, duties, or responsibilities of Employee
contemplated herein as of the Effective Date or compensation of Employee as of the Effective Date, excluding for this purpose any isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by Employer promptly after
receipt of written notice; (iv)&nbsp;Employee experiences a material diminution in Employee&#146;s authorities, duties or responsibilities, excluding for this purpose any isolated and inadvertent action not taken in bad faith and which is remedied
by Employer promptly after receipt of written notice; (v)&nbsp;Employee is required to report to any person other than the senior most executive officer of MEDNAX, the Board, or a duly constituted committee thereof, or there is a material diminution
in the authority, duties or responsibilities of the senior most executive officer of MEDNAX; (vi)&nbsp;the requirement by Employer that Employee be based in any office or location outside of the metropolitan area where Employee resides as of the
Effective Date, except for travel reasonably required in the performance of Employee&#146;s duties; (vii)&nbsp;if following a Change in Control (as defined in the 2008 Plan as of the Effective Time), neither the common stock of MEDNAX nor the common
equity of its successor, parent, or subsidiary is listed for trading on a national securities exchange; or (viii)&nbsp;any other action or inaction that constitutes a material breach of this Agreement by Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. Successors; Binding Agreement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <I>Successors</I>. Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise)
acquiring a majority of Employer&#146;s voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same manner and to the same
extent that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment. In such event, &#147;<U>Employer</U>&#148; shall mean Employer as previously defined and any successor to
its business and/or assets which executes and delivers the agreement provided for in this <U>Section</U><U></U><U>&nbsp;6</U> or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law. This
<U>Section</U><U></U><U>&nbsp;6.1</U> shall not limit Employee&#146;s ability to terminate this Agreement in the circumstances described in <U>Section</U><U></U><U>&nbsp;4.6</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <I>Benefit</I>. This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by
Employee&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Employee should die after the termination date and amounts would have been payable to Employee under this
Agreement if Employee had continued to live, including under <U>Section</U><U></U><U>&nbsp;5</U> hereof, then such amounts shall be paid to Employee&#146;s devisee, legatee, or other designee or, if there is no such designee, Employee&#146;s estate.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. Conflicts</B>. Except as otherwise provided in this Agreement, this Agreement
constitutes the entire agreement among the parties pertaining to the subject matter hereof, and supersedes and revokes any and all prior or existing agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be
solely determinative of the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. Restrictive Covenants; Confidential Information; Work Product; Injunctive
Relief. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <I>No Material Competition</I>. Employer and Employee acknowledge and agree that a strong relationship and connection
exists between Employer and its current and prospective patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services. Employer and Employee further acknowledge and agree that
the restrictive covenants described in this Section are designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the following:
(1)&nbsp;the use and disclosure of the Confidential Information as described in <U>Section</U><U></U><U>&nbsp;8.4</U> hereof; (2)&nbsp;the professional development activities described in <U>Section</U><U></U><U>&nbsp;1.2</U> hereof; and
(3)&nbsp;the goodwill of Employer, as promoted by Employee as provided in <U>Section</U><U></U><U>&nbsp;1.2</U> hereof. The foregoing listing is by way of example only and shall not be construed to be an exclusive or exhaustive list of such
interests. Employee acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to Employer in agreeing to the terms of this Agreement. Employee further acknowledges that the
goodwill and other proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer in violation of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of Employer, <B>Employee shall
not</B>, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly participate or engage in or own an
interest in, directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee,
consultant, independent contractor, stockholder, lender, landlord, finder, agent, broker, trustee, or in any manner whatsoever, if such entity or its affiliates is engaged in, directly or indirectly, &#147;<U>Employer&#146;s Business</U>,&#148; as
defined on <U>Exhibit</U><U></U><U>&nbsp;A</U> hereto. Employee acknowledges that, as of the date hereof, Employee&#146;s responsibilities will include matters affecting the businesses of Employer listed on <U>Exhibit</U><U></U><U>&nbsp;A</U>. For
purposes of this <U>Section</U><U></U><U>&nbsp;8</U>, the &#147;<U>Restricted Period</U>&#148; shall mean the Employment Period plus (i)&nbsp;eighteen (18)&nbsp;months in the event this Agreement is terminated pursuant to
<U>Section</U><U></U><U>&nbsp;4.1</U> hereof, and (ii)&nbsp;twenty-four (24)&nbsp;months in the event the Agreement is terminated for any other reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <I>No Hire</I>. Employee further agrees that <B>Employee shall not</B>, at any time during the Employment Period and for a period of
eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly employ, or
intentionally, knowingly, or willingly permit any company or business directly or indirectly controlled by Employee to (a)&nbsp;employ or otherwise engage (i)&nbsp;any person who is a then current employee or exclusive independent contractor of
Employer or one of its affiliates, or (ii)&nbsp;any person who was an employee or exclusive independent contractor of Employer or one of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliates in the prior six (6)&nbsp;month period, or (b)&nbsp;take any action that would reasonably be expected to induce an employee or independent contractor of Employer or one of its
affiliates to leave his or her employment or engagement with Employer or one of its affiliates (including without limitation for or on behalf of a subsequent employer of Employee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <I><FONT STYLE="white-space:nowrap">Non-Solicitation.</FONT> </I>Employee further agrees that <B>Employee shall not</B>, at any time
during the Employment Period and for a period of eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer,
intentionally, knowingly, or willingly solicit or accept business from or take any action that would reasonably be expected to materially interfere with, diminish or impair the valuable relationships that Employer or its affiliates have with
(i)&nbsp;hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional services or otherwise have established relationships, (ii)&nbsp;patients, (iii)&nbsp;referral sources, (iv)&nbsp;vendors,
(v)&nbsp;any other clients of Employer or its affiliates, or (vi)&nbsp;prospective hospitals, patients, referral sources, vendors or clients whose business Employee was aware that Employer or any affiliate of Employer was in the process of
soliciting at the time of Employee&#146;s termination (including potential acquisition targets). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <I>Confidential Information</I>. At
all times during the term of this Agreement, Employer shall provide Employee with access to &#147;<U>Confidential Information</U>.&#148; As used in this Agreement, the term &#147;<U>Confidential Information</U>&#148; means any and all confidential,
proprietary or trade secret information, whether disclosed, directly or indirectly, verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by Employee, applicable to or in any way
related to: (i)&nbsp;patients with whom Employer has a physician/patient relationship; (ii)&nbsp;the present or future business of Employer; or (iii)&nbsp;the research and development of Employer. Without limiting the generality of the foregoing,
Confidential Information includes: (a)&nbsp;the development and operation of Employer&#146;s medical practices, including information relating to budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and
other information concerning such facilities and operations and specifically including the procedures and business plans developed by Employer for use at the hospitals where Employer conducts its business; (b)&nbsp;contractual arrangements between
Employer and insurers or managed care associations or other payors; (c)&nbsp;the databases of Employer; (d)&nbsp;the clinical and research protocols of Employer, including coding guidelines; (e)&nbsp;the referral sources of Employer; (f)&nbsp;other
confidential information of Employer that is not generally known to the public that gives Employer the opportunity to obtain an advantage over competitors who do not know or use it, including the names, addresses, telephone numbers or special needs
of any of its patients, its patient lists, its marketing methods and related data, lists or other written records used in Employer&#146;s business, compensation paid to employees and other terms of employment, accounting ledgers and financial
statements, contracts and licenses, business systems, business plan and projections, and computer programs. The parties agree that, as between them, this Confidential Information constitutes important, material, and confidential trade secrets that
affect the successful conduct of Employer&#146;s business and its goodwill. Employer acknowledges that the Confidential Information specifically enumerated above is special and unique information and is not information that would be considered a
part of the general knowledge and skill Employee has or might otherwise obtain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Confidential Information shall not include any information
that (i)&nbsp;was known by Employee from a third party source before disclosure by or on behalf of Employer, (ii)&nbsp;becomes available to Employee from a source other than Employer that is not, to Employee&#146;s knowledge, bound by a duty of
confidentiality to Employer, (iii)&nbsp;becomes generally available or known in the industry other than as a result of its disclosure by Employee, or (iv)&nbsp;has been independently developed by Employee and may be disclosed by Employee without
breach of this Agreement, provided, in each case, that Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions. Pursuant to the Defend Trade Secrets Act of 2016, Employee acknowledges
that Employee shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A)&nbsp;is made (i)&nbsp;in confidence to a federal, state, or local government official, either directly
or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal. In addition, if Employee files a lawsuit for retaliation by Employer for reporting a suspected violation of law, Employee may disclose the trade secret to Employee&#146;s attorney and may use the trade secret information in the court
proceeding, if Employee (X)&nbsp;files any document containing the trade secret under seal and (Y)&nbsp;does not disclose the trade secret, except pursuant to court order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, notwithstanding anything herein to the contrary, nothing in this Agreement or any other agreement between Employer and Employee
shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any
investigation by any such federal government agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless disclosure is otherwise required by applicable law or stock exchange rules,
Employee agrees that the terms of this Agreement shall be deemed Confidential Information for purposes of this Section. Employee shall keep the terms of this Agreement strictly confidential and will not, without the prior written consent of
Employer, disclose the details of this Agreement to any third party in any manner whatsoever in whole or in part, with the exception of Employee&#146;s representatives (such as tax advisors and attorneys) who need to know such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Employee agrees that Employee will not at any time, whether during or subsequent to the term of Employee&#146;s employment with Employer, in
any fashion, form or manner, unless specifically consented to in writing by Employer, either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any manner whatsoever, any Confidential Information
of any kind, nature, or description, subject to applicable law. The parties agree that any breach by Employee of any term of this <U>Section</U><U></U><U>&nbsp;8.4</U> resulting in material harm to MEDNAX or Employer is a material breach of this
Agreement and shall constitute &#147;<U>Cause</U>&#148; for the termination of Employee&#146;s employment hereunder pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U> hereof. In the event that Employee is ordered to disclose any Confidential
Information, whether in a legal or a regulatory proceeding or otherwise, Employee shall provide Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be achieved, the entry of
a protective order or other appropriate protective device or procedure in order to assure, to the extent practicable, compliance with the provisions of this Agreement. In the case of any disclosure required by law, Employee shall disclose only that
portion of the Confidential Information that Employee is ordered to disclose in a legally binding subpoena, demand or similar order issued pursuant to a legal or regulatory proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All Confidential Information, and all equipment, notebooks, documents, memoranda, reports,
files, samples, books, correspondence, lists, other written and graphic records, in any media (including electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct,
observe, possess, or control shall be and remain Employer&#146;s sole property (collectively &#147;<U>Employer Property</U>&#148;). Upon termination or expiration of this Agreement, or earlier upon Employer&#146;s request, Employee shall promptly
deliver to Employer all Employer Property, retaining none. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 <I>Ownership of Work Product.</I> Employee agrees and acknowledges that
(i)&nbsp;all copyrights, patents, trade secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by
Employee during the course of performing work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employer&#146;s Business
(collectively, the &#147;<U>Work Product</U>&#148;), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code. To the extent the Work Product
may not be considered a work made for hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further
consideration. Upon request of Employer, Employee shall take such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate
assignments of all right, title, and interest in and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements,
additions to, or modifications thereto, which Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employer&#146;s successors and assigns, as fully
and as entirely as the same might be held by Employee had this assignment not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <I>Clearance Procedure for Proprietary
Rights Not Claimed by Employer.</I> In the event that Employee wishes to create or develop, <I>other than</I> on Employer&#146;s time or using Employer&#146;s resources, anything that may be considered Work Product but to which Employee believes
Employee should be entitled to the personal benefit of, Employee agrees to follow the clearance procedure set forth in this Section. Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a
sufficiently detailed written description of the work under consideration for Employer to make a determination regarding the work. Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of
confidentiality with respect to such request or description. Employer will determine in its sole discretion, within thirty (30)&nbsp;days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by
Employer. If Employer determines that it does not claim rights in such work, Employer agrees to so notify Employee in writing and Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer. If
Employer fails to so notify Employee within such thirty (30)&nbsp;day period, then Employer shall be deemed to have agreed that such work is not considered Work Product for purposes of this Agreement. Employee agrees to submit for further review any
significant improvement, modification, or adaptation that could reasonably be related to Employer&#146;s Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer.
Clearance under this procedure does not relieve Employee of the restrictive covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7 <I><FONT STYLE="white-space:nowrap">Non-Disparagement.</FONT> </I>During the Employment
Period and for a period of ten (10)&nbsp;years after the termination of this Agreement, Employee will not, directly or indirectly, as an individual or on behalf of a firm, corporation, partnership or other legal entity, intentionally, knowingly, or
willingly make any comment that would reasonably be expected to be materially disparaging or negative to any other person or entity regarding Employer or any of its affiliates, agents, attorneys, employees, officers and directors, Employee&#146;s
work conditions or circumstances surrounding Employee&#146;s separation from Employer or otherwise impugn or criticize the name or reputation of Employer, its affiliates, agents, attorneys, employees, officers or directors, orally or in writing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <I>Review by Employee.</I> Employee has carefully read and considered the terms and provisions of this
<U>Section</U><U></U><U>&nbsp;8</U>, and having done so, agrees that the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;8</U> are fair and reasonably required for the protection of the interests of Employer. In the event that any term
or provision set forth in this <U>Section</U><U></U><U>&nbsp;8</U> shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that such invalid or unenforceable term(s) or provision(s) may be severed
from this Agreement without, in any manner, affecting the remaining portions hereof. Without limiting other possible remedies available to Employer, Employee agrees that injunctive or other equitable relief will be available to enforce the covenants
set forth in this <U>Section</U><U></U><U>&nbsp;8</U>, such relief to be without the necessity of posting a bond. In the event that, notwithstanding the foregoing, any part of the covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U> shall
be held to be invalid, overbroad, or unenforceable by an arbitrator or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable provision(s) may be modified or severed from this Agreement without, in
any manner, affecting the remaining portions of this <U>Section</U><U></U><U>&nbsp;8</U> (all of which shall remain in full force and effect). In the event that any provision of this <U>Section</U><U></U><U>&nbsp;8</U> related to time period or
areas of restriction shall be declared by an arbitrator or a court of competent jurisdiction to exceed the maximum time period, area or activities such arbitrator or court deems reasonable and enforceable, said time period or areas of restriction
shall be deemed modified to the minimum extent necessary to make the geographic or temporal restrictions or activities reasonable and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <I>Survival; Notice of Breach and Right to Cure. </I>If Employer reasonably believes that Employee has breached a provision of this
<U>Section</U><U></U><U>&nbsp;8</U>, Employer shall provide prompt written notice thereof to Employee that explains such reasonably believed breach (the &#147;<U>Alleged Breach</U>&#148;). Employer agrees to work in good faith with Employee to
provide Employee a reasonable opportunity to promptly cure such Alleged Breach. In the event that Employee, acting in good faith, promptly takes actions that would reasonably be expected to cure the Alleged Breach, including, with respect to a
comment made by Employee that Employer reasonably believes is in breach of <U>Section</U><U></U><U>&nbsp;8.7</U> hereof, by Employee retracting such comment, then Employee shall be deemed not to be in breach of this
<U>Section</U><U></U><U>&nbsp;8</U> with respect to the Alleged Breach. Employer and Employee further agree that Employee shall not be deemed to be in breach of any term of <U>Section</U><U></U><U>&nbsp;8.4</U> hereof unless such breach results in
material harm to MEDNAX or Employer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> shall survive the termination of
this Agreement and Employee&#146;s employment with Employer. In the event of a breach of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof, Employer retains the right
to terminate any continuing payments to Employee provided for in <U>Section</U><U></U><U>&nbsp;4</U> hereof. In the event of a breach of any provisions of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to
<U>Section</U><U></U><U>&nbsp;11</U> hereof, the period for which those provisions would remain in effect shall be extended for a period of time equal to that period beginning when such breach commenced and ending when the activities constituting
such breach shall have been finally terminated, in each case as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof. The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> are expressly intended to benefit and be
enforceable by other affiliated entities of Employer, who are express third party beneficiaries hereof. Employee shall not assist others in engaging in any of the activities described in the foregoing restrictive covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. Tax Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1
<I>Section</I><I></I><I>&nbsp;409A</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>In General. </I>The parties intend that this Agreement will be administered in accordance
with Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with
Section&nbsp;409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> For purposes of
Section&nbsp;409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. The parties agree that this Agreement may be amended, as reasonably requested by either
party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. Employer makes no
representation or warranty and shall have no liability to Employee or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption
from, or the conditions of, Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I><FONT STYLE="white-space:nowrap">Six-Month</FONT> Delay. </I>Anything in this
Agreement to the contrary notwithstanding, if at the time of Employee&#146;s separation from service within the meaning of Section&nbsp;409A of the Code, Employer determines that Employee is a &#147;specified employee&#148; within the meaning of
Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#146;s &#147;separation from service&#148; (within the meaning of Section&nbsp;409A)
that would be considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;, such payment shall not be payable and such benefit shall not be provided until the date that is within fifteen (15)&nbsp;days after the
end of the <FONT STYLE="white-space:nowrap">six-month</FONT> period beginning on the date of such &#147;separation from service&#148; or, if earlier, within fifteen (15)&nbsp;days after the appointment of the personal representative or executor of
Employee&#146;s estate following Employee&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that
would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Reimbursements. </I>All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by Employer or incurred by Employee during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <I>Separation from Service. </I>To the extent that any payment or benefit described in this Agreement constitutes <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#146;s termination of employment, then such payments or
benefits shall be payable only upon Employee&#146;s &#147;separation from service&#148; as defined under Section&nbsp;409A. The determination of whether and when a separation from service has occurred shall be made in accordance with the
presumptions set forth in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <I>Later Calendar
Year</I>. To the extent that any payment or benefit described in this Agreement constitutes <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and not otherwise exempt from
the application of Section&nbsp;409A, then, if the period during which Employee may consider and sign the Release or the period in which the Employer can make a severance payment spans two calendar years, any payment or benefit described in this
Agreement will not be made or begin until the later calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2 <B><I>Section</I></B><B><I></I></B><B><I>&nbsp;280G</I></B>.
Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer or its affiliates to Employee or for Employee&#146;s benefit
pursuant to the terms of this Agreement or otherwise (the &#147;<U>Covered Payments</U>&#148;) constitute parachute payments (the &#147;<U>Parachute Payments</U>&#148;) within the meaning of Section&nbsp;280G of the Code and, but for this
<U>Section</U><U></U><U>&nbsp;9</U>, would be subject to the excise tax imposed under Section&nbsp;4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to
such taxes (collectively, the &#147;<U>Excise Tax</U>&#148;), then prior to making the Covered Payments, a calculation shall be made comparing (i)&nbsp;the Net Benefit (as defined below) to Employee of the Covered Payments after payment of the
Excise Tax to (ii)&nbsp;the Net Benefit to Employee if the Covered Payments are limited to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (i)&nbsp;above is less than the amount under
(ii)&nbsp;above will the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax (that amount, the &#147;<U>Reduced Amount</U>&#148;). &#147;<U>Net Benefit</U>&#148;
shall mean the present value of the Covered Payments net of all federal, state, local, foreign income, employment and excise taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
Any such reduction shall be made in accordance with Section&nbsp;409A and the following: (i)&nbsp;the Covered Payments consisting of cash severance benefits that do not constitute nonqualified deferred compensation subject to Section&nbsp;409A shall
be reduced first, in reverse chronological order; (ii)&nbsp;all other Covered Payments consisting of cash payments, and Covered Payments consisting of accelerated vesting of equity based awards to which Treas. Reg. &#167; <FONT
STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> does not apply, and that in either case do not constitute nonqualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deferred compensation subject to Section&nbsp;409A, shall be reduced second, in reverse chronological order; (iii)&nbsp;all Covered Payments consisting of cash payments that constitute
nonqualified deferred compensation subject to Section&nbsp;409A shall be reduced third, in reverse chronological order; and (iv)&nbsp;all Covered Payments consisting of accelerated vesting of equity-based awards to which Treas. Reg. &#167; <FONT
STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> applies shall be the last Covered Payments to be reduced. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any determination required under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made in writing in good faith by an independent
accounting firm selected by Employer (the &#147;<U>Accountants</U>&#148;). Employer and Employee shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this
<U>Section</U><U></U><U>&nbsp;9</U>. For purposes of making the calculations and determinations required by this <U>Section</U><U></U><U>&nbsp;9</U>, the Accountants may rely on reasonable, good-faith assumptions and approximations concerning the
application of Section&nbsp;280G and Section&nbsp;4999 of the Code. The Accountants&#146; determinations shall be final and binding on Employer and Employee. Employer shall be responsible for all fees and expenses incurred by the Accountants in
connection with the calculations required by this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) It is possible that after the determinations
and selections made pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, Employee will receive Covered Payments that are in the aggregate more than the amount intended or required to be provided after application of this
<U>Section</U><U></U><U>&nbsp;9</U> (&#147;<U>Overpayment</U>&#148;) or less than the amount intended or required to be provided after application of this <U>Section</U><U></U><U>&nbsp;9</U> (&#147;<U>Underpayment</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event that: (A)&nbsp;the Accountants determine, based upon the assertion of a deficiency by the Internal Revenue
Service against either Employer or Employee that the Accountants believe has a high probability of success, that an Overpayment has been made or (B)&nbsp;it is established pursuant to a final determination of a court or an Internal Revenue Service
proceeding that has been finally and conclusively resolved that an Overpayment has been made, then Employee shall pay any such Overpayment to Employer together with interest at the applicable federal rate (as defined in Section&nbsp;7872(f)(2)(A) of
the Code) from the date of Employee&#146;s receipt of the Overpayment until the date of repayment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) In the event
that: (A)&nbsp;the Accountants, based upon controlling precedent or substantial authority, determine that an Underpayment has occurred or (B)&nbsp;a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment
will be paid promptly by Employer to or for the benefit of Employee together with interest at the applicable federal rate (as defined in Section&nbsp;7872(f)(2)(A) of the Code) from the date the amount should have otherwise been paid to Employee
until the payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3 <I>Tax Withholding. </I>All amounts payable under this Agreement shall be subject to applicable income and
employment tax withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Dispute Resolution; Injunctive Relief</B>. If any controversy or claim arises out of
or relating to this Agreement, or any alleged breach hereof, Employee and Employer shall first try to resolve such controversy or claim through mediation using the services of the American Arbitration Association. If any such controversy or claim
cannot be resolved by mediation pursuant to the foregoing, Employee and Employer agree that such controversy or claim shall be finally determined by a single arbitrator, jointly selected by Employee and Employer, provided that if Employee and
Employer are unable to agree upon a single arbitrator after reasonable efforts, the arbitrator shall be an impartial arbitrator selected by the American Arbitration Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employer shall bear all costs associated with such mediation and, if necessary, arbitration, including but not limited to all costs of the
mediator and arbitrator, and shall reimburse Employee on a monthly basis for Employee&#146;s reasonable legal and other expenses, including all fees, incurred in connection with any such mediation and, if necessary, arbitration, provided, however,
that if Employer ultimately prevails in any arbitration (as determined by the arbitrator), the arbitrator shall have the power to require Employee to reimburse Employer for all or a portion of the advanced legal fees and other expenses as determined
by the arbitrator (and, if the arbitrator finds that Employer prevailed on certain claims and Employee prevailed on others, the arbitrator shall have the power to require Employee to reimburse Employer for a portion of the advanced legal fees and
other expenses determined by the arbitrator based on those claims on which Employer prevailed). The mediation and, if necessary, arbitration proceedings shall be held in Sunrise, Florida, unless otherwise mutually agreed by the parties, and shall be
conducted in accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes then in effect. Judgment on any award rendered by the arbitrator may be entered and enforced by any court having jurisdiction
thereof. Any such mediation and, if necessary, arbitration shall be treated as confidential by all parties thereto, except as otherwise provided by law or as otherwise necessary to enforce any judgment or order issued by the arbitrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, if Employer or Employee shall require immediate injunctive relief, then the party shall be
entitled to seek such relief in any court having jurisdiction, and if the party elects to do so, the other party hereby consents to the jurisdiction of the state and federal courts sitting in the State of Florida and to the applicable service of
process. Employee and Employer hereby waive and agree not to assert, to the fullest extent permitted by applicable law, any claim that (i)&nbsp;they are not subject to the jurisdiction of such courts, (ii)&nbsp;they are immune from any legal process
issued by such courts and (iii)&nbsp;any litigation or other proceeding commenced in such courts is brought in an inconvenient forum. In the event that Employer brings suit against Employee seeking injunctive relief, Employer agrees to advance all
of Employee&#146;s reasonable legal and other expenses, including all fees, incurred by Employee in connection with such action, provided, however, that if Employer ultimately prevails in seeking injunctive relief, Employee shall reimburse Employer
all such advanced legal fees and other expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. Governing Law</B>. This Agreement shall be governed by and construed in
accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. Notices</B>. Any notice required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been
given when (i)&nbsp;delivered by hand, (ii)&nbsp;delivered by electronic mail that is confirmed by <FONT STYLE="white-space:nowrap">non-automated</FONT> means, or (iii)&nbsp;when delivered or delivery is refused if sent by registered or certified
U.S. mail, return receipt requested, postage prepaid, or via reputable overnight courier, addressed as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Employer:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX Services, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sunrise, FL 33323</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: dominic_andreano@mednax.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Employee:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C. Marc Richards</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o MEDNAX Services, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sunrise, FL 33323</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: marc_richards@mednax.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid manner.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13. Benefits; Binding Effect</B>. This Agreement shall be for the benefit of and binding upon the parties hereto and their respective
heirs, personal representatives, legal representatives, successors and, where applicable, assigns. Notwithstanding the foregoing, Employee may not assign the rights or benefits hereunder without the prior written consent of Employer. This Agreement
may be assigned by Employer upon notice to Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14. Severability</B>. The invalidity of any one or more of the words, phrases,
sentences, clauses or sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and, in the event
that any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or sentences, clause or
clauses, or section or sections had not been inserted. If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would cure such invalidity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15. Waivers</B>. The waiver by either party hereto of a breach or violation of any term or provision of this Agreement shall not
operate nor be construed as a waiver of any subsequent breach or violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16. Damages</B>. Nothing contained herein shall be
construed to prevent Employer or Employee from seeking and recovering from the other damages sustained by either or both of them as a result of a breach of any term or provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17. </B><B>No Third Party Beneficiary</B>. Except as provided in <U>Section</U><U></U><U>&nbsp;8.9</U> hereof, nothing expressed or implied
in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employee&#146;s heirs, personal representative(s) and/or legal representative) any rights or
remedies under or by reason of this Agreement. No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement which agreements or representations are not
set forth expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The
remainder of this page has been left blank intentionally. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have executed this Agreement this 27th day of
September, 2020, effective as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYER:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>MEDNAX SERVICES, INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Mark. S. Ordan</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ C. Marc Richards </I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark S. Ordan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">C. Marc Richards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Shirley A. Weis</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Shirley A. Weis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chair, Compensation Committee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Employment Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS OF EMPLOYER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of the date hereof, Employer, directly or through its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively
referred to herein as &#147;<U>Employer&#146;s Business</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) Neonatology, including hospital well baby care; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) Maternal-Fetal Medicine, including Obstetrical Hospitalist Care; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Pediatric Cardiology; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4)
Pediatric Intensive Care, including Pediatric Hospitalist Care; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5) Newborn hearing screening services; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(6) Pediatric Surgery; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(7)
Pediatric Emergency Medicine; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(8) Radiology and Teleradiology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to Employer&#146;s Business in this Agreement shall include such other medical service lines, practice management services and
other businesses in which Employer is engaged during the Employment Period; <I>provided,</I> that to be considered a part of Employer&#146;s Business, Employer must have engaged in such other service line, practice management service or other
business at least six (6)&nbsp;months prior to the termination date of this Agreement. For purposes of this <U>Exhibit</U><U></U><U>&nbsp;A</U>, businesses of Employer shall include the businesses conducted by Employer&#146;s subsidiaries, entities
under common control and affiliates as defined under Rule 144 of the Securities Act of 1933, as amended. Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for
financial reporting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Employer acknowledges and agrees to the following exceptions and
clarifications regarding the scope of Employer&#146;s Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <I>Hospital Services. </I>Employer and Employee acknowledge that, as
of the date hereof, Employer does not currently operate hospitals, hospital systems or universities. Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as Employer&#146;s Business where such hospitals,
hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employer&#146;s Business. Therefore, the parties desire to clarify their intent with respect to the limitations on
Employee&#146;s ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period. <U>Section</U><U></U><U>&nbsp;8.1</U> shall not be deemed to
restrict Employee&#146;s ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included in Employer&#146;s Business. Furthermore, even if a hospital,
hospital system or university provides medical services that are included in Employer&#146;s Business, Employee may work for such hospital, hospital system or university if Employee has no direct supervisory responsibility for or involvement in the
hospital&#146;s, hospital system&#146;s or university&#146;s provision of medical services that are Employer&#146;s Business. For the avoidance of doubt, Employer and Employee agree that if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employee becomes the Chief Financial Officer, Chief Operating Officer, or Chief Executive Officer of a hospital system or health system, or other executive officer of similar level to the
foregoing, that Employee shall not be in breach of the provisions of this Agreement. Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be involved in the medical services of a hospital, hospital system or
university that are included in Employer&#146;s Business so long as such hospital, hospital system or university is located at least ten (10)&nbsp;miles from a medical practice owned or operated by Employer or its affiliate. Subject to paragraph B
below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <I>De Minimus Exception. </I>Employer agrees that a medical service line (other than those listed in items (1)&nbsp;through (8) above),
practice management service or other business in which Employer is engaged shall not be considered to be a part of Employer&#146;s Business if such medical service line, practice management service or other business constitutes less than three
percent (3%) of Employer&#146;s annual revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. <I>Divested Lines of Service. </I>Employer agrees that any medical service line
(including those listed in items (1)&nbsp;through (8) above), practice management, or other business in which Employer is engaged that is divested pursuant to a disposition, sale of assets or equity, or otherwise after the Effective Date shall not
be considered to be a part of Employer&#146;s Business effective as of the effective date of such divestiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. <I>Certain Ownership
Interests. </I>It shall not be deemed to be a violation of <U>Section</U><U></U><U>&nbsp;8.1</U> for Employee to: (i)&nbsp;own, directly or indirectly, one percent (1%) or less of a publicly-traded entity that has a market capitalization of
$1&nbsp;billion or more; (ii)&nbsp;own, directly or indirectly, five percent (5%) or less of a publicly-traded entity that has a market capitalization of less than $1&nbsp;billion; or (iii)&nbsp;own, directly or indirectly, less than ten percent
(10%) of a privately-held business or company, if Employee is at all times a passive investor with no board representation, management authority or other special rights to control operations of such business or company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>GENERAL RELEASE OF CLAIMS </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. C. Marc Richards (&#147;<U>Employee</U>&#148;), for himself or herself and his or her family, heirs, executors, administrators, legal
representatives and their respective successors and assigns, in exchange for the consideration received pursuant to <U>Section</U><U></U><U>&nbsp;4</U>.[&#9679;] of that certain Employment Agreement, dated as of September&nbsp;27, 2020, by and
between Employee and Employer, to which this release is attached as <U>Exhibit</U><U></U><U>&nbsp;B</U> (the &#147;<U>Employment Agreement</U>&#148;), does hereby release and forever discharge MEDNAX Services, Inc. (&#147;<U>Employer</U>&#148;), its
subsidiaries, affiliated companies, successors and assigns, and its current or former directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the &#147;<U>Released Parties</U>&#148;) from any and all
actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or
in connection with Employee&#146;s employment or termination thereof, whether for discrimination, harassment, retaliation, tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or
defamation or injuries incurred on the job or incurred as a result of loss of employment. Employee acknowledges that Employer encouraged Employee to consult with an attorney of Employee&#146;s choosing, and through this General Release of Claims
encourages Employee to consult with Employee&#146;s attorney with respect to possible claims under the Age Discrimination in Employment Act (&#147;<U>ADEA</U>&#148;) and that Employee understands that the ADEA is a Federal statute that, among other
things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that Employee may have
as of the date hereof. Employee further understands that by signing this General Release of Claims Employee is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1
that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i)&nbsp;any actions to enforce rights to receive any payments or benefits which
may be due Employee pursuant to <U>Section</U><U></U><U>&nbsp;4</U>.[&#9679;] of the Employment Agreement, or under any of Employer&#146;s employee benefit plans, (ii)&nbsp;any rights or claims that may arise as a result of events occurring after
the date this General Release of Claims is executed, (iii)&nbsp;any indemnification rights Employee may have as a former officer or director of Employer or its subsidiaries or affiliated companies, (iv)&nbsp;any claims for benefits under any
directors&#146; and officers&#146; liability policy maintained by Employer or its subsidiaries or affiliated companies in accordance with the terms of such policy, (v)&nbsp;any rights as a holder of equity securities of Employer, (vi)&nbsp;any
claims that cannot be waived as a matter of law, (vii)&nbsp;any claims Employee may have to government-sponsored and administered benefits such as unemployment insurance, workers&#146; compensation insurance (excluding claims for retaliation under
workers&#146; compensation laws), state disability insurance, and paid family leave benefits, and (viii)&nbsp;any benefits that vested on or prior to the termination date pursuant to a written benefit plan sponsored by Employer and governed by the
federal law known as &#147;ERISA&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Employee represents that Employee has not filed against the Released Parties any
complaints, charges, or lawsuits arising out of Employee&#146;s employment, or any other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that Employee will never individually or with any person
file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a
&#147;<U>Proceeding</U>&#148;), provided, however, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived Employee&#146;s rights under ADEA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement or any other agreement between Employer and Employee
shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any
investigation by any such federal government agency; however, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary relief or other
individual remedies, provided that, for purposes of clarity, this limitation on monetary recovery does not apply to whistleblower proceedings before the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Employee hereby acknowledges that Employer has informed Employee that Employee has up to <FONT STYLE="white-space:nowrap">twenty-one</FONT>
(21)&nbsp;days to sign this General Release of Claims and Employee may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this General Release of Claims earlier. Employee also
understands that Employee shall have seven (7)&nbsp;days following the date on which Employee signs this General Release of Claims within which to revoke it by providing a written notice of Employee&#146;s revocation to Employer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Employee acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal
laws of the State of Florida applicable to contracts made and to be performed entirely within such State. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Employee acknowledges that
Employee has read this General Release of Claims, that Employee has been advised that Employee should consult with an attorney before Employee executes this general release of claims, and that Employee understands all of its terms and executes it
voluntarily and with full knowledge of its significance and the consequences thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. This General Release of Claims shall take effect
on the eighth day following Employee&#146;s execution of this General Release of Claims unless Employee&#146;s written revocation is delivered to Employer within seven (7)&nbsp;days after such execution. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>d44327dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is made and entered into by and between <B>MEDNAX
SERVICES, INC.</B>, a Florida corporation (&#147;<U>Employer</U>&#148;), and Dominic J. Andreano (&#147;<U>Employee</U>&#148;) effective as of September&nbsp;27, 2020 (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>Employer is presently engaged in &#147;Employer&#146;s Business&#148; as defined on <U>Exhibit</U><U></U><U>&nbsp;A</U>
hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employer desires to continue employing Employee and benefit from Employee&#146;s contributions to Employer; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employer and Employee previously entered in an Amended and Restated Employment Agreement dated February&nbsp;13, 2020, as
amended, which will be superseded in its entirety upon the execution of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the
mutual covenants and premises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employer and Employee hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. Employment. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1
<I>Employment and Term</I>. Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer on the terms and conditions set forth herein for an &#147;<U>Initial Term</U>&#148; commencing as of the Effective Date and continuing
for a period of three (3)&nbsp;years, unless sooner terminated as hereinafter set forth. Thereafter, the employment of Employee hereunder shall automatically renew for successive one (1)&nbsp;year periods until terminated in accordance herewith. The
Initial Term and any automatic renewals shall be referred to as the &#147;<U>Employment Period</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 <I>Duties of Employee</I>.
As of the Effective Date and thereafter during the remaining Employment Period, Employee shall serve as Executive Vice President, General Counsel and Secretary of Employer and MEDNAX, Inc., a Florida corporation and the parent corporation of
Employer (&#147;<U>MEDNAX</U>&#148;), and perform such duties as are customary to the position Employee holds or as may be assigned to Employee from time to time by the most senior executive officer of MEDNAX (&#147;<U>Employee&#146;s
Supervisor</U>&#148;) or the Board of Directors of MEDNAX (the &#147;<U>Board</U>&#148;) including, but not limited to, also serving as an officer and/or director, or equivalent, of subsidiaries and/or affiliates of MEDNAX; <I>provided, </I>that
such duties as assigned shall be customary to Employee&#146;s role as an executive officer of Employer and MEDNAX. Employee&#146;s employment shall be full-time and, as such, Employee agrees to devote substantially all of Employee&#146;s attention
and professional time to the business and affairs of Employer and MEDNAX. Employee shall perform Employee&#146;s duties honestly, diligently, competently, in good faith and in the best interest of Employer and MEDNAX. During the Employment Period,
Employee agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably withheld), serve as a director on a corporate board of directors </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or in any other similar capacity for any institution other than Employer and MEDNAX, and their respective subsidiaries and affiliates in accordance with this
<U>Section</U><U></U><U>&nbsp;1.2</U>. During the Employment Period, it shall not be a violation of this Agreement to (i)&nbsp;serve on civic or charitable boards or committees, or (ii)&nbsp;deliver lectures, fulfill speaking engagements or teach at
educational institutions, so long as such activities have been approved by Employee&#146;s Supervisor and do not interfere with the performance of Employee&#146;s responsibilities as an employee of Employer in accordance with this Agreement,
including the restrictions of <U>Section</U><U></U><U>&nbsp;8</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 <I>Place of Performance</I>. Employee shall be based at
Employer&#146;s offices located in Sunrise, Florida, except for required travel relating to Employer&#146;s Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. Base Salary
and Performance Bonus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <I>Base Salary</I>. Employer shall pay Employee during the Employment Period an annual salary of Five
Hundred Thousand Dollars ($500,000) (the &#147;<U>Base Salary</U>&#148;), payable in accordance with Employer&#146;s normal business practices for senior executives (including tax withholding), but in no event less frequently than monthly.
Employee&#146;s Base Salary shall be reviewed at least annually by the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;) and may be increased in its discretion. After any such increase in Base Salary, the term
&#147;<U>Base Salary</U>&#148; shall refer to the increased amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <I>Performance Bonus</I>. Employee shall be eligible to receive a
cash bonus (the &#147;<U>Performance Bonus</U>&#148;) for each year (or prorated with respect to any partial years of employment) during the Employment Period, provided that, except as otherwise provided herein, Employee has remained employed by
Employer as of the end of the applicable year (or as of the end of the Employment Period for the final calendar year of the Employment Period). Employee&#146;s target bonus opportunity for any particular year (&#147;<U>Target Bonus</U>&#148;) shall
be one hundred percent (100%) of Base Salary. The amount of bonus payable to Employee for any particular year will be determined by the Compensation Committee, in its sole discretion, taking into account the performance of Employer and Employee for
that particular year (or portion thereof). All such bonuses shall be paid no later than March 15th of the calendar year immediately following the calendar year in which it is earned. Notwithstanding the foregoing, the Performance Bonus with respect
to the 2020 calendar year shall be paid at one hundred percent (100%) of Base Salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Benefits. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <I>Expense Reimbursement</I>. Employer shall promptly reimburse Employee for all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred by Employee during the Employment Period on behalf of or in connection with Employer&#146;s Business pursuant to the reimbursement standards and guidelines of
Employer in effect from time to time, including reimbursement for appropriate professional organizations. Employee shall account for such expenses and submit reasonable supporting documentation in accordance with Employer&#146;s policies in effect
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <I>Employee Benefits</I>. During the Employment Period, Employee shall be entitled to participate in such health,
welfare, disability, retirement savings and other fringe benefit plans and programs (subject to the terms and conditions of such plans and programs) as may be provided from time to time to employees of Employer and to the extent that such plans and
programs are applicable to other similarly situated employees of Employer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <I>Leave Time</I>. During the Employment Period, Employee shall be entitled to paid
vacation and leave days each calendar year in accordance with the leave policies established by Employer from time to time. Any leave time not used during each fiscal year of Employer may be carried over into the next year to the extent permitted by
Employer policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <I>Equity Plans. </I>During the Employment Period, the Chief Executive Officer of MEDNAX shall recommend to the
Compensation Committee that Employee receive, on an annual basis following the Effective Date, and at the same time as other executive officers of Employer, grants of awards (each an &#147;<U>Equity Award</U>&#148;) pursuant to MEDNAX&#146;s Amended
and Restated 2008 Incentive Compensation Plan, as amended (the &#147;<U>2008 Plan</U>&#148;), or any other similar plan adopted by MEDNAX (together with the 2008 Plan, each an &#147;<U>Equity Plan</U>&#148;), with a grant value determined by the
Compensation Committee in the same manner as for other executive officers of Employer. Every Equity Award made to Employee shall be subject to the terms and conditions of this Agreement and the terms of the applicable Equity Plan, and shall be made
subject to an award agreement that is consistent with terms applicable to other executive officers of Employer. Notwithstanding any contrary provision in this Agreement or any Equity Plan then maintained by MEDNAX, if Employee remains continuously
employed with Employer through the date of a Change in Control (as defined in the Equity Plan pursuant to which the Equity Award is issued), then upon such Change in Control (i)&nbsp;all time-based Equity Awards granted to Employee by MEDNAX shall
immediately become fully vested, <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable and (ii)&nbsp;all performance-based Equity Awards for which the applicable performance condition has been met at the time of
such Change in Control shall immediately become fully vested, <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable. For purposes of clarification, the vesting of any performance-based Equity Awards for which the
performance condition has not been met at the time of such Change in Control shall not be accelerated or otherwise modified pursuant to this <U>Section</U><U></U><U>&nbsp;3.4</U> but such Equity Awards may nonetheless be accelerated or otherwise
modified as determined by the Company under the terms of the Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. Termination; Compensation and Benefits Upon Termination.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <I>Termination for Cause</I>. Employer may terminate Employee&#146;s employment under this Agreement for Cause (as defined
below). The termination date for a termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.1</U> shall be the date specified by Employer in a written notice to Employee of finding of Cause. If
Employee&#146;s employment is terminated for Cause, Employer shall pay (i)&nbsp;Employee&#146;s Base Salary through the termination date at the rate in effect at the termination date, (ii)&nbsp;reimbursement for reasonable business expenses incurred
prior to the termination date, subject to Employer policy and the provisions of <U>Section</U><U></U><U>&nbsp;3.1</U> hereof, and (iii)&nbsp;any other benefits that are vested benefits under applicable Employer benefit plans or that are required by
applicable law (the foregoing clauses (i)-(iii), the &#147;<U>Accrued Obligations</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <I>Disability</I>. Employer may terminate Employee&#146;s employment under this
Agreement upon the Disability (as defined below) of Employee. The termination date for a termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U> shall be the date specified by Employer in a notice to Employee. In the
event of Employee&#146;s Disability, (i)&nbsp;Employee shall continue to receive Employee&#146;s Base Salary for ninety (90)&nbsp;days under the Company&#146;s short term disability policy, which may be amended or modified in the Company&#146;s
discretion upon written notice to Employee (the &#147;<U>Initial Disability Period</U>&#148;), and (ii)&nbsp;following such Initial Disability Period, if Employee&#146;s Disability continues, the Company may terminate Employee&#146;s employment
immediately upon written notice. If Employee&#146;s employment is terminated in connection with Employee&#146;s Disability, in addition to the Accrued Obligations and subject to and conditioned on Employee&#146;s compliance with the terms of
<U>Section</U><U></U><U>&nbsp;5</U> hereof, Employee shall be eligible to receive (A)&nbsp;a bonus with respect to Employer&#146;s fiscal year in which the termination date occurs, equal to Employee&#146;s minimum Target Bonus for the year of
termination, multiplied by the number of days in the fiscal year prior to and including the date of termination and divided by three hundred sixty five (365) (a &#147;<U><FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus</U>&#148;) payable
within thirty (30)&nbsp;days of the termination date; and (B)&nbsp;all time-based Equity Awards granted to Employee by MEDNAX prior to termination of Employee&#146;s employment shall immediately become fully vested,
<FONT STYLE="white-space:nowrap">non-forfeitable</FONT> and, if applicable, exercisable, and all performance-based shares awards shall remain outstanding and shall vest based upon actual performance determined at the end of the applicable
performance period (the &#147;<U>Equity Acceleration</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <I>Death</I>. Employee&#146;s employment under this Agreement shall
terminate automatically upon the death of Employee, without any requirement of notice by Employer to Employee&#146;s estate. The date of Employee&#146;s death shall be the termination date for a termination of Employee&#146;s employment under this
Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.3</U>. Upon Employee&#146;s death during the Employment Period, Employer shall pay or provide to the person or entity designated by Employee in a notice filed with Employer or, if no person
is designated, to Employee&#146;s estate (i)&nbsp;the Accrued Obligations; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus; and (iii)&nbsp;the Equity Acceleration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <I>Termination by Employer Without Cause</I>. Employer may terminate Employee&#146;s employment under this Agreement without Cause by
giving Employee written notice of such termination. The termination date shall be the date specified by Employer in such notice, which may be up to ninety (90)&nbsp;days from the date of such notice. Upon any termination of Employee&#146;s
employment without Cause pursuant to this <U>Section</U><U></U><U>&nbsp;4.4</U>, in addition to the Accrued Obligations and subject to and conditioned on Employee&#146;s compliance with the terms of <U>Section</U><U></U><U>&nbsp;5</U> hereof,
Employee shall be eligible to receive: (i)&nbsp;a <FONT STYLE="white-space:nowrap">Pro-Rated</FONT> Bonus; (ii)&nbsp;severance payments equivalent to Employee&#146;s monthly Base Salary for a period of twenty-four (24)&nbsp;months after the
termination date (the &#147;<U>Severance Period</U>&#148;), payable in installments in Employer&#146;s normal payroll; (iii)&nbsp;continuation of health, medical, hospitalization and other similar health insurance programs on the same basis as
regular, full-time employees of Employer and their eligible dependents during the Severance Period (or, at Employer&#146;s option, Employer may provide health insurance to Employee and Employee&#146;s eligible dependents through an insurance
carrier(s) selected by Employer in lieu of providing the foregoing coverage, provided the coverage afforded by such insurance is substantially comparable to the foregoing coverage, and Employee shall pay the cost of such insurance up to the amount
that would have been paid by Employee under the foregoing coverage and Employer shall pay the excess cost, if any); and (iv)&nbsp;an amount equal to the greater of (A) 1.5 times Employee&#146;s Average Annual Performance Bonus (as defined below) or
(B) 1.5 times Employee&#146;s Target Bonus amount, payable within thirty (90)&nbsp;days of the termination date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <I>Termination by Employee without Good Reason</I>. Employee may terminate
Employee&#146;s employment under this Agreement without Good Reason (as defined below) upon not less than ninety (90)&nbsp;days prior written notice to Employer. Upon receipt of such notice from Employee, Employer may, at its option, accelerate the
effective date of Employee&#146;s termination of employment at any time in advance of the expiration of such ninety (90)&nbsp;day period (which acceleration shall not constitute Good Reason or a termination by Employer without Cause). The
termination date under this <U>Section</U><U></U><U>&nbsp;4.5</U> shall be the date specified by Employer, but in no event more than ninety (90)&nbsp;days after Employer&#146;s receipt of notice from Employee as contemplated by this
<U>Section</U><U></U><U>&nbsp;4.5</U>. Upon any termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.5</U>, Employee shall be entitled to the Accrued Obligations; provided, however, that if
Employee provides notice of termination without Good Reason within ninety (90)&nbsp;days prior to the second (2nd) anniversary of the Effective Date, then Employee shall be eligible to receive the same payments and benefits, subject to the same
conditions, for a termination without Cause as set forth in <U>Section</U><U></U><U>&nbsp;4.4</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <I>Termination by Employee
for Good Reason.</I> Employee may terminate Employee&#146;s employment hereunder for Good Reason. If Employee desires to terminate Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U>, Employee must,
within ninety (90)&nbsp;days after the occurrence of events giving rise to the Good Reason, provide Employer with a written notice describing the Good Reason in reasonable detail. If Employer fails to cure the matter cited within thirty
(30)&nbsp;days after the date of Employee&#146;s notice, then this Agreement shall terminate as of the end of such thirty (30)&nbsp;day cure period, provided, however, that Employer may, at its option, require Employee to terminate employment at any
time in advance of the expiration of such thirty (30)&nbsp;day cure period. If Employee&#146;s employment under this Agreement is terminated pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U>, then Employee shall be eligible to receive the same
payments and benefits, subject to the same conditions, for a termination without Cause as set forth in <U>Section</U><U></U><U>&nbsp;4.4</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <I>Continuation of Benefit Plans</I>. Following any termination that results in the expiration of Employee&#146;s continued benefit plan
coverage, Employee and each of Employee&#146;s eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to COBRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <I>Continuing Obligations</I>. The obligations imposed on Employee with respect to
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and assignment of rights to inventions or developments in this
Agreement or any other agreement executed by the parties shall continue, notwithstanding the termination of the employment relationship between the parties and regardless of the reason for such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. Conditions to Severance; Certain Definitions. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <I>Release. </I>Employer shall provide Employee with a general release in the form attached as <U>Exhibit</U><U></U><U>&nbsp;B</U>
(subject to such modifications as Employer may reasonably request) (the &#147;<U>Release</U>&#148;) within seven (7)&nbsp;days after Employee&#146;s termination date. Payments or benefits to which Employee may be entitled pursuant to
<U>Section</U><U></U><U>&nbsp;4</U> hereof (other than the Accrued Obligations) (the &#147;<U>Severance Amounts</U>&#148;) shall be conditioned upon (i)&nbsp;Employee executing the Release within twenty one (21)&nbsp;days after receiving it from
Employer (or such longer period as may be set forth </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the Release) and the Release becoming irrevocable upon the expiration of seven (7)&nbsp;days following Employee&#146;s execution of it, (ii)&nbsp;Employee agreeing to submit to a reasonable
exit interview if requested by Employer, and (iii)&nbsp;Employee&#146;s compliance with all post-termination obligations to Employer and its subsidiaries and affiliates and surrendering to Employer all proprietary or confidential information and
articles belonging to Employer or its subsidiaries or affiliates. Payment of the Severance Amounts shall be suspended during the period (the &#147;<U>Suspension Period</U>&#148;) that begins on Employee&#146;s termination date and ends on the date
(&#147;<U>Suspension Termination Date</U>&#148;) that is at least forty-five (45)&nbsp;days after Employee&#146;s termination date; provided, however, that this suspension shall not apply, and Employer shall be required to provide, any continued
health insurance coverage (or COBRA reimbursement) that would be required under <U>Section</U><U></U><U>&nbsp;4</U> hereof during the Suspension Period. If Employee executes the Release and the Release becomes irrevocable by no later than the
Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll period that follows the Suspension Termination Date, and any Severance Amounts that are payable
after the Suspension Termination Date shall be paid at the times provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <I>Certain
Definitions</I>. As used in this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Average Annual Performance Bonus</U>&#148; shall mean an amount equal to the
average of the percentage of the Performance Bonus target achieved by Employee for the three (3)&nbsp;full calendar years prior to the termination date (or such lesser period as Employee may have been employed by Employer), and calculated based on
Employee&#146;s Base Salary and Target Bonus in Employee&#146;s current position. For illustration purposes, if Employee earned 40%, 100% and 70% of Employee&#146;s Target Bonus in each of the three full calendar years prior to termination, and
Employee&#146;s current Target Bonus was 100% of Base Salary, and Base Salary was $450,000.00, then Employee&#146;s Average Annual Performance Bonus would equal $315,000.00. ((40%+ 100% + 70%) / 3 x 100% x $450,000.00 = $315,000.00). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Cause</U>&#148; shall mean the occurrence of any of: (i)&nbsp;Employee&#146;s engagement in (A)&nbsp;willful misconduct resulting
in material harm to MEDNAX or Employer, or (B)&nbsp;gross negligence; (ii)&nbsp;Employee&#146;s conviction of, or pleading nolo contendere to, a felony or any other crime involving fraud, financial misconduct, or misappropriation of Employer&#146;s
assets; (iii)&nbsp;Employee&#146;s willful and continual failure, after written notice from Employee&#146;s Supervisor or the Board to (A)&nbsp;perform substantially Employee&#146;s employment duties consistent with Employee&#146;s position and
authority, or (B)&nbsp;follow, consistent with Employee&#146;s position, duties, and authorities, the reasonable lawful mandates of Employee&#146;s Supervisor or the Board; (iv)&nbsp;Employee&#146;s failure or refusal to comply with a reasonable
policy, standard or regulation of Employer in any material respect, including but not limited to Employer&#146;s sexual harassment, other unlawful harassment, workplace discrimination or substance abuse policies; or (v)&nbsp;Employee&#146;s breach
of <U>Section</U><U></U><U>&nbsp;8.4</U> hereof resulting in material harm to MEDNAX or Employer. No act or omission shall be deemed willful or grossly negligent for purposes of this definition if taken or omitted to be taken by Employee in a good
faith belief that such act or omission to act was in the best interests of Employer or MEDNAX or if done at the express direction of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Subject to the requirements of applicable law, &#147;<U>Disability</U>&#148; shall mean
(i)&nbsp;Employee&#146;s inability to perform Employee&#146;s duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii)&nbsp;a determination by an independent qualified physician
selected by Employer and acceptable to Employee (which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an
additional ninety (90)&nbsp;or more days in any one hundred twenty (120)&nbsp;day period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Good Reason</U>&#148; shall mean:
(i)&nbsp;a decrease in Employee&#146;s Base Salary; (ii)&nbsp;a decrease in Employee&#146;s Target Bonus opportunity; (iii)&nbsp;Employee is assigned any position, duties, responsibilities or compensation that is inconsistent with the position,
duties, or responsibilities of Employee contemplated herein as of the Effective Date or compensation of Employee as of the Effective Date, excluding for this purpose any isolated, insubstantial and inadvertent action not taken in bad faith and which
is remedied by Employer promptly after receipt of written notice; (iv)&nbsp;Employee experiences a material diminution in Employee&#146;s authorities, duties or responsibilities, excluding for this purpose any isolated and inadvertent action not
taken in bad faith and which is remedied by Employer promptly after receipt of written notice; (v)&nbsp;Employee is required to report to any person other than the senior most executive officer of MEDNAX, the Board, or a duly constituted committee
thereof, or there is a material diminution in the authority, duties or responsibilities of the senior most executive officer of MEDNAX; (vi)&nbsp;the requirement by Employer that Employee be based in any office or location outside of the
metropolitan area where Employee resides as of the Effective Date, except for travel reasonably required in the performance of Employee&#146;s duties; (vii)&nbsp;if following a Change in Control (as defined in the 2008 Plan as of the Effective
Time), neither the common stock of MEDNAX nor the common equity of its successor, parent, or subsidiary is listed for trading on a national securities exchange, or (viii)&nbsp;any other action or inaction that constitutes a material breach of this
Agreement by Employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. Successors; Binding Agreement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <I>Successors</I>. Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise)
acquiring a majority of Employer&#146;s voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same manner and to the same
extent that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment. In such event, &#147;<U>Employer</U>&#148; shall mean Employer as previously defined and any successor to
its business and/or assets which executes and delivers the agreement provided for in this <U>Section</U><U></U><U>&nbsp;6</U> or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law. This
<U>Section</U><U></U><U>&nbsp;6.1</U> shall not limit Employee&#146;s ability to terminate this Agreement in the circumstances described in <U>Section</U><U></U><U>&nbsp;4.6</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <I>Benefit</I>. This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by
Employee&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Employee should die after the termination date and amounts would have been payable to Employee under this
Agreement if Employee had continued to live, including under <U>Section</U><U></U><U>&nbsp;5</U> hereof, then such amounts shall be paid to Employee&#146;s devisee, legatee, or other designee or, if there is no such designee, Employee&#146;s estate.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Conflicts</B>. Except as otherwise provided in this Agreement, this Agreement
constitutes the entire agreement among the parties pertaining to the subject matter hereof, and supersedes and revokes any and all prior or existing agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be
solely determinative of the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. Restrictive Covenants; Confidential Information; Work Product; Injunctive
Relief. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 <I>No Material Competition</I>. Employer and Employee acknowledge and agree that a strong relationship and connection
exists between Employer and its current and prospective patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services. Employer and Employee further acknowledge and agree that
the restrictive covenants described in this Section are designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the following:
(1)&nbsp;the use and disclosure of the Confidential Information as described in <U>Section</U><U></U><U>&nbsp;8.4</U> hereof; (2)&nbsp;the professional development activities described in <U>Section</U><U></U><U>&nbsp;1.2</U> hereof; and
(3)&nbsp;the goodwill of Employer, as promoted by Employee as provided in <U>Section</U><U></U><U>&nbsp;1.2</U> hereof. The foregoing listing is by way of example only and shall not be construed to be an exclusive or exhaustive list of such
interests. Employee acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to Employer in agreeing to the terms of this Agreement. Employee further acknowledges that the
goodwill and other proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer in violation of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of Employer, <B>Employee shall
not</B>, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly participate or engage in or own an
interest in, directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee,
consultant, independent contractor, stockholder, lender, landlord, finder, agent, broker, trustee, or in any manner whatsoever, if such entity or its affiliates is engaged in, directly or indirectly, &#147;<U>Employer&#146;s Business</U>,&#148; as
defined on <U>Exhibit</U><U></U><U>&nbsp;A</U> hereto. Employee acknowledges that, as of the date hereof, Employee&#146;s responsibilities will include matters affecting the businesses of Employer listed on <U>Exhibit</U><U></U><U>&nbsp;A</U>. For
purposes of this <U>Section</U><U></U><U>&nbsp;8</U>, the &#147;<U>Restricted Period</U>&#148; shall mean the Employment Period plus (i)&nbsp;eighteen (18)&nbsp;months in the event this Agreement is terminated pursuant to
<U>Section</U><U></U><U>&nbsp;4.1</U> hereof, and (ii)&nbsp;twenty-four (24)&nbsp;months in the event the Agreement is terminated for any other reason. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <I>No Hire</I>. Employee further agrees that <B>Employee shall not</B>, at any time
during the Employment Period and for a period of eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer,
intentionally, knowingly, or willingly employ, or intentionally, knowingly, or willingly permit any company or business directly or indirectly controlled by Employee to (a)&nbsp;employ or otherwise engage (i)&nbsp;any person who is a then current
employee or exclusive independent contractor of Employer or one of its affiliates, or (ii)&nbsp;any person who was an employee or exclusive independent contractor of Employer or one of its affiliates in the prior six (6)&nbsp;month period, or
(b)&nbsp;take any action that would reasonably be expected to induce an employee or independent contractor of Employer or one of its affiliates to leave his or her employment or engagement with Employer or one of its affiliates (including without
limitation for or on behalf of a subsequent employer of Employee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <I><FONT STYLE="white-space:nowrap">Non-Solicitation.</FONT>
</I>Employee further agrees that <B>Employee shall not</B>, at any time during the Employment Period and for a period of eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any
other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly solicit or accept business from or take any action that would reasonably be expected to materially interfere with, diminish or impair the
valuable relationships that Employer or its affiliates have with (i)&nbsp;hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional services or otherwise have established relationships,
(ii)&nbsp;patients, (iii)&nbsp;referral sources, (iv)&nbsp;vendors, (v)&nbsp;any other clients of Employer or its affiliates, or (vi)&nbsp;prospective hospitals, patients, referral sources, vendors or clients whose business Employee was aware that
Employer or any affiliate of Employer was in the process of soliciting at the time of Employee&#146;s termination (including potential acquisition targets). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4 <I>Confidential Information</I>. At all times during the term of this Agreement, Employer shall provide Employee with access to
&#147;<U>Confidential Information</U>.&#148; As used in this Agreement, the term &#147;<U>Confidential Information</U>&#148; means any and all confidential, proprietary or trade secret information, whether disclosed, directly or indirectly,
verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by Employee, applicable to or in any way related to: (i)&nbsp;patients with whom Employer has a physician/patient relationship;
(ii)&nbsp;the present or future business of Employer; or (iii)&nbsp;the research and development of Employer. Without limiting the generality of the foregoing, Confidential Information includes: (a)&nbsp;the development and operation of
Employer&#146;s medical practices, including information relating to budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and other information concerning such facilities and operations and specifically
including the procedures and business plans developed by Employer for use at the hospitals where Employer conducts its business; (b)&nbsp;contractual arrangements between Employer and insurers or managed care associations or other payors;
(c)&nbsp;the databases of Employer; (d)&nbsp;the clinical and research protocols of Employer, including coding guidelines; (e)&nbsp;the referral sources of Employer; (f)&nbsp;other confidential information of Employer that is not generally known to
the public that gives Employer the opportunity to obtain an advantage over competitors who do not know or use it, including the names, addresses, telephone numbers or special needs of any of its patients, its patient lists, its marketing methods and
related data, lists or other written records used in Employer&#146;s business, compensation paid to employees and other terms of employment, accounting ledgers and financial statements, contracts and licenses, business systems, business plan and
projections, and computer programs. The parties agree that, as between them, this Confidential Information constitutes important, material, and confidential trade secrets that affect the successful conduct of Employer&#146;s business and its
goodwill. Employer acknowledges that the Confidential Information specifically enumerated above is special and unique information and is not information that would be considered a part of the general knowledge and skill Employee has or might
otherwise obtain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Confidential Information shall not include any information
that (i)&nbsp;was known by Employee from a third party source before disclosure by or on behalf of Employer, (ii)&nbsp;becomes available to Employee from a source other than Employer that is not, to Employee&#146;s knowledge, bound by a duty of
confidentiality to Employer, (iii)&nbsp;becomes generally available or known in the industry other than as a result of its disclosure by Employee, or (iv)&nbsp;has been independently developed by Employee and may be disclosed by Employee without
breach of this Agreement, provided, in each case, that Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions. Pursuant to the Defend Trade Secrets Act of 2016, Employee acknowledges
that Employee shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A)&nbsp;is made (i)&nbsp;in confidence to a federal, state, or local government official, either directly
or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal. In addition, if Employee files a lawsuit for retaliation by Employer for reporting a suspected violation of law, Employee may disclose the trade secret to Employee&#146;s attorney and may use the trade secret information in the court
proceeding, if Employee (X)&nbsp;files any document containing the trade secret under seal and (Y)&nbsp;does not disclose the trade secret, except pursuant to court order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, notwithstanding anything herein to the contrary, nothing in this Agreement or any other agreement between Employer and Employee
shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any
investigation by any such federal government agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Unless disclosure is otherwise required by applicable law or stock exchange rules,
Employee agrees that the terms of this Agreement shall be deemed Confidential Information for purposes of this Section. Employee shall keep the terms of this Agreement strictly confidential and will not, without the prior written consent of
Employer, disclose the details of this Agreement to any third party in any manner whatsoever in whole or in part, with the exception of Employee&#146;s representatives (such as tax advisors and attorneys) who need to know such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Employee agrees that Employee will not at any time, whether during or subsequent to the term of Employee&#146;s employment with Employer, in
any fashion, form or manner, unless specifically consented to in writing by Employer, either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any manner whatsoever, any Confidential Information
of any kind, nature, or description, subject to applicable law. The parties agree that any breach by Employee of any term of this <U>Section</U><U></U><U>&nbsp;8.4</U> resulting in material harm to MEDNAX or Employer is a material breach of this
Agreement and shall constitute &#147;<U>Cause</U>&#148; for the termination of Employee&#146;s employment hereunder pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U> hereof. In the event that Employee is ordered to disclose any Confidential
Information, whether in a legal or a regulatory proceeding or otherwise, Employee shall provide Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
achieved, the entry of a protective order or other appropriate protective device or procedure in order to assure, to the extent practicable, compliance with the provisions of this Agreement. In
the case of any disclosure required by law, Employee shall disclose only that portion of the Confidential Information that Employee is ordered to disclose in a legally binding subpoena, demand or similar order issued pursuant to a legal or
regulatory proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All Confidential Information, and all equipment, notebooks, documents, memoranda, reports, files, samples, books,
correspondence, lists, other written and graphic records, in any media (including electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct, observe, possess, or
control shall be and remain Employer&#146;s sole property (collectively &#147;<U>Employer Property</U>&#148;). Upon termination or expiration of this Agreement, or earlier upon Employer&#146;s request, Employee shall promptly deliver to Employer all
Employer Property, retaining none. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5 <I>Ownership of Work Product.</I> Employee agrees and acknowledges that (i)&nbsp;all copyrights,
patents, trade secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by Employee during the course
of performing work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employer&#146;s Business (collectively, the &#147;<U>Work
Product</U>&#148;), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code. To the extent the Work Product may not be considered a work made
for hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further consideration. Upon request of Employer,
Employee shall take such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate assignments of all right, title, and interest in
and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements, additions to, or modifications thereto, which
Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employer&#146;s successors and assigns, as fully and as entirely as the same might be held by
Employee had this assignment not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6 <I>Clearance Procedure for Proprietary Rights Not Claimed by Employer.</I> In the event
that Employee wishes to create or develop, <I>other than</I> on Employer&#146;s time or using Employer&#146;s resources, anything that may be considered Work Product but to which Employee believes Employee should be entitled to the personal benefit
of, Employee agrees to follow the clearance procedure set forth in this Section. Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a sufficiently detailed written description of the
work under consideration for Employer to make a determination regarding the work. Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of confidentiality with respect to such request or
description. Employer will determine in its sole discretion, within thirty (30)&nbsp;days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by Employer. If Employer determines that it does not
claim rights in such work, Employer agrees to so notify Employee in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
writing and Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer. If Employer fails to so notify Employee within such thirty
(30)&nbsp;day period, then Employer shall be deemed to have agreed that such work is not considered Work Product for purposes of this Agreement. Employee agrees to submit for further review any significant improvement, modification, or adaptation
that could reasonably be related to Employer&#146;s Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer. Clearance under this procedure does not relieve Employee
of the restrictive covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7
<I><FONT STYLE="white-space:nowrap">Non-Disparagement.</FONT> </I>During the Employment Period and for a period of ten (10)&nbsp;years after the termination of this Agreement, Employee will not, directly or indirectly, as an individual or on behalf
of a firm, corporation, partnership or other legal entity, intentionally, knowingly, or willingly make any comment that would reasonably be expected to be materially disparaging or negative to any other person or entity regarding Employer or any of
its affiliates, agents, attorneys, employees, officers and directors, Employee&#146;s work conditions or circumstances surrounding Employee&#146;s separation from Employer or otherwise impugn or criticize the name or reputation of Employer, its
affiliates, agents, attorneys, employees, officers or directors, orally or in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8 <I>Review by Employee.</I> Employee has
carefully read and considered the terms and provisions of this <U>Section</U><U></U><U>&nbsp;8</U>, and having done so, agrees that the restrictions set forth in this <U>Section</U><U></U><U>&nbsp;8</U> are fair and reasonably required for the
protection of the interests of Employer. In the event that any term or provision set forth in this <U>Section</U><U></U><U>&nbsp;8</U> shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that
such invalid or unenforceable term(s) or provision(s) may be severed from this Agreement without, in any manner, affecting the remaining portions hereof. Without limiting other possible remedies available to Employer, Employee agrees that injunctive
or other equitable relief will be available to enforce the covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U>, such relief to be without the necessity of posting a bond. In the event that, notwithstanding the foregoing, any part of the
covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U> shall be held to be invalid, overbroad, or unenforceable by an arbitrator or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable
provision(s) may be modified or severed from this Agreement without, in any manner, affecting the remaining portions of this <U>Section</U><U></U><U>&nbsp;8</U> (all of which shall remain in full force and effect). In the event that any provision of
this <U>Section</U><U></U><U>&nbsp;8</U> related to time period or areas of restriction shall be declared by an arbitrator or a court of competent jurisdiction to exceed the maximum time period, area or activities such arbitrator or court deems
reasonable and enforceable, said time period or areas of restriction shall be deemed modified to the minimum extent necessary to make the geographic or temporal restrictions or activities reasonable and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9 <I>Survival; Notice of Breach and Right to Cure. </I>If Employer reasonably believes that Employee has breached a provision of this
<U>Section</U><U></U><U>&nbsp;8</U>, Employer shall provide prompt written notice thereof to Employee that explains such reasonably believed breach (the &#147;<U>Alleged Breach</U>&#148;). Employer agrees to work in good faith with Employee to
provide Employee a reasonable opportunity to promptly cure such Alleged Breach. In the event that Employee, acting in good faith, promptly takes actions that would reasonably be expected to cure the Alleged Breach, including, with respect to a
comment made by Employee that Employer reasonably believes is in breach of <U>Section</U><U></U><U>&nbsp;8.7</U> hereof, by Employee retracting such comment, then Employee shall be deemed not to be in breach of this
<U>Section</U><U></U><U>&nbsp;8</U> with respect to the Alleged Breach. Employer and Employee further agree that Employee shall not be deemed to be in breach of any term of <U>Section</U><U></U><U>&nbsp;8.4</U> hereof unless such breach results in
material harm to MEDNAX or Employer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> shall survive the termination of
this Agreement and Employee&#146;s employment with Employer. In the event of a breach of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof, Employer retains the right
to terminate any continuing payments to Employee provided for in <U>Section</U><U></U><U>&nbsp;4</U> hereof. In the event of a breach of any provisions of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to
<U>Section</U><U></U><U>&nbsp;11</U> hereof, the period for which those provisions would remain in effect shall be extended for a period of time equal to that period beginning when such breach commenced and ending when the activities constituting
such breach shall have been finally terminated, in each case as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof. The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> are expressly intended to benefit and be
enforceable by other affiliated entities of Employer, who are express third party beneficiaries hereof. Employee shall not assist others in engaging in any of the activities described in the foregoing restrictive covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. Tax Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1
<I>Section 409A</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>In General. </I>The parties intend that this Agreement will be administered in accordance with
Section&nbsp;409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with
Section&nbsp;409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).</FONT> For purposes of
Section&nbsp;409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. The parties agree that this Agreement may be amended, as reasonably requested by either
party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. Employer makes no
representation or warranty and shall have no liability to Employee or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption
from, or the conditions of, Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I><FONT STYLE="white-space:nowrap">Six-Month</FONT> Delay. </I>Anything in this
Agreement to the contrary notwithstanding, if at the time of Employee&#146;s separation from service within the meaning of Section&nbsp;409A of the Code, Employer determines that Employee is a &#147;specified employee&#148; within the meaning of
Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#146;s &#147;separation from service&#148; (within the meaning of Section&nbsp;409A)
that would be considered <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148;, such payment shall not be payable and such benefit shall not be provided until the date that is within fifteen (15)&nbsp;days after the
end of the <FONT STYLE="white-space:nowrap">six-month</FONT> period beginning on the date of such &#147;separation from service&#148; or, if earlier, within fifteen (15)&nbsp;days after the appointment of the personal representative or executor of
Employee&#146;s estate following Employee&#146;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a <FONT STYLE="white-space:nowrap">catch-up</FONT> payment covering amounts that
would otherwise have been paid during the <FONT STYLE="white-space:nowrap">six-month</FONT> period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Reimbursements. </I>All <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by Employer or incurred by Employee during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits provided or
reimbursable expenses incurred in one taxable year shall not affect the <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits is not subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <I>Separation from Service. </I>To the extent that any payment or benefit described in this Agreement constitutes <FONT
STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#146;s termination of employment, then such payments or
benefits shall be payable only upon Employee&#146;s &#147;separation from service&#148; as defined under Section&nbsp;409A. The determination of whether and when a separation from service has occurred shall be made in accordance with the
presumptions set forth in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <I>Later Calendar
Year</I>. To the extent that any payment or benefit described in this Agreement constitutes <FONT STYLE="white-space:nowrap">&#147;non-qualified</FONT> deferred compensation&#148; under Section&nbsp;409A of the Code, and not otherwise exempt from
the application of Section&nbsp;409A, then, if the period during which Employee may consider and sign the Release or the period in which the Employer can make a severance payment spans two calendar years, any payment or benefit described in this
Agreement will not be made or begin until the later calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2 <B><I>Section</I></B><B><I></I></B><B><I>&nbsp;280G</I></B>.
Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer or its affiliates to Employee or for Employee&#146;s benefit
pursuant to the terms of this Agreement or otherwise (the &#147;<U>Covered Payments</U>&#148;) constitute parachute payments (the &#147;<U>Parachute Payments</U>&#148;) within the meaning of Section&nbsp;280G of the Code and, but for this
<U>Section</U><U></U><U>&nbsp;9</U>, would be subject to the excise tax imposed under Section&nbsp;4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to
such taxes (collectively, the &#147;<U>Excise Tax</U>&#148;), then prior to making the Covered Payments, a calculation shall be made comparing (i)&nbsp;the Net Benefit (as defined below) to Employee of the Covered Payments after payment of the
Excise Tax to (ii)&nbsp;the Net Benefit to Employee if the Covered Payments are limited to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (i)&nbsp;above is less than the amount under
(ii)&nbsp;above will the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax (that amount, the &#147;<U>Reduced Amount</U>&#148;). &#147;<U>Net Benefit</U>&#148;
shall mean the present value of the Covered Payments net of all federal, state, local, foreign income, employment and excise taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Any such reduction shall be made in accordance with Section&nbsp;409A and the
following: (i)&nbsp;the Covered Payments consisting of cash severance benefits that do not constitute nonqualified deferred compensation subject to Section&nbsp;409A shall be reduced first, in reverse chronological order; (ii)&nbsp;all other Covered
Payments consisting of cash payments, and Covered Payments consisting of accelerated vesting of equity based awards to which Treas. Reg. &#167; <FONT STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> does
not apply, and that in either case do not constitute nonqualified deferred compensation subject to Section&nbsp;409A, shall be reduced second, in reverse chronological order; (iii)&nbsp;all Covered Payments consisting of cash payments that
constitute nonqualified deferred compensation subject to Section&nbsp;409A shall be reduced third, in reverse chronological order; and (iv)&nbsp;all Covered Payments consisting of accelerated vesting of equity-based awards to which Treas. Reg.
&#167; <FONT STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> applies shall be the last Covered Payments to be reduced. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any determination required under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made in writing in good faith by an independent
accounting firm selected by Employer (the &#147;<U>Accountants</U>&#148;). Employer and Employee shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this
<U>Section</U><U></U><U>&nbsp;9</U>. For purposes of making the calculations and determinations required by this <U>Section</U><U></U><U>&nbsp;9</U>, the Accountants may rely on reasonable, good-faith assumptions and approximations concerning the
application of Section&nbsp;280G and Section&nbsp;4999 of the Code. The Accountants&#146; determinations shall be final and binding on Employer and Employee. Employer shall be responsible for all fees and expenses incurred by the Accountants in
connection with the calculations required by this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) It is possible that after the determinations
and selections made pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, Employee will receive Covered Payments that are in the aggregate more than the amount intended or required to be provided after application of this
<U>Section</U><U></U><U>&nbsp;9</U> (&#147;<U>Overpayment</U>&#148;) or less than the amount intended or required to be provided after application of this <U>Section</U><U></U><U>&nbsp;9</U> (&#147;<U>Underpayment</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event that: (A)&nbsp;the Accountants determine, based upon the assertion of a deficiency by the Internal Revenue
Service against either Employer or Employee that the Accountants believe has a high probability of success, that an Overpayment has been made or (B)&nbsp;it is established pursuant to a final determination of a court or an Internal Revenue Service
proceeding that has been finally and conclusively resolved that an Overpayment has been made, then Employee shall pay any such Overpayment to Employer together with interest at the applicable federal rate (as defined in Section&nbsp;7872(f)(2)(A) of
the Code) from the date of Employee&#146;s receipt of the Overpayment until the date of repayment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) In the event
that: (A)&nbsp;the Accountants, based upon controlling precedent or substantial authority, determine that an Underpayment has occurred or (B)&nbsp;a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment
will be paid promptly by Employer to or for the benefit of Employee together with interest at the applicable federal rate (as defined in Section&nbsp;7872(f)(2)(A) of the Code) from the date the amount should have otherwise been paid to Employee
until the payment date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3 <I>Tax Withholding. </I>All amounts payable under this Agreement shall be subject to
applicable income and employment tax withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Dispute Resolution; Injunctive Relief</B>. If any controversy or claim
arises out of or relating to this Agreement, or any alleged breach hereof, Employee and Employer shall first try to resolve such controversy or claim through mediation using the services of the American Arbitration Association. If any such
controversy or claim cannot be resolved by mediation pursuant to the foregoing, Employee and Employer agree that such controversy or claim shall be finally determined by a single arbitrator, jointly selected by Employee and Employer, provided that
if Employee and Employer are unable to agree upon a single arbitrator after reasonable efforts, the arbitrator shall be an impartial arbitrator selected by the American Arbitration Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employer shall bear all costs associated with such mediation and, if necessary, arbitration, including but not limited to all costs of the
mediator and arbitrator, and shall reimburse Employee on a monthly basis for Employee&#146;s reasonable legal and other expenses, including all fees, incurred in connection with any such mediation and, if necessary, arbitration, provided, however,
that if Employer ultimately prevails in any arbitration (as determined by the arbitrator), the arbitrator shall have the power to require Employee to reimburse Employer for all or a portion of the advanced legal fees and other expenses as determined
by the arbitrator (and, if the arbitrator finds that Employer prevailed on certain claims and Employee prevailed on others, the arbitrator shall have the power to require Employee to reimburse Employer for a portion of the advanced legal fees and
other expenses determined by the arbitrator based on those claims on which Employer prevailed). The mediation and, if necessary, arbitration proceedings shall be held in Sunrise, Florida, unless otherwise mutually agreed by the parties, and shall be
conducted in accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes then in effect. Judgment on any award rendered by the arbitrator may be entered and enforced by any court having jurisdiction
thereof. Any such mediation and, if necessary, arbitration shall be treated as confidential by all parties thereto, except as otherwise provided by law or as otherwise necessary to enforce any judgment or order issued by the arbitrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, if Employer or Employee shall require immediate injunctive relief, then the party shall be
entitled to seek such relief in any court having jurisdiction, and if the party elects to do so, the other party hereby consents to the jurisdiction of the state and federal courts sitting in the State of Florida and to the applicable service of
process. Employee and Employer hereby waive and agree not to assert, to the fullest extent permitted by applicable law, any claim that (i)&nbsp;they are not subject to the jurisdiction of such courts, (ii)&nbsp;they are immune from any legal process
issued by such courts and (iii)&nbsp;any litigation or other proceeding commenced in such courts is brought in an inconvenient forum. In the event that Employer brings suit against Employee seeking injunctive relief, Employer agrees to advance all
of Employee&#146;s reasonable legal and other expenses, including all fees, incurred by Employee in connection with such action, provided, however, that if Employer ultimately prevails in seeking injunctive relief, Employee shall reimburse Employer
all such advanced legal fees and other expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Governing Law</B>. This Agreement shall be governed by and construed in
accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Notices</B>. Any notice required or permitted to be given under this Agreement
shall be in writing and shall be deemed to have been given when (i)&nbsp;delivered by hand, (ii)&nbsp;delivered by electronic mail that is confirmed by <FONT STYLE="white-space:nowrap">non-automated</FONT> means, or (iii)&nbsp;when delivered or
delivery is refused if sent by registered or certified U.S. mail, return receipt requested, postage prepaid, or via reputable overnight courier, addressed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">If to Employer:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">MEDNAX Services, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Sunrise, FL 33323</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">Email: marc_richards@mednax.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Employee:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dominic J. Andreano</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o MEDNAX Services, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sunrise, FL 33323</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: dominic_andreano@mednax.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid manner.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Benefits; Binding Effect</B>. This Agreement shall be for the benefit of and binding upon the parties hereto and their
respective heirs, personal representatives, legal representatives, successors and, where applicable, assigns. Notwithstanding the foregoing, Employee may not assign the rights or benefits hereunder without the prior written consent of Employer. This
Agreement may be assigned by Employer upon notice to Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Severability</B>. The invalidity of any one or more of the
words, phrases, sentences, clauses or sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and,
in the event that any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or
sentences, clause or clauses, or section or sections had not been inserted. If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would
cure such invalidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Waivers</B>. The waiver by either party hereto of a breach or violation of any term or provision of
this Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>Damages</B>. Nothing
contained herein shall be construed to prevent Employer or Employee from seeking and recovering from the other damages sustained by either or both of them as a result of a breach of any term or provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>No Third Party Beneficiary</B>. Except as provided in <U>Section</U><U></U><U>&nbsp;8.9</U> hereof, nothing expressed or implied
in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employee&#146;s heirs, personal representative(s) and/or legal representative) any rights or
remedies under or by reason of this Agreement. No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement which agreements or representations are not
set forth expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The
remainder of this page has been left blank intentionally. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have executed this Agreement effective as of the
Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYER:</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>MEDNAX SERVICES, INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Mark S. Ordan</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Dominic J. Andreano</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mark S. Ordan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dominic J. Andreano</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Shirley A. Weis</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shirley A. Weis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chair, Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Amended and Restated Employment Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS OF EMPLOYER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of the date hereof, Employer, directly or through its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively
referred to herein as &#147;<U>Employer&#146;s Business</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) Neonatology, including hospital well baby care; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) Maternal-Fetal Medicine, including Obstetrical Hospitalist Care; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Pediatric Cardiology; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4)
Pediatric Intensive Care, including Pediatric Hospitalist Care; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5) Newborn hearing screening services; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(6) Pediatric Surgery; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(7)
Pediatric Emergency Medicine; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(8) Radiology and Teleradiology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to Employer&#146;s Business in this Agreement shall include such other medical service lines, practice management services and
other businesses in which Employer is engaged during the Employment Period; <I>provided,</I> that to be considered a part of Employer&#146;s Business, Employer must have engaged in such other service line, practice management service or other
business at least six (6)&nbsp;months prior to the termination date of this Agreement. For purposes of this <U>Exhibit</U><U></U><U>&nbsp;A</U>, businesses of Employer shall include the businesses conducted by Employer&#146;s subsidiaries, entities
under common control and affiliates as defined under Rule 144 of the Securities Act of 1933, as amended. Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for
financial reporting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Employer acknowledges and agrees to the following exceptions and
clarifications regarding the scope of Employer&#146;s Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <I>Hospital Services. </I>Employer and Employee acknowledge that, as
of the date hereof, Employer does not currently operate hospitals, hospital systems or universities. Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as Employer&#146;s Business where such hospitals,
hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employer&#146;s Business. Therefore, the parties desire to clarify their intent with respect to the limitations on
Employee&#146;s ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period. <U>Section</U><U></U><U>&nbsp;8.1</U> shall not be deemed to
restrict Employee&#146;s ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included in Employer&#146;s Business. Furthermore, even if a hospital,
hospital system or university provides medical services that are included in Employer&#146;s Business, Employee may work for such hospital, hospital system or university if Employee has no direct supervisory responsibility for or involvement in the
hospital&#146;s, hospital system&#146;s or university&#146;s provision of medical services that are Employer&#146;s Business. For the avoidance of doubt, Employer and Employee agree that if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employee becomes the Chief Operating Officer, Chief Legal Officer, General Counsel or Chief Executive Officer of a hospital system or health system, or other executive officer of similar level to
the foregoing, that Employee shall not be in breach of the provisions of this Agreement. Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be involved in the medical services of a hospital, hospital system or
university that are included in Employer&#146;s Business so long as such hospital, hospital system or university is located at least ten (10)&nbsp;miles from a medical practice owned or operated by Employer or its affiliate. Subject to paragraph B
below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <I>De Minimus Exception. </I>Employer agrees that a medical service line (other than those listed in items (1)&nbsp;through (8) above),
practice management service or other business in which Employer is engaged shall not be considered to be a part of Employer&#146;s Business if such medical service line, practice management service or other business constitutes less than three
percent (3%) of Employer&#146;s annual revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. <I>Divested Lines of Service. </I>Employer agrees that any medical service line
(including those listed in items (1)&nbsp;through (8) above), practice management, or other business in which Employer is engaged that is divested pursuant to a disposition, sale of assets or equity, or otherwise after the Effective Date shall not
be considered to be a part of Employer&#146;s Business effective as of the effective date of such divestiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. <I>Certain Ownership
Interests. </I>It shall not be deemed to be a violation of <U>Section</U><U></U><U>&nbsp;8.1</U> for Employee to: (i)&nbsp;own, directly or indirectly, one percent (1%) or less of a publicly-traded entity that has a market capitalization of
$1&nbsp;billion or more; (ii)&nbsp;own, directly or indirectly, five percent (5%) or less of a publicly-traded entity that has a market capitalization of less than $1&nbsp;billion; or (iii)&nbsp;own, directly or indirectly, less than ten percent
(10%) of a privately-held business or company, if Employee is at all times a passive investor with no board representation, management authority or other special rights to control operations of such business or company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>GENERAL RELEASE OF CLAIMS </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Dominic J. Andreano (&#147;<U>Employee</U>&#148;), for himself or herself and his or her family, heirs, executors, administrators, legal
representatives and their respective successors and assigns, in exchange for the consideration received pursuant to <U>Section</U><U></U><U>&nbsp;4</U>.[&#9679;] of that certain Employment Agreement, dated as of September&nbsp;27, 2020, by and
between Employee and Employer, to which this release is attached as <U>Exhibit</U><U></U><U>&nbsp;B</U> (the &#147;<U>Employment Agreement</U>&#148;), does hereby release and forever discharge MEDNAX Services, Inc. (&#147;<U>Employer</U>&#148;), its
subsidiaries, affiliated companies, successors and assigns, and its current or former directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the &#147;<U>Released Parties</U>&#148;) from any and all
actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or
in connection with Employee&#146;s employment or termination thereof, whether for discrimination, harassment, retaliation, tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or
defamation or injuries incurred on the job or incurred as a result of loss of employment. Employee acknowledges that Employer encouraged Employee to consult with an attorney of Employee&#146;s choosing, and through this General Release of Claims
encourages Employee to consult with Employee&#146;s attorney with respect to possible claims under the Age Discrimination in Employment Act (&#147;<U>ADEA</U>&#148;) and that Employee understands that the ADEA is a Federal statute that, among other
things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that Employee may have
as of the date hereof. Employee further understands that by signing this General Release of Claims Employee is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1
that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i)&nbsp;any actions to enforce rights to receive any payments or benefits which
may be due Employee pursuant to <U>Section</U><U></U><U>&nbsp;4</U>.[&#9679;] of the Employment Agreement, or under any of Employer&#146;s employee benefit plans, (ii)&nbsp;any rights or claims that may arise as a result of events occurring after
the date this General Release of Claims is executed, (iii)&nbsp;any indemnification rights Employee may have as a former officer or director of Employer or its subsidiaries or affiliated companies, (iv)&nbsp;any claims for benefits under any
directors&#146; and officers&#146; liability policy maintained by Employer or its subsidiaries or affiliated companies in accordance with the terms of such policy, (v)&nbsp;any rights as a holder of equity securities of Employer, (vi)&nbsp;any
claims that cannot be waived as a matter of law, (vii)&nbsp;any claims Employee may have to government-sponsored and administered benefits such as unemployment insurance, workers&#146; compensation insurance (excluding claims for retaliation under
workers&#146; compensation laws), state disability insurance, and paid family leave benefits, and (viii)&nbsp;any benefits that vested on or prior to the termination date pursuant to a written benefit plan sponsored by Employer and governed by the
federal law known as &#147;ERISA&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Employee represents that Employee has not filed against the Released Parties any
complaints, charges, or lawsuits arising out of Employee&#146;s employment, or any other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that Employee will never individually or with any person
file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a
&#147;<U>Proceeding</U>&#148;), provided, however, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived Employee&#146;s rights under ADEA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement or any other agreement between Employer and Employee
shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any
investigation by any such federal government agency; however, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary relief or other
individual remedies, provided that, for purposes of clarity, this limitation on monetary recovery does not apply to whistleblower proceedings before the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Employee hereby acknowledges that Employer has informed Employee that Employee has up to <FONT STYLE="white-space:nowrap">twenty-one</FONT>
(21)&nbsp;days to sign this General Release of Claims and Employee may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this General Release of Claims earlier. Employee also
understands that Employee shall have seven (7)&nbsp;days following the date on which Employee signs this General Release of Claims within which to revoke it by providing a written notice of Employee&#146;s revocation to Employer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Employee acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal
laws of the State of Florida applicable to contracts made and to be performed entirely within such State. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Employee acknowledges that
Employee has read this General Release of Claims, that Employee has been advised that Employee should consult with an attorney before Employee executes this general release of claims, and that Employee understands all of its terms and executes it
voluntarily and with full knowledge of its significance and the consequences thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. This General Release of Claims shall take effect
on the eighth day following Employee&#146;s execution of this General Release of Claims unless Employee&#146;s written revocation is delivered to Employer within seven (7)&nbsp;days after such execution. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>d44327dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Mark S. Ordan, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEDNAX, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;6, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>Mark S. Ordan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>d44327dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, C. Marc Richards, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEDNAX, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;6, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>C. Marc Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">C. Marc Richards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Financial Officer)</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>d44327dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to 18 U.S.C Section&nbsp;1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Adopted by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of MEDNAX, Inc. on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
September&nbsp;30, 2020 (the &#147;Report&#148;), each of the undersigned hereby certifies, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that (i)&nbsp;the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d)
of the Securities Exchange Act of 1934 and (ii)&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of MEDNAX, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 has been provided to MEDNAX, Inc. and will be retained by MEDNAX,
Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">November&nbsp;6, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark S. Ordan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>C. Marc Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">C. Marc Richards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Financial Officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>md-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-November-2020 [02:58:04] {AM}-->
<schema targetNamespace="http://www.mednax.com/20200930" elementFormDefault="qualified" xmlns:md="http://www.mednax.com/20200930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.mednax.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
<link:definition>1002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" id="ConsolidatedStatementsOfIncome">
<link:definition>1004 - Statement - Consolidated Statements of Income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" id="ConsolidatedStatementsOfEquity">
<link:definition>1005 - Statement - Consolidated Statements of Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" id="BasisOfPresentationAndNewAccountingPronouncements">
<link:definition>1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" id="CoronavirusPandemicCovid19">
<link:definition>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" id="CashEquivalentsAndInvestments">
<link:definition>1009 - Disclosure - Cash Equivalents and Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1010 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
<link:definition>1011 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations" id="BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations">
<link:definition>1012 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
<link:definition>1013 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
<link:definition>1014 - Disclosure - Common and Common Equivalent Shares</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
<link:definition>1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
<link:definition>1016 - Disclosure - Common Stock Repurchase Programs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" id="BasisOfPresentationAndNewAccountingPronouncementsPolicies">
<link:definition>1018 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" id="CashEquivalentsAndInvestmentsTables">
<link:definition>1019 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1020 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
<link:definition>1021 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables" id="BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables">
<link:definition>1022 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
<link:definition>1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
<link:definition>1024 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" id="BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<link:definition>1025 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" id="CoronavirusPandemicCovid19AdditionalInformationDetail">
<link:definition>1026 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" id="CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<link:definition>1027 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" id="CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<link:definition>1028 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<link:definition>1029 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" id="FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<link:definition>1030 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" id="AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<link:definition>1031 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<link:definition>1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<link:definition>1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail" id="BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail">
<link:definition>1034 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations -  Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail" id="BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail">
<link:definition>1035 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Management Services Service Line (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" id="BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<link:definition>1036 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Discontinued Operations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<link:definition>1037 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" id="AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<link:definition>1038 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<link:definition>1039 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSalariesAndBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSuppliesAndOtherOperatingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" substitutionGroup="xbrli:item" />
<element name="RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesStockSwaps" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodSharesStockSwaps" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueStockSwaps" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodValueStockSwaps" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAbstract" substitutionGroup="xbrli:item" />
<element name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockRepurchasesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CommonStockRepurchasesTextBlock" substitutionGroup="xbrli:item" />
<element name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" substitutionGroup="xbrli:item" />
<element name="NorthAmericanPartnersInAnesthesiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NorthAmericanPartnersInAnesthesiaMember" substitutionGroup="xbrli:item" />
<element name="RadiologyPartnersIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RadiologyPartnersIncMember" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationAndNewAccountingPronouncementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_BasisOfPresentationAndNewAccountingPronouncementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="UnnamedCorporateJointVentureOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnnamedCorporateJointVentureOneMember" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_BasisOfPresentationLineItems" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondAndThirdQuartersOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondAndThirdQuartersOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFourthQuarterOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFourthQuarterOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFirstQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFirstQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="CreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ExtraordinaryItemsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsDomain" substitutionGroup="xbrli:item" />
<element name="CovidNinenteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CovidNinenteenMember" substitutionGroup="xbrli:item" />
<element name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ContributionsInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfDeferredPaymentOfSocialSecurityTaxes" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" substitutionGroup="xbrli:item" />
<element name="PercentageIncreaseDecreaseInSalaryAndWage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageIncreaseDecreaseInSalaryAndWage" substitutionGroup="xbrli:item" />
<element name="SupplementaryLeverageRatioRequired" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_SupplementaryLeverageRatioRequired" substitutionGroup="xbrli:item" />
<element name="EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2023Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2023Member" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2027Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2027Member" substitutionGroup="xbrli:item" />
<element name="RuralAreaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RuralAreaMember" substitutionGroup="xbrli:item" />
<element name="CashEquivalentsAndInvestmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CashEquivalentsAndInvestmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CashEquivalentsAndInvestmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CashEquivalentsAndInvestmentsLineItems" substitutionGroup="xbrli:item" />
<element name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MoneyMarketFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MutualFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TwoThousandTwentyThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentySevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="HospitalsContractsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_HospitalsContractsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ScheduleOfFinancingReceivablesLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" substitutionGroup="xbrli:item" />
<element name="ContractedManagedCareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ContractedManagedCareMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DeferredTaxAssetsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsDomain" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsGoodwillMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsGoodwillMember" substitutionGroup="xbrli:item" />
<element name="DivestitureOfMeddataMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DivestitureOfMeddataMember" substitutionGroup="xbrli:item" />
<element name="RadiologyServicesMedicalGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RadiologyServicesMedicalGroupMember" substitutionGroup="xbrli:item" />
<element name="MaximumConsiderationReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MaximumConsiderationReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccountsReceivableRetained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccountsReceivableRetained" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CapitalLossCarryForward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_CapitalLossCarryForward" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfPediatricSubspecialtyPracticesAcquired" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_NumberOfPediatricSubspecialtyPracticesAcquired" substitutionGroup="xbrli:item" />
<element name="TaxYearTwoThousandAndTwentyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TaxYearTwoThousandAndTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="PediatricSubspecialtyPracticeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_PediatricSubspecialtyPracticeMember" substitutionGroup="xbrli:item" />
<element name="DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" substitutionGroup="xbrli:item" />
<element name="DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedPayrollTaxesAndBenefitsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInAccruedSalariesAndBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_IncreaseDecreaseInAccruedSalariesAndBonuses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonqualifiedstockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NonqualifiedstockOptionsMember" substitutionGroup="xbrli:item" />
<element name="AmendedAndRestatedTwoThousandEightPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_AmendedAndRestatedTwoThousandEightPlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="CommonStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommonStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockLineItems" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>md-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-November-2020 [02:58:03] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_IncomeTaxesReceivable" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_MD_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_MD_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_MD_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_MD_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="36" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNet" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_MD_PracticeSalariesAndBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_MD_PracticeSalariesAndBenefits" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_MD_PracticeSuppliesAndOtherOperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_MD_PracticeSuppliesAndOtherOperatingExpenses" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_MD_AccruedPayrollTaxesAndBenefitsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_MD_AccruedPayrollTaxesAndBenefitsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts" use="optional" order="31" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" use="optional" order="36" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>md-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-November-2020 [02:58:04] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurements" roleURI="http://www.mednax.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurementsTables" roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BasisOfPresentationAndNewAccountingPronouncementsPolicies" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BasisOfPresentationAndNewAccountingPronouncements" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestments" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestmentsTables" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StatementTable_99" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_763820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_763820" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_763938" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_395111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763938" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_395111" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_763935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_763938" xlink:to="loc_us-gaap_StatementTable_763935" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_763936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_763935" xlink:to="loc_us-gaap_StatementClassOfStockAxis_763936" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_763937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_763936" xlink:to="loc_us-gaap_ClassOfStockDomain_763937" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_763937_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_763936" xlink:to="loc_us-gaap_ClassOfStockDomain_763937_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_763939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_763935" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_763939" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_763940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_763939" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_763940" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_763940_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_763939" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_763940_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_763942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_763940" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_763942" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyPartnersIncMember" xlink:label="loc_md_RadiologyPartnersIncMember_764007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_763940" xlink:to="loc_md_RadiologyPartnersIncMember_764007" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems_393378" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_393377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_393377" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_763313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_763313" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_763314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_763313" xlink:to="loc_us-gaap_RelatedPartyDomain_763314" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_763314_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_763313" xlink:to="loc_us-gaap_RelatedPartyDomain_763314_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember" xlink:label="loc_us-gaap_CorporateJointVentureMember_763315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_763314" xlink:to="loc_us-gaap_CorporateJointVentureMember_763315" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_686007" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_686004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_StatementTable_686004" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_686005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementClassOfStockAxis_686005" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_686024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_StatementScenarioAxis_686024" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_686027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_686027" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_686028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_686028" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_686029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_686029" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_686030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_CreditFacilityAxis_686030" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_686032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_md_CreditAgreementMember_686032" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_720100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_us-gaap_LetterOfCreditMember_720100" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_686017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_md_ExtraordinaryItemsAxis_686017" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_686019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ExtraordinaryItemsDomain_686018" xlink:to="loc_md_CovidNinenteenMember_686019" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_686021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_TitleOfIndividualAxis_686021" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_686023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" xlink:to="loc_srt_ExecutiveOfficerMember_686023" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_689758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_DebtInstrumentAxis_689758" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_689760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2023Member_689760" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_689762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2027Member_689762" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_686033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_RangeAxis_686033" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_686035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MaximumMember_686035" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_686037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MinimumMember_686037" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_686038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_GeographicDistributionAxis_686038" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_686041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_RuralAreaMember_686041" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_686070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_SupplementaryLeverageRatioRequired_686070" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_720098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCredit_720098" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" use="optional" order="48" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable_393444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_md_CashEquivalentsAndInvestmentsTable_393444" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_393445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_393445" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_393447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" xlink:to="loc_us-gaap_CashEquivalentsMember_393447" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_393448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_srt_RangeAxis_393448" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_393416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_InvestmentTypeAxis_393416" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_393421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_CertificatesOfDepositMember_393421" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_494118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_494118" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_670778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_AvailableForSaleSecurities_670778" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670787" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_StatementTable_670784" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670785" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_670796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_670796" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_670797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_670797" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_670789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_670789" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_670790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_670790" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_670791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MutualFundsFairValueDisclosure_670791" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670808" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_StatementTable_670805" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670806" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_DebtInstrumentAxis_670813" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_670815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentyThreeMember_670815" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_670816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentySevenMember_670816" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_670809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesAbstract_670809" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_670810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_670809" xlink:to="loc_us-gaap_NotesPayable_670810" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_670812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_670812" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_764136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_764136" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_764008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_AssetImpairmentCharges_764008" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_StatementTable_468356" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsGoodwillMember" xlink:label="loc_md_DeferredTaxAssetsGoodwillMember_468391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DeferredTaxAssetsDomain_468388" xlink:to="loc_md_DeferredTaxAssetsGoodwillMember_468391" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_670845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_670845" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember_720124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_DivestitureOfMeddataMember_720124" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember_764134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_RadiologyServicesMedicalGroupMember_764134" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_718609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_srt_RangeAxis_718609" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_718610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_718609" xlink:to="loc_srt_RangeMember_718610" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_718610_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_718609" xlink:to="loc_srt_RangeMember_718610_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_718611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MaximumMember_718611" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_718612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MinimumMember_718612" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_720107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_TaxPeriodAxis_720107" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_720108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_720107" xlink:to="loc_us-gaap_TaxPeriodDomain_720108" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_720108_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_720107" xlink:to="loc_us-gaap_TaxPeriodDomain_720108_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_720108" xlink:to="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_764130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_764130" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_764130" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_764130" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="loc_md_PediatricSubspecialtyPracticeMember_764132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131" xlink:to="loc_md_PediatricSubspecialtyPracticeMember_764132" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_718608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_MaximumConsiderationReceivable_718608" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained_718614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_AccountsReceivableRetained_718614" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CapitalLossCarryForward" xlink:label="loc_md_CapitalLossCarryForward_720105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_CapitalLossCarryForward_720105" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763944" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_763945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_763945" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_763947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_Goodwill_763947" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_763948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_763948" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:label="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_764129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_764129" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_764133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_764133" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_764013" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_764013" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_395121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_395121" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_395122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_395122" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_395123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_395123" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_395125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_395125" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_395154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_395154" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_409867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_409867" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_764127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_764127" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_763906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_763906" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent_395124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent_395124" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_764013" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_395127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_395127" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_395130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_395130" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_395158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_395158" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent_763907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent_763907" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent_763908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent_763908" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_764010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_764013" xlink:to="loc_us-gaap_StatementTable_764010" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_764011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_764010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_764011" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_764012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_764011" xlink:to="loc_us-gaap_ClassOfStockDomain_764012" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_764012_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_764011" xlink:to="loc_us-gaap_ClassOfStockDomain_764012_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_764014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_764010" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_764014" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_764015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_764014" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_764015" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_764015_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_764014" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_764015_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember_764016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_764015" xlink:to="loc_md_RadiologyServicesMedicalGroupMember_764016" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_720115" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment_763916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment_763916" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_720112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_us-gaap_StatementTable_720112" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_720113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_720112" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_720113" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_720114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_720113" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_720114" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_720114_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_720113" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_720114_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyPartnersIncMember" xlink:label="loc_md_RadiologyPartnersIncMember_720116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_720114" xlink:to="loc_md_RadiologyPartnersIncMember_720116" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_763920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_720114" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_763920" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393221" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_us-gaap_StatementTable_393218" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393219" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NonqualifiedstockOptionsMember" xlink:label="loc_md_NonqualifiedstockOptionsMember_763510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_md_NonqualifiedstockOptionsMember_763510" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_md_CommonStockTable_637" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_642" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="18" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>md-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-November-2020 [02:58:03] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income Taxes Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xml:lang="en-US">Assets held for sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred income tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:to="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities excluding accrued income taxes current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Current portion of finance lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Liabilities held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long-term debt and finance lease liabilities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:to="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long term debt and capital lease obligations excluding long term line of credit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock; $.01 par value; 200,000 shares authorized; 85,504 and 84,248 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained (deficit) earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total MEDNAX, Inc. shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xml:lang="en-US">Liabilities held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, aggregate shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Weighted average common shares:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common and common equivalent shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (loss) from continuing operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment and other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total non-operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice Salaries and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSalariesAndBenefits" xlink:to="lab_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice Supplies And Other Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice supplies and other operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="lab_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Transformational and restructuring related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">(Loss) income from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Net incremental loss on the sale of MedData</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">(Loss) income from continuing operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:to="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">It represents Income (Loss) from continuing operations, per basic and diluted share</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Loss from discontinued operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Retained Earnings And Accumulated Other Comprehensive Income [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Retained (Deficit) Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Retained earnings and accumulated other comprehensive income [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Forfeitures of restricted stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock swaps, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock issued during period shares stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xml:lang="en-US">Forfeitures of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock and conversion of restricted stock units to common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock Issued During Period Value Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock swaps</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodValueStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock issued during period value stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Repurchased common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Stock Repurchased During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Repurchased common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized holding gain (loss) on investments, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Contribution from noncontrolling Interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in financing activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Repurchases of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments for credit facility amendment and financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from issuance of senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Borrowings on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xml:lang="en-US">Proceeds from Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xml:lang="en-US">Contribution from noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Payments on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Payments on finance lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash used in financing activities&#8212;discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used in financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition payments, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Payments to Acquire Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Purchases of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from maturities or sales of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from sale of business, net of cash sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by (used in) investing activities&#8212;discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of premiums, discounts and issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable / receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by operating activities&#8212;discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by operating activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAbstract" xlink:to="lab_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic ("COVID-19")</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Cash Equivalents and Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable And Net Revenue Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable and Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts receivable and net revenue disclosure.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xml:lang="en-US">Business Combinations Assets Held For Sale And Discontinued Operations Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xlink:to="lab_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xml:lang="en-US">Business combinations assets held for sale and discontinued operations disclosure.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Business Combinations Assets Held For Sale And Discontinued Operations Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Business Combinations, Assets Held for Sale and Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Business combinations assets held for sale and discontinued operations disclosure text block.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Common and Common Equivalent Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Incentive Plans and Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchase Programs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockRepurchasesTextBlock" xlink:to="lab_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Entire disclosure of common stock repurchases.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Schedule of Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Tabular disclosure of financial instruments measured at carrying amount.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Schedule of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts Receivable, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedule of Percentage of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="lab_md_NorthAmericanPartnersInAnesthesiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [member].</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyPartnersIncMember" xlink:label="loc_md_RadiologyPartnersIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RadiologyPartnersIncMember" xml:lang="en-US">Radiology Partners Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RadiologyPartnersIncMember" xml:lang="en-US">Radiology Partners Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RadiologyPartnersIncMember" xlink:to="lab_md_RadiologyPartnersIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RadiologyPartnersIncMember" xml:lang="en-US">Radiology Partners Inc.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BasisOfPresentationAndNewAccountingPronouncementsTable" xml:lang="en-US">Basis of Presentation and New Accounting Pronouncements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="lab_md_BasisOfPresentationAndNewAccountingPronouncementsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnnamedCorporateJointVentureOneMember" xlink:to="lab_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BasisOfPresentationLineItems" xml:lang="en-US">Basis Of Presentation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BasisOfPresentationLineItems" xlink:to="lab_md_BasisOfPresentationLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method ownership percentage in joint venture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember" xlink:label="loc_us-gaap_CorporateJointVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateJointVentureMember" xml:lang="en-US">Corporate Joint Venture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:to="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFourthQuarterOf2020Member" xlink:to="lab_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFirstQuarterOf2021Member" xlink:to="lab_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondQuarterOf2021Member" xlink:to="lab_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CreditAgreementMember" xlink:to="lab_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letters of Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAxis" xlink:to="lab_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsDomain" xlink:to="lab_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">COVID-19 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CovidNinenteenMember" xlink:to="lab_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Deferred Payment Of Social Security Taxes | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:to="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Decrease In Salary | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Credit Facility Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Leverage ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SupplementaryLeverageRatioRequired" xlink:to="lab_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated EBITDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Line of credit outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of credit remaining borrowing capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">SeniorUnsecurdNotes2023 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">Senior Unsecurd Notes 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2023Member" xlink:to="lab_md_Seniorunsecurdnotes2023Member" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">SeniorUnsecurdNotes2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">Senior Unsecurd Notes 2027 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2027Member" xlink:to="lab_md_Seniorunsecurdnotes2027Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionAxis" xml:lang="en-US">Geographic Distribution [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionAxis" xlink:to="lab_us-gaap_GeographicDistributionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionDomain" xml:lang="en-US">Geographic Distribution [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomain" xlink:to="lab_us-gaap_GeographicDistributionDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RuralAreaMember" xlink:to="lab_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CashEquivalentsAndInvestmentsTable" xml:lang="en-US">Cash Equivalents and Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable" xlink:to="lab_md_CashEquivalentsAndInvestmentsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CashEquivalentsAndInvestmentsLineItems" xml:lang="en-US">Cash Equivalents And Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems" xlink:to="lab_md_CashEquivalentsAndInvestmentsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">Municipal Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">Federal Home Loan Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Other Corporate Bonds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Corporate Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherCorporateBondsMember" xlink:to="lab_us-gaap_AllOtherCorporateBondsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Available-for-sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money Market Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MoneyMarketFundsFairValueDisclosure" xlink:to="lab_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Fair value of money market funds.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MutualFundsFairValueDisclosure" xlink:to="lab_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual funds fair value disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable Fair Value Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">2023 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentyThreeMember" xlink:to="lab_md_TwoThousandTwentyThreeMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">2027 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentySevenMember" xlink:to="lab_md_TwoThousandTwentySevenMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesAbstract" xml:lang="en-US">Receivables [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, Gross, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Gross accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for contractual adjustments and uncollectibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Health Care, Patient Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Net patient service revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospital contract administrative fees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_HospitalsContractsMember" xlink:to="lab_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Product and Service, Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Other revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems" xlink:to="lab_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule of financing receivables.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xml:lang="en-US">Health Care Organization Revenue and Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage Of Net Patient Service Revenue By Type Of Payor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue by type payor.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContractedManagedCareMember" xlink:to="lab_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember" xlink:to="lab_us-gaap_GovernmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Self-Pay [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Private-Pay Patients [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfPayMember" xlink:to="lab_us-gaap_SelfPayMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Third-Party Payor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Other Third-Parties [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsAxis" xml:lang="en-US">Deferred Tax Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsAxis" xlink:to="lab_md_DeferredTaxAssetsAxis" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsDomain" xml:lang="en-US">Deferred Tax Assets [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsDomain" xlink:to="lab_md_DeferredTaxAssetsDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsGoodwillMember" xlink:label="loc_md_DeferredTaxAssetsGoodwillMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsGoodwillMember" xml:lang="en-US">Deferred Tax Assets Goodwill [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsGoodwillMember" xlink:to="lab_md_DeferredTaxAssetsGoodwillMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DivestitureOfMeddataMember" xml:lang="en-US">Divestiture of MedData [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DivestitureOfMeddataMember" xlink:to="lab_md_DivestitureOfMeddataMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DivestitureOfMeddataMember" xml:lang="en-US">Divestiture of MedData.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RadiologyServicesMedicalGroupMember" xml:lang="en-US">Radiology Services Medical Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RadiologyServicesMedicalGroupMember" xml:lang="en-US">Radiology Services Medical Group [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RadiologyServicesMedicalGroupMember" xlink:to="lab_md_RadiologyServicesMedicalGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RadiologyServicesMedicalGroupMember" xml:lang="en-US">Radiology Services Medical Group</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Preliminary and incremental gain loss on sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum Consideration Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum consideration receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MaximumConsiderationReceivable" xlink:to="lab_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum consideration receivable.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts Receivable Retained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts receivable retained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsReceivableRetained" xlink:to="lab_md_AccountsReceivableRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts receivable retained.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CapitalLossCarryForward" xlink:label="loc_md_CapitalLossCarryForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CapitalLossCarryForward" xml:lang="en-US">Capital Loss Carry Forward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CapitalLossCarryForward" xml:lang="en-US">Capital loss carry forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CapitalLossCarryForward" xlink:to="lab_md_CapitalLossCarryForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CapitalLossCarryForward" xml:lang="en-US">Capital loss carry forward.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Increase decrease in valuation allowance deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business acquisition total consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Business acquisition consideration paid in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xml:lang="en-US">Other intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Non-cash charge against goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:label="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NumberOfPediatricSubspecialtyPracticesAcquired" xml:lang="en-US">Number Of Pediatric Subspecialty Practices Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NumberOfPediatricSubspecialtyPracticesAcquired" xml:lang="en-US">Number of other pediatric subspecialty practices acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:to="lab_md_NumberOfPediatricSubspecialtyPracticesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NumberOfPediatricSubspecialtyPracticesAcquired" xml:lang="en-US">Number of other pediatric subspecialty practices acquired.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business acquisition contingent consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TaxYearTwoThousandAndTwentyFiveMember" xml:lang="en-US">Tax Year Two Thousand and Twenty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TaxYearTwoThousandAndTwentyFiveMember" xml:lang="en-US">Tax Year Two Thousand and Twenty Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TaxYearTwoThousandAndTwentyFiveMember" xlink:to="lab_md_TaxYearTwoThousandAndTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_TaxYearTwoThousandAndTwentyFiveMember" xml:lang="en-US">Tax year two thousand and twenty five [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="loc_md_PediatricSubspecialtyPracticeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PediatricSubspecialtyPracticeMember" xml:lang="en-US">Pediatric Subspecialty Practice [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PediatricSubspecialtyPracticeMember" xml:lang="en-US">Pediatric Subspecialty Practice [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PediatricSubspecialtyPracticeMember" xlink:to="lab_md_PediatricSubspecialtyPracticeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PediatricSubspecialtyPracticeMember" xml:lang="en-US">Pediatric Subspecialty Practice</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xml:lang="en-US">Deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Leases Right Of Use Assets Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xml:lang="en-US">Operating leases right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating And Finance Leases Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xml:lang="en-US">Operating and finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xml:lang="en-US">Disposal group including discontinued operation operating and finance leases liabilities current.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xml:lang="en-US">Disposal Group Including Discontinued Operation Long Term Professional Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xml:lang="en-US">Disposal group including discontinued operation long term professional liabilities current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xml:lang="en-US">Represents disposal group, including discontinued operation, operating expenses</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xml:lang="en-US">Disposal Group Including Discontinued Operation Cost of Salaries and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xml:lang="en-US">Cost of service salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cost of Salaries and Benefits</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Disposal Group Including Discontinued Operation Cost of Service Supplies and Other Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Cost of service supplies and other operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cost of Service Supplies and Other Operating Expenses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xml:lang="en-US">Disposal Group Including Discontinued Operation Gain or Loss on Assets Held for Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xml:lang="en-US">Loss on sale, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain or Loss on Assets Held for Sale.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xml:lang="en-US">Disposal Group Including Discontinued Operation Other Income Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xml:lang="en-US">Non-operating (expense) income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xml:lang="en-US">Disposal group including discontinued operation other income (expense).</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xml:lang="en-US">Income tax (provision) benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xml:lang="en-US">Disposal Group Including Discontinued Operation Transformational and Restructuring Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xml:lang="en-US">Transformational and restructuring related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xml:lang="en-US">Disposal group including discontinued operation transformational and restructuring expenses.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xml:lang="en-US">Disposal Group Including Discontinued Operation Goodwill Impairment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xml:lang="en-US">Goodwill impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xml:lang="en-US">Disposal group including discontinued operation goodwill impairment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses, total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued Payroll Taxes And Benefits Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued salaries and bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Accrued professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Increase Decrease In Accrued Salaries And Bonuses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Net decrease in accrued salaries and bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:to="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Increase decrease in accrued salaries and bonuses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities not included in the diluted net income per common share calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Weighted average number of dilutive common share equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NonqualifiedstockOptionsMember" xlink:label="loc_md_NonqualifiedstockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NonqualifiedstockOptionsMember" xml:lang="en-US">NonQualifiedStock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NonqualifiedstockOptionsMember" xml:lang="en-US">Non Qualified Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NonqualifiedstockOptionsMember" xlink:to="lab_md_NonqualifiedstockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NonqualifiedstockOptionsMember" xml:lang="en-US">Non-qualified&#160;stock options.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated Two Thousand Eight Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated 2008 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and restated two thousand eight plan.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 non-qualified employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock, reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Vesting period of options, maximum years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Shares available for future grants and awards under Stock Incentive Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Percentage of market value of common stock at which employees are permitted to purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Aggregate number Shares issued under Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockTable" xlink:to="lab_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockLineItems" xlink:to="lab_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Amount withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Number of shares withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Common stock authorized for repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Company's Common stock repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>md-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-November-2020 [02:58:04] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BasisOfPresentationAndNewAccountingPronouncements" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestments" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurements" roleURI="http://www.mednax.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BasisOfPresentationAndNewAccountingPronouncementsPolicies" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestmentsTables" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurementsTables" roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" roleURI="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200930.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187927" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_494056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentType_494056" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_494062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentQuarterlyReport_494062" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_494063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentTransitionReport_494063" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_500141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AmendmentFlag_500141" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_494057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentPeriodEndDate_494057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_500152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalYearFocus_500152" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_500153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalPeriodFocus_500153" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_494058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityRegistrantName_494058" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_500154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCentralIndexKey_500154" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_500155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CurrentFiscalYearEndDate_500155" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_494068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCurrentReportingStatus_494068" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_494069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityInteractiveDataCurrent_494069" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_494079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_494079" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_494064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_Security12bTitle_494064" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_494065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_TradingSymbol_494065" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_494066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_SecurityExchangeName_494066" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_494070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFileNumber_494070" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_494071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityIncorporationStateCountryCode_494071" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_494072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityTaxIdentificationNumber_494072" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_494073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressAddressLine1_494073" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_494076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressCityOrTown_494076" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_494075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressStateOrProvince_494075" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_494078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressPostalZipCode_494078" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_494077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CityAreaCode_494077" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_494074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_LocalPhoneNumber_494074" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_494059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFilerCategory_494059" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_494061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntitySmallBusiness_494061" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_494060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityEmergingGrowthCompany_494060" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_494067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityShellCompany_494067" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_AssetsAbstract_24" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_AssetsCurrentAbstract_25" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_40" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_684080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_IncomeTaxesReceivable_684080" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_OtherAssetsCurrent_41" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_395184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_395184" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AssetsCurrent_42" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Goodwill_32" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_393135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_393135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_505340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_505340" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_34" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_409691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_409691" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Assets_35" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_27" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_53" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_395187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_395187" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesCurrent_54" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_46" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_409692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_409692" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_StockholdersEquityAbstract_28" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_PreferredStockValue_55" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_CommonStockValue_56" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_393147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_393147" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquity_59" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_763320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_MinorityInterest_763320" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_763321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_763321" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_61" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_63" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesIssued_64" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_66" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesIssued_67" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_68" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_70" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingExpensesAbstract_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSalariesAndBenefits_89" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_91" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_92" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_393211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_RestructuringCharges_393211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_500469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingExpenses_500469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingIncomeLoss_78" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeNet_79" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InterestExpense_80" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_82" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_395230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_395230" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareAbstract_71" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareBasic_74" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareDiluted_75" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" xlink:to="loc_us-gaap_StatementTable_99" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementLineItems_98" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_763820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_763820" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_122" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_124" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_ProfitLoss_166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_ShareBasedCompensation_134" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_136" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_160" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_148" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_149" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_151" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_156" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations_169" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393388" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_393389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393388" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_393389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract_685995" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_685996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAbstract_685995" xlink:to="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_685996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393394" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_393395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393394" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_393395" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393301" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_393302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393301" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_393302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_727" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_727" xlink:to="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_763876" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock_763877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_763876" xlink:to="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock_763877" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_751" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_751" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentShares">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_781" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_781" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_782" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchasePrograms">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_794" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_794" xlink:to="loc_md_CommonStockRepurchasesTextBlock_795" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393384" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_393386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393384" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_393386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393404" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_393406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393404" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_393406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393304" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_393310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393304" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_393310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_393311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393304" xlink:to="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_393311" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_730" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395110" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_763935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395110" xlink:to="loc_us-gaap_StatementTable_763935" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_763936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_763935" xlink:to="loc_us-gaap_StatementClassOfStockAxis_763936" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_763937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_763936" xlink:to="loc_us-gaap_ClassOfStockDomain_763937" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_763939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_763935" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_763939" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_763940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_763939" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_763940" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyPartnersIncMember" xlink:label="loc_md_RadiologyPartnersIncMember_764007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_763940" xlink:to="loc_md_RadiologyPartnersIncMember_764007" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_763942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_763940" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_763942" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_763938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_763935" xlink:to="loc_us-gaap_StatementLineItems_763938" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_395111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763938" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_395111" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_754" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_754" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_784" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_784" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393368" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393368" xlink:to="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_393377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_393377" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_763313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_763313" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_763314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_763313" xlink:to="loc_us-gaap_RelatedPartyDomain_763314" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember" xlink:label="loc_us-gaap_CorporateJointVentureMember_763315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_763314" xlink:to="loc_us-gaap_CorporateJointVentureMember_763315" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems_393378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_md_BasisOfPresentationLineItems_393378" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract_686001" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_686004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAbstract_686001" xlink:to="loc_us-gaap_StatementTable_686004" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_686005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementClassOfStockAxis_686005" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_686017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_md_ExtraordinaryItemsAxis_686017" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_686019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsDomain_686018" xlink:to="loc_md_CovidNinenteenMember_686019" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_686021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_TitleOfIndividualAxis_686021" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_686023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" xlink:to="loc_srt_ExecutiveOfficerMember_686023" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_686024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_StatementScenarioAxis_686024" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_686027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_686027" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_686028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_686028" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_686029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_686029" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_686030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_CreditFacilityAxis_686030" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_686032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_md_CreditAgreementMember_686032" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_720100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_us-gaap_LetterOfCreditMember_720100" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_686033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_RangeAxis_686033" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_686035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MaximumMember_686035" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_686037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MinimumMember_686037" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_686038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_GeographicDistributionAxis_686038" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_686041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_RuralAreaMember_686041" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_689758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_DebtInstrumentAxis_689758" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_689760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2023Member_689760" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_689762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2027Member_689762" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_686007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementLineItems_686007" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_686070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_SupplementaryLeverageRatioRequired_686070" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_720098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCredit_720098" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393443" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable_393444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393443" xlink:to="loc_md_CashEquivalentsAndInvestmentsTable_393444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_393445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_393445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_393447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" xlink:to="loc_us-gaap_CashEquivalentsMember_393447" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_393448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_srt_RangeAxis_393448" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393412" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393412" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_393416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_InvestmentTypeAxis_393416" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_494118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_494118" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_393421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_CertificatesOfDepositMember_393421" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_670778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_AvailableForSaleSecurities_670778" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_670782" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_670782" xlink:to="loc_us-gaap_StatementTable_670784" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670785" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_670796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_670796" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_670797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_670797" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementLineItems_670787" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_670789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_670789" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_670790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_670790" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_670791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MutualFundsFairValueDisclosure_670791" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_670803" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_670803" xlink:to="loc_us-gaap_StatementTable_670805" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670806" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_DebtInstrumentAxis_670813" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_670815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentyThreeMember_670815" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_670816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentySevenMember_670816" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementLineItems_670808" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_670809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesAbstract_670809" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_670810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_670809" xlink:to="loc_us-gaap_NotesPayable_670810" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_670812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_670812" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_249" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_250" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_252" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_md_ScheduleOfFinancingReceivablesLineItems_259" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395169" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395169" xlink:to="loc_us-gaap_StatementTable_468356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DeferredTaxAssetsGoodwillMember" xlink:label="loc_md_DeferredTaxAssetsGoodwillMember_468391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DeferredTaxAssetsDomain_468388" xlink:to="loc_md_DeferredTaxAssetsGoodwillMember_468391" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_670845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_670845" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember_720124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_DivestitureOfMeddataMember_720124" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember_764134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_RadiologyServicesMedicalGroupMember_764134" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_718609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_srt_RangeAxis_718609" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_718610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_718609" xlink:to="loc_srt_RangeMember_718610" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_718611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MaximumMember_718611" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_718612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MinimumMember_718612" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_720107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_TaxPeriodAxis_720107" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_720108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_720107" xlink:to="loc_us-gaap_TaxPeriodDomain_720108" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_720108" xlink:to="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_764130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_764130" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_764130" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="loc_md_PediatricSubspecialtyPracticeMember_764132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_764131" xlink:to="loc_md_PediatricSubspecialtyPracticeMember_764132" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_StatementLineItems_468359" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CapitalLossCarryForward" xlink:label="loc_md_CapitalLossCarryForward_720105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_CapitalLossCarryForward_720105" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_718608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_MaximumConsiderationReceivable_718608" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained_718614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_AccountsReceivableRetained_718614" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_763944" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_763945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_763945" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_763947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_Goodwill_763947" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_763948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_763948" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_764008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_AssetImpairmentCharges_764008" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NumberOfPediatricSubspecialtyPracticesAcquired" xlink:label="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_764129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_NumberOfPediatricSubspecialtyPracticesAcquired_764129" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_764133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_764133" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_764136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_764136" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395113" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_764010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395113" xlink:to="loc_us-gaap_StatementTable_764010" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_764011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_764011" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_764012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_764011" xlink:to="loc_us-gaap_ClassOfStockDomain_764012" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_764014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764010" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_764014" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_764015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_764014" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_764015" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="loc_md_RadiologyServicesMedicalGroupMember_764016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_764015" xlink:to="loc_md_RadiologyServicesMedicalGroupMember_764016" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_764013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764010" xlink:to="loc_us-gaap_StatementLineItems_764013" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_764013" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_395121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_395121" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_395122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_395122" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_395123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_395123" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent_395124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent_395124" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_409867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_409867" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_395125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_395125" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_764127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_764127" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_763906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_763906" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_395154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_395119" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_395154" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_764013" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_395127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_395127" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent_763907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent_763907" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent_763908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent_763908" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_395130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_395130" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_395158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_395126" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_395158" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract" xlink:label="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395132" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_720112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract_395132" xlink:to="loc_us-gaap_StatementTable_720112" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_720113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_720112" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_720113" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_720114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_720113" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_720114" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_RadiologyPartnersIncMember" xlink:label="loc_md_RadiologyPartnersIncMember_720116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_720114" xlink:to="loc_md_RadiologyPartnersIncMember_720116" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_763920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_720114" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_763920" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_720115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_720112" xlink:to="loc_us-gaap_StatementLineItems_720115" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment_763916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment_763916" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_364" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableCurrent_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccruedSalariesCurrent_366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_InterestPayableCurrent_370" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_393216" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_393216" xlink:to="loc_us-gaap_StatementTable_393218" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393219" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementLineItems_393221" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_568" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_NonqualifiedstockOptionsMember" xlink:label="loc_md_NonqualifiedstockOptionsMember_763510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_md_NonqualifiedstockOptionsMember_763510" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_634" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_634" xlink:to="loc_md_CommonStockTable_637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_642" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200930.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_md_CommonStockLineItems_636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>d44327d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="md-20200930.xsd" xlink:type="simple"/>
    <context id="P01_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_02_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">md:TaxYearTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_NonqualifiedstockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">md:NonqualifiedstockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:DivestitureOfMeddataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyServicesMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_DeferredTaxAssetsGoodwillMemberMDDeferredTaxAssetsAxis_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">md:PediatricSubspecialtyPracticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:DeferredTaxAssetsAxis">md:DeferredTaxAssetsGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:RadiologyPartnersIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">md:RuralAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-06</startDate>
            <endDate>2020-05-06</endDate>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_31_2020_CorporateJointVentureMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2020To09_30_2020">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2020"
      decimals="INF"
      id="hidden15530513"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2020"
      decimals="INF"
      id="hidden15530515"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2020To09_30_2020">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2020To09_30_2020">0000893949</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2020To09_30_2020">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn11_02_2020"
      decimals="INF"
      id="hidden15530485"
      unitRef="Unit_shares">85598299</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentType contextRef="P01_01_2020To09_30_2020">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P01_01_2020To09_30_2020">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2020To09_30_2020">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2020To09_30_2020">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2020To09_30_2020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2020To09_30_2020">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2020To09_30_2020">MEDNAX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2020To09_30_2020">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2020To09_30_2020">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2020To09_30_2020">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2020To09_30_2020">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2020To09_30_2020">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2020To09_30_2020">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2020To09_30_2020">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2020To09_30_2020">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2020To09_30_2020">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2020To09_30_2020">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2020To09_30_2020">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2020To09_30_2020">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2020To09_30_2020">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2020To09_30_2020">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2020To09_30_2020">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2020To09_30_2020">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="P01_01_2020To09_30_2020">false</dei:EntityShellCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">294512000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">107870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">81574000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">267125000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">434266000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">13317000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">17108000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">22797000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">20287000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11837000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">951548000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">85916000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1651160000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">731507000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">78570000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">72677000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1480668000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1479850000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">27665000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">28587000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">58993000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">56413000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">62950000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">86644000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">64820000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">48643000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1641580000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3424826000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:Assets>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">388517000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">410637000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2440000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">18695000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">18254000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6039000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">78712000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">106888000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">488364000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">541818000</us-gaap:LiabilitiesCurrent>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1742263000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1730238000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">40220000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44643000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">242366000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">204914000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">63630000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">56468000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">42977000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22819000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46005000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2619820000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2646905000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2020"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2020"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2020"
      decimals="INF"
      unitRef="Unit_shares">85504000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2020"
      decimals="INF"
      unitRef="Unit_shares">85504000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">855000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1023974000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1990000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-222058000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">510134000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">804761000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">245000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">805006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3424826000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">460635000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">454913000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1317321000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1321159000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">309904000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">301306000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">909168000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">880686000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">22440000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">22581000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">66455000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">72688000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">66346000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">63284000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">194276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">185318000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7195000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">6408000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">20749000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">18830000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">34291000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">12766000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">60846000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">32025000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">440176000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">406345000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1251494000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1189547000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">20459000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">48568000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">65827000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">131612000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">10534000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">802000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">13064000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">2777000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">27250000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">29909000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">83180000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">91271000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">282000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">786000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1081000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1753000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-16434000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-28321000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-69035000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-86741000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">4025000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">20247000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-3208000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">44871000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">6677000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">7360000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">10859000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">12590000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2652000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">12887000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-14067000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">32281000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-38392000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1268803000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-718125000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1539314000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-41044000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1255916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-732192000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1507033000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.39</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.16</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.38</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.39</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.62</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-18.36</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.31</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.62</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-18.26</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-17.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-15.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-17.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83862000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">82441000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83260000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">83846000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83862000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">82883000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">84302000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">84248000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">510212000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_15530683"
      unitRef="Unit_USD">-213000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      id="Fact_15530684"
      unitRef="Unit_USD">-213000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">78000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1831000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">968000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-19000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">125000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2541000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2542000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">85150000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">852000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">995257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">491287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1487396000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-672436000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-672436000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_15530706"
      unitRef="Unit_USD">2078000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      id="Fact_15530707"
      unitRef="Unit_USD">2078000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">277000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2541000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2544000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-57000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">34000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">501000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">85536000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1004786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-179071000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">826570000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-41044000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-41044000</us-gaap:NetIncomeLoss>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_15532133"
      unitRef="Unit_USD">245000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      id="Fact_15532134"
      unitRef="Unit_USD">245000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2020To09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_15530731"
      unitRef="Unit_USD">47000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      id="Fact_15530732"
      unitRef="Unit_USD">47000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">89000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1323000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1324000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">282000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-92000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">23316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">23316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">311000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P07_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5449000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">5452000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">85504000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1023974000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2020_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-219823000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">805006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">87820000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">878000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">992647000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2094359000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3087884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">140000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3541000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3542000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">978000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-6000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <md:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-20000</md:StockIssuedDuringPeriodSharesStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-666000</md:StockIssuedDuringPeriodValueStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-666000</md:StockIssuedDuringPeriodValueStockSwaps>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2525000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28740000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">50217000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78982000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">86387000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">977872000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1801076000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2779812000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-8245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-8245000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">232000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">232000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">155000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3673000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">3675000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">123000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-61000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">15080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2508000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">29196000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">36306000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">65527000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">84096000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">967429000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1756757000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">2725027000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2019To09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1255916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1255916000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2019To09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-32000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-32000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">124000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2605000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">2606000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">12000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-27000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8090000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">8090000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">20000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">415000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">415000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">84185000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">977709000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2019_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">500809000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1479360000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-732192000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1507033000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-718125000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1539314000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">20749000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">18830000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">4293000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">36120000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">27512000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">30214000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-13484000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-3370000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-30006000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-7491000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1716000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">22545000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-7703000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-21825000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-36433000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-2238000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-28837000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-25838000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">15703000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">4508000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">8157000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-19768000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">71645000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">36237000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">144841000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">186177000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">216486000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">222414000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2225000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">31200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">36090000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">13907000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">30865000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">26240000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">21809000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">14862000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1080000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-28179000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-33729000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3079000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-20793000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-25100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-54522000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">527500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1225800000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">527500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1755500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">500000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">510000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">9194000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">433000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">5697000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">9157000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">245000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">8495000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">144925000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-3496000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-174662000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-1248000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-8909000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-4744000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-183571000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">186642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-15679000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">107870000</us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">40774000</us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">294512000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">25095000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation and New Accounting Pronouncements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;r&lt;/div&gt;esults of the interim periods presented. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#x201c;MDX&#x201d;) together with the accounts of MDX&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#x201c;MEDNAX&#x201d; and the &#x201c;Company&#x201d; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is a party to a joint venture in which it owns a 37.5% economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the Company entered into a joint venture in which it owns a 51% economic interest and for which it is deemed the primary beneficiary. The equity interests of the outside investor in the equity of this consolidated entity is accounted for and presented as noncontrolling interests on the Company&#x2019;s Consolidated Balance Sheets. Although &lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;joint&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt; venture was &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;formed&lt;/div&gt; during the third quarter of 2020, it has not yet begun operations. Any future results of operations attributable to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;noncontrolling interests&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; will be accounted for and presented as such&lt;/div&gt; on the Company&#x2019;s Consolidated Statements of Income. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Report on Form 10-K (the &#x201c;Form&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;10-K&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2019.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020, the Company divested its anesthesiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,&lt;/div&gt;&#160;2020, the Company &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;entered into&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a definitive agreement to divest its radiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 6 &#x2013; Assets Held for Sale and Discontinued Operations for additional information. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures.&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn09_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn08_31_2020_CorporateJointVentureMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures.&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Coronavirus Pandemic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;):&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and related &#x201c;stay at home&#x201d; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#x2019;s affiliated clinicians. &#160;&#160;&#160;&#160;Beginning in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-March&lt;/div&gt; 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#x2019;s affiliated clinicians provided anesthesiology services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; procedures and the prohibition of such procedures by several states. Within the Company&#x2019;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;with much of this reduction focused in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; studies. See Note 6 &#x2013; Assets Held for Sale and Discontinued Operations for information regarding the divestment of the Company&#x2019;s anesthesiology services medical group and the planned divestment of the Company&#x2019;s radiology services medical group. The Company&#x2019;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; Overall, the Company&#x2019;s operating results were significantly impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; beginning in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-March&lt;/div&gt; 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; These steps included a suspension of most activities related to the Company&#x2019;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#x2019;s response to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) the Company enacted a combination of salary reductions and furloughs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-clinical&lt;/div&gt; employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. The Company also divested its anesthesiology services medical group in May 2020, where operating results were significantly impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;In response to the anticipated impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; on the Company&#x2019;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#x2019;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At September&#160;30, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023 and its 6.25% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months. At September&#160;30, 2020, the Company had no outstanding&#160;principal balance on its Credit Agreement. The Company had outstanding letters of credit of $0.2&#160;million which reduced the amount available on its Credit Agreement to $899.8&#160;million at September&#160;30, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021.&lt;/div&gt; &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;CARES Act &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#x201c;HHS&#x201d;) is administering this program and began disbursing funds in April 2020, of which the Company&#x2019;s affiliated physician practices &lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;within continuing operations &lt;/div&gt;&lt;/div&gt;received an aggregate of approximately $20.0&#160;million during the nine months ended September&#160;30, 2020. The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin: 6pt 0in 18pt 23.8pt; text-indent: 24.5pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The COVID-19 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;pandemic has&lt;/div&gt; materially &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;impacted the Company&#x2019;s&lt;/div&gt; financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock>
    <md:PercentageIncreaseDecreaseInSalaryAndWage
      contextRef="P01_01_2020To09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageIncreaseDecreaseInSalaryAndWage>
    <md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">139200000</md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</md:SupplementaryLeverageRatioRequired>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To09_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0525</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To09_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LineOfCredit
      contextRef="PAsOn09_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="PAsOn09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">899800000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn09_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000.0</md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash Equivalents and Investments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s cash equivalents consisted entirely of money market funds totaling $2.4&#160;million and $16.8&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held at September&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;56,680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,529&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;81,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn09_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-5"
      unitRef="Unit_USD">2400000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-5"
      unitRef="Unit_USD">16800000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held at September&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;56,680&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,529&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;81,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn09_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">56680000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">32962000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn09_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">13523000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">29066000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn09_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6529000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8013000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn09_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4842000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4469000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">81574000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuati&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;n inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center;"&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 8%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 8%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;81,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual Funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,446&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;759,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,035,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 18pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#x2019;s line of credit approximates fair value. If the Company&#x2019;s line of credit was measured at fair value, it would be categorized as Level&#160;2 in the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt; Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;81,574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 58%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual Funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,446&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">2411000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">16775000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn09_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">81574000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">14446000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">14264000</md:MutualFundsFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;759,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,035,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">759375000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">766875000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn09_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn09_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1035000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1025600000</us-gaap:NotesPayableFairValueDisclosure>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Receivable and Net Revenue: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,119,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,750,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(852,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,315,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;267,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;434,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patient &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;service &lt;/div&gt;revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;382,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;400,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,133,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,159,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;61,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51,149&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;154,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;149,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,389&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;460,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;454,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,317,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,321,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay&lt;/div&gt; patients&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; </md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,119,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,750,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(852,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,315,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;267,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;434,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1119171000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1750264000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">852046000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1315998000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">267125000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">434266000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;382,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;400,330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,133,313&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,159,363&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;61,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51,149&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;154,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;149,407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,434&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,389&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;460,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;454,913&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,317,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,321,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">382936000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">400330000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1133313000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To09_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1159363000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">61186000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">51149000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To09_30_2020_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">154840000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To09_30_2019_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">149407000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">16513000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">3434000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To09_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">29168000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To09_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">12389000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">460635000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">454913000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1317321000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1321159000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay&lt;/div&gt; patients&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.69</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To09_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.69</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To09_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To09_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To09_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To09_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To09_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To09_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To09_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business Combinations, Assets Held for Sale and Discontinued Operations: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;During the nine months ended September&#160;30, 2020, the Company completed the acquisition of one pediatric subspecialty practice for total consideration of $2.1&#160;million, of which $1.9&#160;million was paid in cash and $0.2&#160;million was recorded as a contingent consideration liability. This acquisition expanded the Company&#x2019;s national network of physician practices. In connection with this acquisition, the Company recorded &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-deductible&lt;/div&gt; goodwill of $0.8&#160;million and other intangible assets consisting primarily of physician and hospital agreements of $1.3&#160;million.&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Divestiture of &lt;div style="display:inline;"&gt;the &lt;/div&gt;Radiology Services Medical Group &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&lt;/div&gt;&#160;2020, the Company entered into a &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;securities purchase&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement with Radiology Partners, Inc., pursuant to which Radiology Partners, Inc. will acquire the Company&#x2019;s radiology services medical group for $885&#160;million &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash, subject to certain customary adjustments.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;This divestiture will allow the Company to focus solely on its Pediatrix and Obstetrix medical groups. The Company determined that the criterion to classify the radiology services medical group as assets held for sale within the Company&#x2019;s Consolidated Balance Sheets effective September&#160;30, 2020 were met. Accordingly, the assets and liabilities of the radiology services medical group were classified as current assets and current liabilities held for sale at September&#160;30, 2020 as the Company expects to divest of the radiology services medical group within the next twelve months. The classification to assets held for sale impacted the net book value of the assets and liabilities expected to be transferred upon sale. The estimated fair value of the radiology services medical group was determined using the purchase price in the &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;purchase&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement along with estimated broker, accounting, legal and &lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;selling&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; expenses.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;The Company deemed the carrying amount of &lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;assets&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; within the medical group, specifically accounts receivable and property and equipment, to represent fair value and therefore recorded a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge of&#160;$43.0&#160;million against goodwill, which represented the difference between the estimated fair value of the radiology services medical group and the carrying amount of the net assets held for sale. Recognition of the charge against goodwill resulted in a tax benefit which &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;generated an additional $4.0&#160;million deferred tax asset that increased the fair value of the medical group. An incremental &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge is then required to reduce the &lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;radiology services &lt;/div&gt;&lt;/div&gt;medical group&#x2019;s net assets to its previously determined fair value. Accordingly, the Company recorded the incremental &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge of $4.0&#160;million for a total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge of $47.0&#160;million, reducing the goodwill balance of the radiology services medical group. Upon completion of the divestiture, the Company could record an additional gain or loss on disposal at the time final net proceeds are determined.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, in accordance with accounting guidance for discontinued operations, the expected divestiture of the radiology services medical group was deemed to represent a fundamental strategic shift that will have a major effect on the Company&#x2019;s operations, and accordingly, the operating results of the radiology services medical group were reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 with prior periods recast to conform with the current period presentation. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents the major classes of assets and liabilities of the radiology services medical group that are included as assets and liabilities held for sale in the accompanying Consolidated Balance Sheets as of September&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;current&#160;&lt;/div&gt;assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating leases &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;640,818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;685,170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;170,059&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;180,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;36,305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;40,724&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;951,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,033,614&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;39,505&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;42,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating and finance leases&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;23,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;78,712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;78,888&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the results of discontinued operations related to the radiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;125,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;125,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;340,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;366,678&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service salaries and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84,718&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;80,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;234,169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;238,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service supplies and other operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transformational and restructuring related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;160,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;228,562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;369,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;443,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(34,822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(102,912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(29,295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(76,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-operating&lt;/div&gt; income, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,059&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,035&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(33,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(100,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(26,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(72,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.59in; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax (provision) benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,907&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(33,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(96,946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(28,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(75,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Divestiture of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Anesthesiology Services Medical Group &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#x201c;NAPA&#x201d;) to divest the Company&#x2019;s anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $50.0&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250&#160;million based upon the multiple of invested capital returned to NAPA&#x2019;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching $250&#160;million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology services medical group, which net of various other working capital items, approximated $110.0&#160;million &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at March&#160;31, 2020. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&lt;/div&gt;The &lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; operating results of the anesthesiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A single &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;anesthesiology &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;practice&#160;was not included in the divestiture of the anesthesiology services medical group, and &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;continues to operate as an affiliate of the Company. Its&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; results of operations are reflected in the three months ended September&#160;30, 2020 while the incremental loss on sale &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the anesthesiology services medical group &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recorded during the three months ended September&#160;30, 2020 reflects a true up of various divested account balances during the third quarter of 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;The total preliminary loss on sale &lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the anesthesiology services medical group &lt;/div&gt;&lt;/div&gt;recorded during the nine months ended September&#160;30, 2020 was $648.7&#160;million. Upon completion of a valuation for the contingent economic interest and working capital &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;true-up,&lt;/div&gt; final net proceeds will be determined, and the Company will adjust the loss on sale at that time. In addition, as a result of the sale, the Company currently estimates that it will generate an approximately $1.68&#160;billion capital loss carryforward &lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;that will expire&lt;/div&gt;&lt;/div&gt; in 2025. Based on management&#x2019;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $419.0&#160;million valuation allowance against this deferred tax asset as of September&#160;30, 2020.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the results of discontinued operations related to the anesthesiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;309,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;377,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;924,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service salaries and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;351,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;746,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service supplies and other operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transformational and restructuring related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,785&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;28,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,506&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,331,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,331,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on sale, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;644,653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,498&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,615,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,067,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,180,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,798&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,305,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(689,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,255,498&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-operating&lt;/div&gt; (expense) income, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,798&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,305,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(689,724&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,255,512&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;129,241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;115,987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,176,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(684,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,139,525&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Divestiture of MedData &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;The Company divested of &lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;its&lt;/div&gt;&lt;/div&gt; management services organization, MedData, in October 2019. During the nine months ended September&#160;30, 2020, the Company recorded a net incremental loss on the sale of MedData of $5.8&#160;million, primarily for the finalization of certain transaction related expenses, a working capital &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;true-up&lt;/div&gt; and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration. This incremental loss is reflected as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the nine months ended September&#160;30, 2020. The operating results of MedData were reported as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2019.&lt;/div&gt; </md:BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock>
    <md:NumberOfPediatricSubspecialtyPracticesAcquired
      contextRef="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_pure">1</md:NumberOfPediatricSubspecialtyPracticesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">2100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">885000000</md:MaximumConsiderationReceivable>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2020To09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">43000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000.0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2020To09_30_2020_DeferredTaxAssetsGoodwillMemberMDDeferredTaxAssetsAxis_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">47000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents the major classes of assets and liabilities of the radiology services medical group that are included as assets and liabilities held for sale in the accompanying Consolidated Balance Sheets as of September&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,603&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;current&#160;&lt;/div&gt;assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,819&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating leases &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;640,818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;685,170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;170,059&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;180,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;36,305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;40,724&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;951,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,033,614&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;39,505&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;42,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating and finance leases&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;23,744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,844&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;78,712&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;78,888&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the results of discontinued operations related to the radiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;125,765&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;125,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;340,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;366,678&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service salaries and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84,718&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;80,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;234,169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;238,402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service supplies and other operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;64,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transformational and restructuring related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,924&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;160,587&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;228,562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;369,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;443,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(34,822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(102,912&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(29,295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(76,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-operating&lt;/div&gt; income, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,059&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,035&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(33,453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(100,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(26,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(72,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.59in; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax (provision) benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,907&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,988&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(33,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(96,946&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(28,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(75,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">54284000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">64603000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">9819000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">9744000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">20078000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">19204000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <md:DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">14165000</md:DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent>
    <md:DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">15008000</md:DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">640818000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">685170000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">170059000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">180978000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">6020000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">18183000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">36305000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">40724000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">951548000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1033614000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">39505000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">42474000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent>
    <md:DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">13619000</md:DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent>
    <md:DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">14355000</md:DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent>
    <md:DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">23744000</md:DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent>
    <md:DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">21978000</md:DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1844000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">81000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">78712000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn12_31_2019_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">78888000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">125765000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">125650000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">340133000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">366678000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">84718000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">80336000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">234169000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">238402000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1449000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1532000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">4273000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1468000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">19876000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">20734000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">57178000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">64490000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">5090000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">7595000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">20328000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">22757000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">2491000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">441000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">6517000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1487000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">46963000</md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment>
    <md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">117924000</md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment>
    <md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">46963000</md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment>
    <md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">117924000</md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">160587000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">228562000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">369428000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">443592000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-34822000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-102912000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-29295000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-76914000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1369000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">2059000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">3035000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">4768000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-33453000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-100853000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-26260000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-72146000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">62000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-3907000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1988000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">3687000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-33515000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-96946000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-28248000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To09_30_2019_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-75833000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000.0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</md:MaximumConsiderationReceivable>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</md:MaximumConsiderationReceivable>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</md:MaximumConsiderationReceivable>
    <md:AccountsReceivableRetained
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">110000000.0</md:AccountsReceivableRetained>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">648700000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <md:CapitalLossCarryForward
      contextRef="PAsOn09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis"
      decimals="-7"
      unitRef="Unit_USD">1680000000</md:CapitalLossCarryForward>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">419000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the results of discontinued operations related to the anesthesiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;309,602&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;377,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;924,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service salaries and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;250,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;351,408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;746,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service supplies and other operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,837&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;18,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,863&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transformational and restructuring related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,785&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;28,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,506&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,331,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,331,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on sale, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;644,653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,498&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,615,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,067,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,180,343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,798&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,305,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(689,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,255,498&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-operating&lt;/div&gt; (expense) income, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,798&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,305,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(689,724&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,255,512&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;129,241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;115,987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,176,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(684,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,139,525&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">2700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">309602000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">377661000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">924845000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">2746000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">250157000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">351408000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">746237000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">38000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">2837000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">5254000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">9537000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">215000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">18338000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">31179000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">57909000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">5605000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">6308000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">17863000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">6785000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">28634000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">17506000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1331291000</md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment>
    <md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1331291000</md:DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment>
    <md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-4499000</md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale>
    <md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-644653000</md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">7498000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1615013000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1067436000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">2180343000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-4798000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1305411000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-689775000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1255498000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-17000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">51000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-14000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-4798000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1305428000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-689724000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1255512000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-100000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-129241000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-5661000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-115987000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-4698000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P07_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1176187000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To09_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-684063000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To09_30_2019_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1139525000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To09_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">5800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Payable and Accrued Expenses: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;60,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;35,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;158,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;193,631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;44,699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;49,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;388,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;410,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net decrease in accrued salaries and bonuses of $35.1&#160;million, from December&#160;31, 2019 to September&#160;30, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September&#160;30, 2020. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter. &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;60,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;35,410&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;158,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;193,631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54,768&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;44,699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;49,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;388,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;410,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">60956000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">35410000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">158579000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">193631000</us-gaap:AccruedSalariesCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">48474000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">54768000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">55469000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44699000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">26940000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">32910000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">38099000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">49219000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">388517000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">410637000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="P01_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">35100000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common and Common Equivalent Shares: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the three and nine months ended September&#160;30, 2020 and 2019 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;82,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common equivalent shares outstanding (a)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;82,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted net income per common share calculation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;829&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;796&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the three months and nine months ended September&#160;30, 2020, no incremental shares are included because the effect wou&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l&lt;/div&gt;d be antidilutive. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="P01_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the three and nine months ended September&#160;30, 2020 and 2019 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;82,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common equivalent shares outstanding (a)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;82,883&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84,302&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted net income per common share calculation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;829&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;796&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the three months and nine months ended September&#160;30, 2020, no incremental shares are included because the effect wou&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l&lt;/div&gt;d be antidilutive. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; </us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83862000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">82441000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83260000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">83846000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">442000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">456000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      id="Fact_15530393"
      unitRef="Unit_shares">83862000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      id="Fact_15530394"
      unitRef="Unit_shares">82883000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      id="Fact_15530395"
      unitRef="Unit_shares">83260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      id="Fact_15530396"
      unitRef="Unit_shares">84302000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">829000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">962000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_shares">1004000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To09_30_2019"
      decimals="-3"
      unitRef="Unit_shares">796000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive Plans and Stock Purchase Plans: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;A&amp;amp;R 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;Under the A&amp;amp;R 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock, deferred stock awards&#160;and stock options ratably over the corresponding vesting periods. During the nine months ended September&#160;30, 2020, the Company granted 1.4&#160;million shares of restricted stock and 1.0&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; of stock underlying&#160;&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; stock options to its employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors under the A&amp;amp;R 2008 Incentive Plan. At September&#160;30, 2020, the Company had 5.0&#160;million shares available for future grants and awards under the A&amp;amp;R 2008 Incentive Plan.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;Under the Company&#x2019;s 1996 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Qualified&lt;/div&gt; Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company&#x2019;s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Qualified&lt;/div&gt; Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; service providers are permitted to purchase the Company&#x2019;s common stock at 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#x2019;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; service providers. During the nine months ended September&#160;30, 2020, approximately 0.4&#160;million shares in the aggregate were issued under the ESPP and SPP. At September&#160;30, 2020, the Company had approximately 0.6&#160;million shares in the aggregate reserved for issuance under the ESPP and SPP.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three and nine months ended September&#160;30, 2020 and 2019, the Company recognized stock-based compensation expense of $4.5&#160;million and $18.2&#160;million, and $7.6&#160;million and $27.6&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_NonqualifiedstockOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn09_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_shares">5000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To09_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">2600000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2020To09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">400000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">18200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2019To09_30_2019"
      decimals="-5"
      unitRef="Unit_USD">7600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To09_30_2019"
      decimals="-5"
      unitRef="Unit_USD">27600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <md:CommonStockRepurchasesTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common Stock Repurchase Programs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;time-to-time&lt;/div&gt;&lt;/div&gt; based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. No shares were purchased under this program during the nine months ended September&#160;30, 2020.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0&#160;million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $107.2&#160;million remained available for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the nine months ended September&#160;30, 2020, the Company withheld approximately 0.5&#160;million shares of its common stock to satisfy minimum statutory withholding obligations of $8.5&#160;million in connection with the vesting of restricted stock and deferred stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. &lt;/div&gt;&lt;/div&gt;</md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn08_31_2018"
      decimals="-5"
      unitRef="Unit_USD">500000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">107200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_shares">500000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2020To09_30_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">8500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2020To09_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September&#160;30, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#x2019;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#x2019;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_15530393"
          xlink:label="Fact_15530393"
          xlink:type="locator"/>
        <link:footnote id="FN_57535" xlink:label="FN_57535" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Due to a loss from continuing operations for the three months and nine months ended September 30, 2020, no incremental shares are included because the effect would be antidilutive.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530393"
          xlink:to="FN_57535"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530394"
          xlink:label="Fact_15530394"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530394"
          xlink:to="FN_57535"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530395"
          xlink:label="Fact_15530395"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530395"
          xlink:to="FN_57535"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530396"
          xlink:label="Fact_15530396"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530396"
          xlink:to="FN_57535"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530683"
          xlink:label="Fact_15530683"
          xlink:type="locator"/>
        <link:footnote id="FN_57539" xlink:label="FN_57539" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Presented within retained (deficit) earnings as the balance is immaterial.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530683"
          xlink:to="FN_57539"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530684"
          xlink:label="Fact_15530684"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530684"
          xlink:to="FN_57539"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530706"
          xlink:label="Fact_15530706"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530706"
          xlink:to="FN_57539"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530707"
          xlink:label="Fact_15530707"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530707"
          xlink:to="FN_57539"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530731"
          xlink:label="Fact_15530731"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530731"
          xlink:to="FN_57539"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15530732"
          xlink:label="Fact_15530732"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15530732"
          xlink:to="FN_57539"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15532133"
          xlink:label="Fact_15532133"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15532133"
          xlink:to="FN_57539"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_15532134"
          xlink:label="Fact_15532134"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_15532134"
          xlink:to="FN_57539"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495642527688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEDNAX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,598,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495635117080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 294,512<span></span>
</td>
<td class="nump">$ 107,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">81,574<span></span>
</td>
<td class="nump">74,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">267,125<span></span>
</td>
<td class="nump">434,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">13,317<span></span>
</td>
<td class="nump">17,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">22,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">20,287<span></span>
</td>
<td class="nump">11,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">951,548<span></span>
</td>
<td class="nump">85,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,651,160<span></span>
</td>
<td class="nump">731,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">78,570<span></span>
</td>
<td class="nump">72,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,480,668<span></span>
</td>
<td class="nump">1,479,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">27,665<span></span>
</td>
<td class="nump">28,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use&#160;assets</a></td>
<td class="nump">58,993<span></span>
</td>
<td class="nump">56,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">62,950<span></span>
</td>
<td class="nump">86,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">64,820<span></span>
</td>
<td class="nump">48,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,641,580<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,424,826<span></span>
</td>
<td class="nump">4,145,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">388,517<span></span>
</td>
<td class="nump">410,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">18,695<span></span>
</td>
<td class="nump">18,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">78,712<span></span>
</td>
<td class="nump">106,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">488,364<span></span>
</td>
<td class="nump">541,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">1,742,263<span></span>
</td>
<td class="nump">1,730,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">40,220<span></span>
</td>
<td class="nump">44,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">242,366<span></span>
</td>
<td class="nump">204,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">63,630<span></span>
</td>
<td class="nump">56,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">42,977<span></span>
</td>
<td class="nump">22,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Liabilities held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,005<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,619,820<span></span>
</td>
<td class="nump">2,646,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000 shares authorized; 85,504 and 84,248 shares issued and outstanding, respectively</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,023,974<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained (deficit) earnings</a></td>
<td class="num">(222,058)<span></span>
</td>
<td class="nump">510,134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total MEDNAX, Inc. shareholders' equity</a></td>
<td class="nump">804,761<span></span>
</td>
<td class="nump">1,498,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">805,006<span></span>
</td>
<td class="nump">1,498,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 3,424,826<span></span>
</td>
<td class="nump">$ 4,145,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities excluding accrued income taxes current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt and capital lease obligations excluding long term line of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495634702088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,504,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,504,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495631563368">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 460,635<span></span>
</td>
<td class="nump">$ 454,913<span></span>
</td>
<td class="nump">$ 1,317,321<span></span>
</td>
<td class="nump">$ 1,321,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">309,904<span></span>
</td>
<td class="nump">301,306<span></span>
</td>
<td class="nump">909,168<span></span>
</td>
<td class="nump">880,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,440<span></span>
</td>
<td class="nump">22,581<span></span>
</td>
<td class="nump">66,455<span></span>
</td>
<td class="nump">72,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66,346<span></span>
</td>
<td class="nump">63,284<span></span>
</td>
<td class="nump">194,276<span></span>
</td>
<td class="nump">185,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,195<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="nump">18,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,291<span></span>
</td>
<td class="nump">12,766<span></span>
</td>
<td class="nump">60,846<span></span>
</td>
<td class="nump">32,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">440,176<span></span>
</td>
<td class="nump">406,345<span></span>
</td>
<td class="nump">1,251,494<span></span>
</td>
<td class="nump">1,189,547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,459<span></span>
</td>
<td class="nump">48,568<span></span>
</td>
<td class="nump">65,827<span></span>
</td>
<td class="nump">131,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">802<span></span>
</td>
<td class="nump">13,064<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27,250)<span></span>
</td>
<td class="num">(29,909)<span></span>
</td>
<td class="num">(83,180)<span></span>
</td>
<td class="num">(91,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">282<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,434)<span></span>
</td>
<td class="num">(28,321)<span></span>
</td>
<td class="num">(69,035)<span></span>
</td>
<td class="num">(86,741)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">20,247<span></span>
</td>
<td class="num">(3,208)<span></span>
</td>
<td class="nump">44,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,677)<span></span>
</td>
<td class="num">(7,360)<span></span>
</td>
<td class="num">(10,859)<span></span>
</td>
<td class="num">(12,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">(Loss) income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,652)<span></span>
</td>
<td class="nump">12,887<span></span>
</td>
<td class="num">(14,067)<span></span>
</td>
<td class="nump">32,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38,392)<span></span>
</td>
<td class="num">(1,268,803)<span></span>
</td>
<td class="num">(718,125)<span></span>
</td>
<td class="num">(1,539,314)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (41,044)<span></span>
</td>
<td class="num">$ (1,255,916)<span></span>
</td>
<td class="num">$ (732,192)<span></span>
</td>
<td class="num">$ (1,507,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract', window );"><strong>(Loss) income from continuing operations:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.03)<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="num">(0.17)<span></span>
</td>
<td class="nump">0.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract', window );"><strong>Loss from discontinued operations:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.46)<span></span>
</td>
<td class="num">(15.39)<span></span>
</td>
<td class="num">(8.62)<span></span>
</td>
<td class="num">(18.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.46)<span></span>
</td>
<td class="num">(15.31)<span></span>
</td>
<td class="num">(8.62)<span></span>
</td>
<td class="num">(18.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.49)<span></span>
</td>
<td class="num">(15.23)<span></span>
</td>
<td class="num">(8.79)<span></span>
</td>
<td class="num">(17.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (15.15)<span></span>
</td>
<td class="num">$ (8.79)<span></span>
</td>
<td class="num">$ (17.88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">82,441<span></span>
</td>
<td class="nump">83,260<span></span>
</td>
<td class="nump">83,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">82,883<span></span>
</td>
<td class="nump">83,260<span></span>
</td>
<td class="nump">84,302<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Due to a loss from continuing operations for the three months and nine months ended September 30, 2020, no incremental shares are included because the effect would be antidilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents Income (Loss) from continuing operations, per basic and diluted share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495552154040">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained (Deficit) Earnings [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,087,884<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 992,647<span></span>
</td>
<td class="nump">$ 2,094,359<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(242,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodValueStockSwaps', window );">Stock swaps</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(78,982)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">(28,740)<span></span>
</td>
<td class="num">(50,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,779,812<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">977,872<span></span>
</td>
<td class="nump">1,801,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,087,884<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">992,647<span></span>
</td>
<td class="nump">2,094,359<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,507,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,479,360<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">977,709<span></span>
</td>
<td class="nump">500,809<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,779,812<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">977,872<span></span>
</td>
<td class="nump">1,801,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,675<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(65,527)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">(29,196)<span></span>
</td>
<td class="num">(36,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,725,027<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">967,429<span></span>
</td>
<td class="nump">1,756,757<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,255,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,255,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,479,360<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">977,709<span></span>
</td>
<td class="nump">500,809<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,498,996<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,542)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,487,396<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">995,257<span></span>
</td>
<td class="nump">491,287<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,498,996<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(732,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">805,006<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">1,023,974<span></span>
</td>
<td class="num">(219,823)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,487,396<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">995,257<span></span>
</td>
<td class="nump">491,287<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(672,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(672,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(501)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">826,570<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">1,004,786<span></span>
</td>
<td class="num">(179,071)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(41,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contribution from noncontrolling Interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,452)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">(5,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 805,006<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">$ 1,023,974<span></span>
</td>
<td class="num">$ (219,823)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Presented within retained (deficit) earnings as the balance is immaterial.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodValueStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodValueStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495628536008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (732,192)<span></span>
</td>
<td class="num">$ (1,507,033)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="nump">718,125<span></span>
</td>
<td class="nump">1,539,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">20,749<span></span>
</td>
<td class="nump">18,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">4,076<span></span>
</td>
<td class="nump">4,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">36,120<span></span>
</td>
<td class="nump">27,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">30,214<span></span>
</td>
<td class="num">(13,484)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">30,006<span></span>
</td>
<td class="nump">7,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,716)<span></span>
</td>
<td class="num">(22,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">7,703<span></span>
</td>
<td class="nump">21,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(36,433)<span></span>
</td>
<td class="num">(2,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable / receivable</a></td>
<td class="num">(28,837)<span></span>
</td>
<td class="num">(25,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="nump">15,703<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">8,157<span></span>
</td>
<td class="num">(19,768)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities &#8211; continuing operations</a></td>
<td class="nump">71,645<span></span>
</td>
<td class="nump">36,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities&#8212;discontinued operations</a></td>
<td class="nump">144,841<span></span>
</td>
<td class="nump">186,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">216,486<span></span>
</td>
<td class="nump">222,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="num">(2,225)<span></span>
</td>
<td class="num">(31,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(36,090)<span></span>
</td>
<td class="num">(13,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">30,865<span></span>
</td>
<td class="nump">26,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(21,809)<span></span>
</td>
<td class="num">(14,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale of business, net of cash sold</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities &#8211; continuing operations</a></td>
<td class="num">(28,179)<span></span>
</td>
<td class="num">(33,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) investing activities&#8212;discontinued operations</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="num">(20,793)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(25,100)<span></span>
</td>
<td class="num">(54,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on credit agreement</a></td>
<td class="nump">527,500<span></span>
</td>
<td class="nump">1,225,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on credit agreement</a></td>
<td class="num">(527,500)<span></span>
</td>
<td class="num">(1,755,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments for credit facility amendment and financing costs</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(9,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on finance lease obligations</a></td>
<td class="num">(433)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,697<span></span>
</td>
<td class="nump">9,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Contribution from noncontrolling interests</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(8,495)<span></span>
</td>
<td class="num">(144,925)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash used in financing activities &#8211; continuing operations</a></td>
<td class="num">(3,496)<span></span>
</td>
<td class="num">(174,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities&#8212;discontinued operations</a></td>
<td class="num">(1,248)<span></span>
</td>
<td class="num">(8,909)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,744)<span></span>
</td>
<td class="num">(183,571)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">186,642<span></span>
</td>
<td class="num">(15,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">107,870<span></span>
</td>
<td class="nump">40,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 294,512<span></span>
</td>
<td class="nump">$ 25,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626393288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation and New Accounting Pronouncements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation and New Accounting Pronouncements: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">r</div>esults of the interim periods presented. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#8220;MDX&#8221;) together with the accounts of MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#8220;MEDNAX&#8221; and the &#8220;Company&#8221; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a 37.5% economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the Company entered into a joint venture in which it owns a 51% economic interest and for which it is deemed the primary beneficiary. The equity interests of the outside investor in the equity of this consolidated entity is accounted for and presented as noncontrolling interests on the Company&#8217;s Consolidated Balance Sheets. Although </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the<div style="display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">joint</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"> venture was <div style="letter-spacing: 0px; top: 0px;;display:inline;">formed</div> during the third quarter of 2020, it has not yet begun operations. Any future results of operations attributable to <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>noncontrolling interests<div style="letter-spacing: 0px; top: 0px;;display:inline;"> will be accounted for and presented as such</div> on the Company&#8217;s Consolidated Statements of Income. </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">Report on Form 10-K (the &#8220;Form<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>10-K&#8221;). </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2019.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, the Company divested its anesthesiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">9,</div>&#160;2020, the Company </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">entered into</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a definitive agreement to divest its radiology services medical group. The operating results of this medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for additional information. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626353576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19")<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAbstract', window );"><strong>Extraordinary Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock', window );">Coronavirus Pandemic ("COVID-19")</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;):</div> </div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. &#160;&#160;&#160;&#160;Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesiology services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for information regarding the divestment of the Company&#8217;s anesthesiology services medical group and the planned divestment of the Company&#8217;s radiology services medical group. The Company&#8217;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, experienced a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Overall, the Company&#8217;s operating results were significantly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#8217;s response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) the Company enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. The Company also divested its anesthesiology services medical group in May 2020, where operating results were significantly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In response to the anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the Company&#8217;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At September&#160;30, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023 and its 6.25% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months. At September&#160;30, 2020, the Company had no outstanding&#160;principal balance on its Credit Agreement. The Company had outstanding letters of credit of $0.2&#160;million which reduced the amount available on its Credit Agreement to $899.8&#160;million at September&#160;30, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds in April 2020, of which the Company&#8217;s affiliated physician practices <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">within continuing operations </div></div>received an aggregate of approximately $20.0&#160;million during the nine months ended September&#160;30, 2020. The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020. </div></div> <div style="margin: 6pt 0in 18pt 23.8pt; text-indent: 24.5pt; font-family: &quot;Times New Roman&quot;, serif; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The COVID-19 <div style="letter-spacing: 0px; top: 0px;;display:inline;">pandemic has</div> materially <div style="letter-spacing: 0px; top: 0px;;display:inline;">impacted the Company&#8217;s</div> financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. </div></div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extraordinary Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495627878520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Equivalents and Investments: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents consisted entirely of money market funds totaling $2.4&#160;million and $16.8&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at September&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">56,680</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,962</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,523</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,066</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,842</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 64%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">81,574</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626355816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuati<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>n inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div> <div style="text-align: center;"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 8%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 8%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,775</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">81,574</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,446</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">759,375</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,035,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 18pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#8217;s line of credit approximates fair value. If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level&#160;2 in the fair value hierarchy. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626445688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable and Net Revenue: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,119,171</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,750,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(852,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,315,998</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 65%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">267,125</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">434,266</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient <div style="letter-spacing: 0px; top: 0px;;display:inline;">service </div>revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. </div></div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">382,936</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">400,330</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,133,313</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,159,363</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">61,186</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51,149</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">154,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">149,407</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,513</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,434</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,168</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,389</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 60%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">460,635</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">454,913</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,317,321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,321,159</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495628016408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Assets Held for Sale and Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract', window );"><strong>Business Combinations Assets Held For Sale And Discontinued Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock', window );">Business Combinations, Assets Held for Sale and Discontinued Operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combinations, Assets Held for Sale and Discontinued Operations: </div></div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">During the nine months ended September&#160;30, 2020, the Company completed the acquisition of one pediatric subspecialty practice for total consideration of $2.1&#160;million, of which $1.9&#160;million was paid in cash and $0.2&#160;million was recorded as a contingent consideration liability. This acquisition expanded the Company&#8217;s national network of physician practices. In connection with this acquisition, the Company recorded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-deductible</div> goodwill of $0.8&#160;million and other intangible assets consisting primarily of physician and hospital agreements of $1.3&#160;million.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of <div style="display:inline;">the </div>Radiology Services Medical Group </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div></div>&#160;2020, the Company entered into a </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">securities purchase</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement with Radiology Partners, Inc., pursuant to which Radiology Partners, Inc. will acquire the Company&#8217;s radiology services medical group for $885&#160;million </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cash, subject to certain customary adjustments.</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;This divestiture will allow the Company to focus solely on its Pediatrix and Obstetrix medical groups. The Company determined that the criterion to classify the radiology services medical group as assets held for sale within the Company&#8217;s Consolidated Balance Sheets effective September&#160;30, 2020 were met. Accordingly, the assets and liabilities of the radiology services medical group were classified as current assets and current liabilities held for sale at September&#160;30, 2020 as the Company expects to divest of the radiology services medical group within the next twelve months. The classification to assets held for sale impacted the net book value of the assets and liabilities expected to be transferred upon sale. The estimated fair value of the radiology services medical group was determined using the purchase price in the </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">purchase</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement along with estimated broker, accounting, legal and </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">selling</div></div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> expenses.</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;The Company deemed the carrying amount of </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>assets</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> within the medical group, specifically accounts receivable and property and equipment, to represent fair value and therefore recorded a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge of&#160;$43.0&#160;million against goodwill, which represented the difference between the estimated fair value of the radiology services medical group and the carrying amount of the net assets held for sale. Recognition of the charge against goodwill resulted in a tax benefit which </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">generated an additional $4.0&#160;million deferred tax asset that increased the fair value of the medical group. An incremental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge is then required to reduce the <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">radiology services </div></div>medical group&#8217;s net assets to its previously determined fair value. Accordingly, the Company recorded the incremental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge of $4.0&#160;million for a total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge of $47.0&#160;million, reducing the goodwill balance of the radiology services medical group. Upon completion of the divestiture, the Company could record an additional gain or loss on disposal at the time final net proceeds are determined.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in accordance with accounting guidance for discontinued operations, the expected divestiture of the radiology services medical group was deemed to represent a fundamental strategic shift that will have a major effect on the Company&#8217;s operations, and accordingly, the operating results of the radiology services medical group were reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 with prior periods recast to conform with the current period presentation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the major classes of assets and liabilities of the radiology services medical group that are included as assets and liabilities held for sale in the accompanying Consolidated Balance Sheets as of September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">54,284</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">64,603</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other <div style="letter-spacing: 0px; top: 0px;;display:inline;">current&#160;</div>assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,819</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,744</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,078</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,204</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating leases <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,165</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,008</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">640,818</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">685,170</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">170,059</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">180,978</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,020</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,183</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36,305</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">40,724</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">951,548</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,033,614</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">39,505</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">42,474</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and finance leases</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,619</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,355</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">23,744</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,978</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,844</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">78,712</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">78,888</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the radiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">125,765</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">125,650</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">340,133</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">366,678</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84,718</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80,336</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">234,169</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">238,402</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,449</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,532</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,876</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,734</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,090</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,595</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,328</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,757</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,491</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">441</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,517</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,963</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,924</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,963</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,924</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">160,587</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">228,562</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">369,428</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">443,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(34,822</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(102,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(29,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(76,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> income, net</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,369</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,059</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,035</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,768</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(33,453</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(100,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(26,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(72,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.59in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax (provision) benefit</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(62</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,907</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,687</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(33,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(96,946</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(28,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(75,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of </div></div><div style="font-style:italic;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anesthesiology Services Medical Group </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest the Company&#8217;s anesthesiology services medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $50.0&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250&#160;million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching $250&#160;million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology services medical group, which net of various other working capital items, approximated $110.0&#160;million </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">at March&#160;31, 2020. <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div>The </div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> operating results of the anesthesiology services medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2020 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A single </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">anesthesiology </div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">practice&#160;was not included in the divestiture of the anesthesiology services medical group, and </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">continues to operate as an affiliate of the Company. Its</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> results of operations are reflected in the three months ended September&#160;30, 2020 while the incremental loss on sale </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the anesthesiology services medical group </div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recorded during the three months ended September&#160;30, 2020 reflects a true up of various divested account balances during the third quarter of 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The total preliminary loss on sale <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">of the anesthesiology services medical group </div></div>recorded during the nine months ended September&#160;30, 2020 was $648.7&#160;million. Upon completion of a valuation for the contingent economic interest and working capital <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up,</div> final net proceeds will be determined, and the Company will adjust the loss on sale at that time. In addition, as a result of the sale, the Company currently estimates that it will generate an approximately $1.68&#160;billion capital loss carryforward <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">that will expire</div></div> in 2025. Based on management&#8217;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $419.0&#160;million valuation allowance against this deferred tax asset as of September&#160;30, 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the anesthesiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,700</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">309,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">377,661</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">924,845</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,746</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,157</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">351,408</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">746,237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,837</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,254</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,537</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,338</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,179</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,909</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,605</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,308</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,863</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,785</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,634</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,506</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,331,291</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,331,291</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on sale, net</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,499</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">644,653</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,498</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,615,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,067,436</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,180,343</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,798</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,305,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(689,775</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,255,498</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> (expense) income, net</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,798</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,305,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(689,724</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,255,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">129,241</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,661</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">115,987</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(4,698</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(1,176,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(684,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(1,139,525</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of MedData </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company divested of <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">its</div></div> management services organization, MedData, in October 2019. During the nine months ended September&#160;30, 2020, the Company recorded a net incremental loss on the sale of MedData of $5.8&#160;million, primarily for the finalization of certain transaction related expenses, a working capital <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up</div> and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration. This incremental loss is reflected as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the nine months ended September&#160;30, 2020. The operating results of MedData were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and nine months ended September&#160;30, 2019.</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations assets held for sale and discontinued operations disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations assets held for sale and discontinued operations disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626367768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Accrued Expenses: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">60,956</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">35,410</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">158,579</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">193,631</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">48,474</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54,768</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">44,699</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,940</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,910</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38,099</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">49,219</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">388,517</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">410,637</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net decrease in accrued salaries and bonuses of $35.1&#160;million, from December&#160;31, 2019 to September&#160;30, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the nine months ended September&#160;30, 2020. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495634780712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common and Common Equivalent Shares: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per common share calculation for the three and nine months ended September&#160;30, 2020 and 2019 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82,441</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,260</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,846</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">442</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">456</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common equivalent shares outstanding (a)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82,883</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,260</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84,302</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted net income per common share calculation</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">829</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">962</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,004</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">796</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a)</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the three months and nine months ended September&#160;30, 2020, no incremental shares are included because the effect wou<div style="letter-spacing: 0px; top: 0px;;display:inline;">l</div>d be antidilutive. </div></div></div></div> </td> </tr> </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495627982904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans and Stock Purchase Plans: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;A&amp;R 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Under the A&amp;R 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock, deferred stock awards&#160;and stock options ratably over the corresponding vesting periods. During the nine months ended September&#160;30, 2020, the Company granted 1.4&#160;million shares of restricted stock and 1.0&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> of stock underlying&#160;</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options to its employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under the A&amp;R 2008 Incentive Plan. At September&#160;30, 2020, the Company had 5.0&#160;million shares available for future grants and awards under the A&amp;R 2008 Incentive Plan.</div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;">Under the Company&#8217;s 1996 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers are permitted to purchase the Company&#8217;s common stock at 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.</div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers. During the nine months ended September&#160;30, 2020, approximately 0.4&#160;million shares in the aggregate were issued under the ESPP and SPP. At September&#160;30, 2020, the Company had approximately 0.6&#160;million shares in the aggregate reserved for issuance under the ESPP and SPP.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three and nine months ended September&#160;30, 2020 and 2019, the Company recognized stock-based compensation expense of $4.5&#160;million and $18.2&#160;million, and $7.6&#160;million and $27.6&#160;million, respectively. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626237496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Repurchase Programs: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time-to-time</div></div> based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the nine months ended September&#160;30, 2020.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0&#160;million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $107.2&#160;million remained available for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the nine months ended September&#160;30, 2020, the Company withheld approximately 0.5&#160;million shares of its common stock to satisfy minimum statutory withholding obligations of $8.5&#160;million in connection with the vesting of restricted stock and deferred stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626375928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of September&#160;30, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495634607048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626238504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at September&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">56,680</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,962</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,523</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,066</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,529</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,842</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 64%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">81,574</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495627913720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/> Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,411</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,775</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">81,574</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 58%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,446</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">759,375</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,035,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626305272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,119,171</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,750,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(852,046</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,315,998</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 65%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">267,125</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">434,266</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">382,936</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">400,330</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,133,313</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,159,363</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">61,186</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51,149</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">154,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">149,407</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,513</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,434</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,168</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,389</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 60%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">460,635</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">454,913</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,317,321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,321,159</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495627894296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Assets Held for Sale and Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyPartnersIncMember', window );">Radiology Partners Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the major classes of assets and liabilities of the radiology services medical group that are included as assets and liabilities held for sale in the accompanying Consolidated Balance Sheets as of September&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">54,284</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">64,603</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other <div style="letter-spacing: 0px; top: 0px;;display:inline;">current&#160;</div>assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,819</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,744</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,078</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,204</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating leases <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,165</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,008</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">640,818</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">685,170</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">170,059</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">180,978</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,020</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,183</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36,305</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">40,724</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">951,548</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,033,614</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">39,505</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">42,474</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and finance leases</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,619</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,355</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">23,744</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,978</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,844</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">78,712</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">78,888</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the radiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">125,765</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">125,650</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">340,133</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">366,678</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84,718</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80,336</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">234,169</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">238,402</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,449</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,532</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,273</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,876</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,734</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,178</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,090</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,595</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,328</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,757</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,491</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">441</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,517</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,963</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,924</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,963</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">117,924</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">160,587</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">228,562</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">369,428</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">443,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(34,822</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(102,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(29,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(76,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> income, net</div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,369</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,059</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,035</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,768</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(33,453</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(100,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(26,260</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(72,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.59in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax (provision) benefit</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(62</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,907</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,988</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,687</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.29in; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(33,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(96,946</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(28,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(75,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the anesthesiology services medical group for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,700</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">309,602</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">377,661</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">924,845</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,746</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,157</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">351,408</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">746,237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,837</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,254</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,537</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,338</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,179</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,909</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,605</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,308</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,863</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,785</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,634</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,506</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,331,291</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,331,291</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on sale, net</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,499</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">644,653</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,498</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,615,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,067,436</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,180,343</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,798</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,305,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(689,775</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,255,498</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> (expense) income, net</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,798</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,305,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(689,724</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,255,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">129,241</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,661</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">115,987</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(4,698</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(1,176,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(684,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(1,139,525</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyPartnersIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_RadiologyPartnersIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495627665544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">60,956</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">35,410</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">158,579</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">193,631</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">48,474</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54,768</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">44,699</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,940</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,910</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38,099</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">49,219</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">388,517</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">410,637</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626089160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per common share calculation for the three and nine months ended September&#160;30, 2020 and 2019 is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82,441</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,260</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,846</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">442</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">456</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common equivalent shares outstanding (a)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,862</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">82,883</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,260</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84,302</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted net income per common share calculation</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">829</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">962</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,004</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">796</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a)</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the three months and nine months ended September&#160;30, 2020, no incremental shares are included because the effect wou<div style="letter-spacing: 0px; top: 0px;;display:inline;">l</div>d be antidilutive. </div></div></div></div> </td> </tr> </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495631802760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495552109528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 899.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member', window );">Senior Unsecurd Notes 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member', window );">Senior Unsecurd Notes 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Estimated EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.00:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.50:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member', window );">Forecast For Fourth Quarter Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.75:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member', window );">Forecast For First Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member', window );">Forecast For Second Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit Facility Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue', window );">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes', window );">Deferred Payment Of Social Security Taxes | %</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Rural Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageIncreaseDecreaseInSalaryAndWage', window );">Decrease In Salary | %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ContributionsInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributions In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ContributionsInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Earnings Before Interest Taxes Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageIncreaseDecreaseInSalaryAndWage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase Decrease In Salary And Wage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageIncreaseDecreaseInSalaryAndWage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Deferred Payment Of Social Security Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfDeferredPaymentOfSocialSecurityTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_SupplementaryLeverageRatioRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplementary Leverage Ratio Required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_SupplementaryLeverageRatioRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAxis=md_CovidNinenteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=md_RuralAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=md_RuralAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495626338984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CashEquivalentsAndInvestmentsLineItems', window );"><strong>Cash Equivalents And Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashEquivalentsAndInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashEquivalentsAndInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495635095912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 81,574<span></span>
</td>
<td class="nump">$ 74,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">56,680<span></span>
</td>
<td class="nump">32,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">13,523<span></span>
</td>
<td class="nump">29,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">6,529<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 4,842<span></span>
</td>
<td class="nump">$ 4,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495642904472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of fair value on a recurring basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 2,411<span></span>
</td>
<td class="nump">$ 16,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual Funds</a></td>
<td class="nump">14,446<span></span>
</td>
<td class="nump">14,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 81,574<span></span>
</td>
<td class="nump">$ 74,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495632070664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember', window );">2023 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">759,375<span></span>
</td>
<td class="nump">766,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember', window );">2027 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="nump">$ 1,025,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495631514728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross accounts receivable</a></td>
<td class="nump">$ 1,119,171<span></span>
</td>
<td class="nump">$ 1,750,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for contractual adjustments and uncollectibles</a></td>
<td class="num">(852,046)<span></span>
</td>
<td class="num">(1,315,998)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 267,125<span></span>
</td>
<td class="nump">$ 434,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495635073016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 460,635<span></span>
</td>
<td class="nump">$ 454,913<span></span>
</td>
<td class="nump">$ 1,317,321<span></span>
</td>
<td class="nump">$ 1,321,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">382,936<span></span>
</td>
<td class="nump">400,330<span></span>
</td>
<td class="nump">1,133,313<span></span>
</td>
<td class="nump">1,159,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">61,186<span></span>
</td>
<td class="nump">51,149<span></span>
</td>
<td class="nump">154,840<span></span>
</td>
<td class="nump">149,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 16,513<span></span>
</td>
<td class="nump">$ 3,434<span></span>
</td>
<td class="nump">$ 29,168<span></span>
</td>
<td class="nump">$ 12,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495634965288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495551977272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Assets Held for Sale and Discontinued Operations -  Additional information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net incremental loss on the sale of MedData</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (38,392)<span></span>
</td>
<td class="num">$ (1,268,803)<span></span>
</td>
<td class="num">$ (718,125)<span></span>
</td>
<td class="num">$ (1,539,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,479,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=md_PediatricSubspecialtyPracticeMember', window );">Pediatric Subspecialty Practice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business acquisition consideration paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_NumberOfPediatricSubspecialtyPracticesAcquired', window );">Number of other pediatric subspecialty practices acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business acquisition contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Deferred Tax Assets, Goodwill and Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary and incremental gain loss on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase decrease in valuation allowance deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net incremental loss on the sale of MedData</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,698)<span></span>
</td>
<td class="num">$ (1,176,187)<span></span>
</td>
<td class="num">(684,063)<span></span>
</td>
<td class="num">$ (1,139,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsReceivableRetained', window );">Accounts receivable retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member] | Tax Year Two Thousand and Twenty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CapitalLossCarryForward', window );">Capital loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember', window );">Divestiture of MedData [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net incremental loss on the sale of MedData</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember', window );">Radiology Services Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Non-cash charge against goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DeferredTaxAssetsAxis=md_DeferredTaxAssetsGoodwillMember', window );">Deferred Tax Assets Goodwill [Member] | Pediatric Subspecialty Practice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Non-cash charge against goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable retained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CapitalLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CapitalLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MaximumConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MaximumConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NumberOfPediatricSubspecialtyPracticesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of other pediatric subspecialty practices acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NumberOfPediatricSubspecialtyPracticesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=md_PediatricSubspecialtyPracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=md_PediatricSubspecialtyPracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=md_TaxYearTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=md_TaxYearTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DeferredTaxAssetsAxis=md_DeferredTaxAssetsGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DeferredTaxAssetsAxis=md_DeferredTaxAssetsGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495634489160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Management Services Service Line (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,641,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember', window );">Radiology Services Medical Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">54,284<span></span>
</td>
<td class="nump">64,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,819<span></span>
</td>
<td class="nump">9,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property and equipment, net</a></td>
<td class="nump">20,078<span></span>
</td>
<td class="nump">19,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent', window );">Operating leases right-of-use assets</a></td>
<td class="nump">14,165<span></span>
</td>
<td class="nump">15,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent', window );">Goodwill</a></td>
<td class="nump">640,818<span></span>
</td>
<td class="nump">685,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent', window );">Intangible assets, net</a></td>
<td class="nump">170,059<span></span>
</td>
<td class="nump">180,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets', window );">Deferred income tax assets</a></td>
<td class="nump">6,020<span></span>
</td>
<td class="nump">18,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">36,305<span></span>
</td>
<td class="nump">40,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total Assets</a></td>
<td class="nump">951,548<span></span>
</td>
<td class="nump">1,033,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">39,505<span></span>
</td>
<td class="nump">42,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent', window );">Operating and finance leases</a></td>
<td class="nump">13,619<span></span>
</td>
<td class="nump">14,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">23,744<span></span>
</td>
<td class="nump">21,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">1,844<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total Liabilities</a></td>
<td class="nump">$ 78,712<span></span>
</td>
<td class="nump">$ 78,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation long term professional liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation operating and finance leases liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_RadiologyServicesMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495630737192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="num">$ (38,392)<span></span>
</td>
<td class="num">$ (1,268,803)<span></span>
</td>
<td class="num">$ (718,125)<span></span>
</td>
<td class="num">$ (1,539,314)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyPartnersIncMember', window );">Radiology Partners Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net revenue</a></td>
<td class="nump">125,765<span></span>
</td>
<td class="nump">125,650<span></span>
</td>
<td class="nump">340,133<span></span>
</td>
<td class="nump">366,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits', window );">Cost of service salaries and benefits</a></td>
<td class="nump">84,718<span></span>
</td>
<td class="nump">80,336<span></span>
</td>
<td class="nump">234,169<span></span>
</td>
<td class="nump">238,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses', window );">Cost of service supplies and other operating expenses</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">4,273<span></span>
</td>
<td class="num">(1,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">19,876<span></span>
</td>
<td class="nump">20,734<span></span>
</td>
<td class="nump">57,178<span></span>
</td>
<td class="nump">64,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,090<span></span>
</td>
<td class="nump">7,595<span></span>
</td>
<td class="nump">20,328<span></span>
</td>
<td class="nump">22,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">2,491<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">6,517<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment', window );">Goodwill impairment</a></td>
<td class="nump">46,963<span></span>
</td>
<td class="nump">117,924<span></span>
</td>
<td class="nump">46,963<span></span>
</td>
<td class="nump">117,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">160,587<span></span>
</td>
<td class="nump">228,562<span></span>
</td>
<td class="nump">369,428<span></span>
</td>
<td class="nump">443,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(34,822)<span></span>
</td>
<td class="num">(102,912)<span></span>
</td>
<td class="num">(29,295)<span></span>
</td>
<td class="num">(76,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense', window );">Non-operating (expense) income, net</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes</a></td>
<td class="num">(33,453)<span></span>
</td>
<td class="num">(100,853)<span></span>
</td>
<td class="num">(26,260)<span></span>
</td>
<td class="num">(72,146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax (provision) benefit</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">3,907<span></span>
</td>
<td class="num">(1,988)<span></span>
</td>
<td class="num">(3,687)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="num">(33,515)<span></span>
</td>
<td class="num">(96,946)<span></span>
</td>
<td class="num">(28,248)<span></span>
</td>
<td class="num">(75,833)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net revenue</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">309,602<span></span>
</td>
<td class="nump">377,661<span></span>
</td>
<td class="nump">924,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits', window );">Cost of service salaries and benefits</a></td>
<td class="nump">2,746<span></span>
</td>
<td class="nump">250,157<span></span>
</td>
<td class="nump">351,408<span></span>
</td>
<td class="nump">746,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses', window );">Cost of service supplies and other operating expenses</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
<td class="nump">5,254<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">18,338<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
<td class="nump">57,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,605<span></span>
</td>
<td class="nump">6,308<span></span>
</td>
<td class="nump">17,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses', window );">Transformational and restructuring related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,785<span></span>
</td>
<td class="nump">28,634<span></span>
</td>
<td class="nump">17,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale', window );">Loss on sale, net</a></td>
<td class="nump">4,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">7,498<span></span>
</td>
<td class="nump">1,615,013<span></span>
</td>
<td class="nump">1,067,436<span></span>
</td>
<td class="nump">2,180,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,798)<span></span>
</td>
<td class="num">(1,305,411)<span></span>
</td>
<td class="num">(689,775)<span></span>
</td>
<td class="num">(1,255,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense', window );">Non-operating (expense) income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes</a></td>
<td class="num">(4,798)<span></span>
</td>
<td class="num">(1,305,428)<span></span>
</td>
<td class="num">(689,724)<span></span>
</td>
<td class="num">(1,255,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax (provision) benefit</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">129,241<span></span>
</td>
<td class="nump">5,661<span></span>
</td>
<td class="nump">115,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="num">$ (4,698)<span></span>
</td>
<td class="num">$ (1,176,187)<span></span>
</td>
<td class="num">$ (684,063)<span></span>
</td>
<td class="num">$ (1,139,525)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Cost of Salaries and Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Cost of Service Supplies and Other Operating Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain or Loss on Assets Held for Sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation goodwill impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents disposal group, including discontinued operation, operating expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation other income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation transformational and restructuring expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_RadiologyPartnersIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_RadiologyPartnersIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495642573048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 60,956<span></span>
</td>
<td class="nump">$ 35,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and bonuses</a></td>
<td class="nump">158,579<span></span>
</td>
<td class="nump">193,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">48,474<span></span>
</td>
<td class="nump">54,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">55,469<span></span>
</td>
<td class="nump">44,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">26,940<span></span>
</td>
<td class="nump">32,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">38,099<span></span>
</td>
<td class="nump">49,219<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 388,517<span></span>
</td>
<td class="nump">$ 410,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495628279096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses', window );">Net decrease in accrued salaries and bonuses</a></td>
<td class="nump">$ 35.1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncreaseDecreaseInAccruedSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495631828344">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">82,441<span></span>
</td>
<td class="nump">83,260<span></span>
</td>
<td class="nump">83,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">83,862<span></span>
</td>
<td class="nump">82,883<span></span>
</td>
<td class="nump">83,260<span></span>
</td>
<td class="nump">84,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the diluted net income per common share calculation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">829<span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Due to a loss from continuing operations for the three months and nine months ended September 30, 2020, no incremental shares are included because the effect would be antidilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495630777400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Non Qualified Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=md_NonqualifiedstockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=md_NonqualifiedstockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140495634733752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of shares withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Amount withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "DX9E$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  I.&91J:2JBNT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)^E"A=#M1?&D(+B@> O)[&ZP:4(RTN[;F\;=+J(/X#$S?[[Y
M!J;306H?\3GZ@)$LIIO9#6.2.FS9D2A(@*2/Z%2J<V+,S;V/3E%^Q@,$I3_4
M :'AO 6'I(PB!0NP"BN1]9W14D=4Y.,9;_2*#Y]Q*#"C 0=T.%("40M@_3(Q
MG.:A@RM@@1%&E[X+:%9BJ?Z)+1U@Y^2<[)J:IJF>-B67=Q#P]O3X4M:M[)A(
MC1KSKV0EG0)NV67RZ^;N?O? ^H8WO!*BXNV.WTHN)&_?%]<??E=AYXW=VW]L
M?!'L._AU%_T74$L#!!0    ( "DX9E&97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MU^MJ>!.@QJ,X5:_,C.]?VMS)36[V>O?LOK+,F6BN*@WE80L\$@?>%ZF%^:D
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M?ZSSL/PF4!:LG7"[ <B"J7-? EDP%Q3;\ANP0X)I;GJT%C%"@!R<!0^UP9@
M63"-E6],&/:2,'M#NH] J[28,86<(;N'9=]!0U$2INB3JC\"8-!1?P-&_4TL
M TL:AN6+J3_J0A/SV.K!\=8JI"'@BCPRB1K\TC!^7US]40#4V+.G1@VJ:1C5
MSRZ.J MXY!NUAN\TS/=?$!S4Y?<9]LR=M+,9'*;W,8*# CESK&R],635=]A
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MH2Y6[4NO;HNZ+I;MG_,TT:*D,="_WQ5%_?BAN<#N56X7_P-02P,$%     @
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M.Q28_C)5Z/:O]]S91N'*RTZZ467?&!24LNK^IU_[0$P:0#]X ]HWH/,&W-&
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M+X/XS;F$MC&SIL"9:"X:LPMBI^H12&292+\."7&LU4YH4W"DQ72"H[)MLI
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MH;0Y.R?WO*THDXVG@;]T3RY3'KYZ51BU5IF$7F76NB$P+.P=N;%8-4'D%IM
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MBX\E1B(YWH#OG&OM@@UT=_"S/P!02P,$%     @ *3AF42B&:)<>!    @D
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MM5N*<L0>20JJ1B'4NT(K[8OY1$5G? *\@Z&RO<N^M*@+R$J^&<>T#Y101(Z
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M]7MT03NF/@_)KQ:J0F *P 9QE3D><]?K[1!+$I^01W'H^  )W3)(>)!XED_
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M'SN^\1&^09D^N8&M<<7;9IAWLH&L4<PPT.37]58;A?_/[Q-!DSYHXH(FQXK
ML<H;#D06PSY_UM[31,-'*H'GA!I,NC90;4'U;7(EW4#662-KC6:$*NCFD/T!
MA&I22(X#BN_-!#&E;#0"]?G5Z!/*_^A&:ZEJJ:A!TH^VG9%)ZJ?3$(5Q[,_2
M>/30"):QFG*<&^SVP#<:^Y-X3.*9'Z;IZ YR4.A5R@H(EU0,75/TG)&I'T;C
MT1J4807+,+*V#<VAEIH9DOC3),9ODLY&9V0:^9/+!-.X3/Q)].F?$PPFJ *U
M<WM"DTPVPK3#U%O[573=3N"'>[O''JC:,:$)AP*AX<7EQ".JW0VM8F3MYG$K
M#4ZW$TM<IZ"L ]X74IJ#8@/T"WKY%U!+ P04    "  I.&913\CO?&H#  !:
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6S%5MUOXD80?^>O&/FJ
MZDYRXP]L(!20(+FH)UU.47*]/E1]6.PQ7F7MI;MKN/SWG5T;0U1"*_6A+^SL
M[,QOOCW,]E(]ZQ+1P/=*U'KNE<9LIT&@LQ(KIJ_D%FMZ*:2JF*&KV@1ZJY#E
M3JD201R&HZ!BO/86,\=[4(N9;(S@-3XHT$U5,?6R0B'W<R_R#HQ'OBF-902+
MV99M\ G-K]L'1;>@1\EYA;7FL@:%Q=Q;1M-5:N6=P#>.>WU"@XUD+>6SO7S*
MYUYH'4*!F;$(C(X=WJ 0%HC<^+/#]'J35O&4/J#?N=@IEC73>"/%;SPWY=R;
M>)!CP1IA'N7^%^SB<0YF4FCW"_M6=IQZD#7:R*I3)@\J7K<G^][EX41A$KZA
M$'<*L?.[->2\O&6&+69*[D%9:4*SA O5:9-SO+9%>3**7CGIF<4=XPJ^,=$@
MW"/3C4+*N-'P_BM;"]0?9H$A*U8VR#K$58L8OX%X#?>R-J6&CW6.^6O]@+SK
M78P/+J[BBX!/N+V"8>A#',;A!;QA'_+0X0W_.>1;KC,A;=0:?E^NM5'4)7]<
ML)'T-A)G(WG+9QJ>O!$(LH"C/1^66B-EE]4Y?.9LS04WG&QWJ<^!^O01LT8I
M7F]@Q337YPIPT;8=XZG>L@SG'LVI1K5#;_&U1"BDH!FTR,86%]RK+3:OV^EV
M8[*FT05#XC>RVK+ZY<=WDS@:_ZRAX#6K,\X$R5.FFK913,D,,(4T7YEL:D-!
M$!@0L[!Q[UR>+2Z-\"&PM0W,BE!I#59K5'U]76IN,>NXD>5&U_">UV1)-IJ>
M]8?IX)C3$_(<W-^@!FT)I@/J4GRA45+/].DK&L*%S[A# 1'\ +&?1/:,1OYX
MG Z>2JG,3P951;'O4)LV]E8^ADGDI^,$QHF?1N'@OC$-)>GN%624^$DRLD<\
M2N!"AZ5]AZ47.^RNK\:GDVKTC;0T<,.4>K'I7E:V,.<:Z:*)_ZN1:FD@(]\Y
MA?&ZC?Y+Q_RKWNA3=M)49WB#D]F=#@AK"%^DH3D>IZ$?AB&=U_YPG![OHY$_
MH3XBT7$G&MD']TC4,#U01UZ<^B.BSK5*</*]KU!MW%;3X.:O_?3WW'YQ+MM]
M<11OM^X]4QNJ @@L2#6\LGM*M9NLO1BY==MC+0WM(D>6M/Q160%Z+R2%TUVL
M@?[OQ.(O4$L#!!0    ( "DX9E$V+J"([ ,  %0)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(Q+GAM;+56VV[C-A!]UU<,W&R1 &ITEZW4,9!DV]T^[#9(
MTO:AZ ,MC6TV$JF2=!SWZSND9*V-)$9>"E_$VYP9SCE#:KJ1ZE&O$ T\-[70
MEZ.5,>U%$.ARA0W3Y[)%03,+J1IFJ*N6@6X5LLH9-740AV$>-(R+T6SJQF[5
M;"K7IN8";Q7H==,PM;W&6FXN1]%H-W#'ERMC!X+9M&5+O$?S6WNKJ!<,*!5O
M4&@N!2A<7(ZNHHOKW*YW"W[GN-%[;; [F4OY:#N_5)>CT :$-9;&(C!Z/.$-
MUK4%HC#^Z3%'@TMKN-_>H?_L]DY[F3.--[+^@U=F=3F:C*#"!5O7YDYN/F._
MG\SBE;+6[A\VW=HT&T&YUD8VO3%%T'#1/=ESGX<]@TGXAD'<&\0N[LZ1B_(C
M,VPV57(#RJXF--MP6W76%!P7EI1[HVB6DYV9796E7 NCX0Y+Y$]L7B,P4<%7
MTL,=/J%8(YP^V&%]-@T,>;1V0=FC7W?H\1OH!7R1PJPT_"0JK [M XIT"#?>
MA7L='P6\Q_8<DM"'.(S#(WC)L/W$X25OX#W@LX'K6I:/\.?57!M%*OGK"&XZ
MX*8.-WTK3BJ>:DVYE MX)<6^S>]KZ3R..B"I/21!3)62JD33!+DS*X2%K*G:
MN%C"*1<T(M>:2-5G%QXET& S1S5D$3X26#<2V9&H\#XIJ345S MO< *1'T6%
M'XTCUQYGH1_GJ7=E_3%16M?*AN,RN68UL.IO4C&5,0%98:T%2=;5I-44G$ZR
MV _3',[@-/*3*/.+8@)GW@G$^=B/XHS<I$E*3O(CM&0#+=F[:=E3^&M,' =Z
M.$BR<;GISC7^+^W*<G CFY:)[???3>)H_*-V/*F^HN9;*)G!I53;%PP]K!3B
M0=W (6E?*98C\YXCU?((0\NSFVV9X40#:%1/G)C:!7,"R23VBR2WJ0Y#/TG"
MCN<D(4*2KIT5?I(GWF>I6VZ(UAW%Q"^=2MQ6CCU>88&T_9P,)CED]$@+B++4
MGZ0A4-M/P['W*V5'#=ZCW,_(2>(3RQ"3LO()1+&?3 K20)J'?IXX#1!(T0>3
M1&,_B3L!TM,&=T0;^:"-_-W:N$554JKH5GJ'4H[#6J6PME7RF=,=@M >0(LC
MO)!(S+9URUJVI;+:,"HAW>M._T]*N>F)I<4-$Q1F15)5"'D!'X"X^?"MY7V2
M3ZB$K6VJUN';$VQ67%4_M$S1[C2DD-F?=ZOH)#%(XUN(NH\7A2$AOOA_C=-@
M[Z9K4"W=?:[!'53=I3>,#J\,5]U-^6UY][[QA:DE%QIJ7)!I>#ZFBE?='=YU
MC&S=O3F7AFYAUUS1:P\JNX#F%U*:7<<Z&%ZD9O\!4$L#!!0    ( "DX9E&(
M U<N)P<  -(1   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;-U876\;
MN15]UZ\@O$9A TPTY PYG-0V8#O;;(!-UHB][4/1!UI#2>S.#+4<RH[WU_?<
M&4G6)K8;;-$^],7FY_TX]][#JSFY#_&7?NE<8I_;INM/#Y8IK=Y,I_ULZ5K;
MOPXKUV%G'F)K$Z9Q,>U7T=EZN-0V4YEE>MI:WQV<G0QK5_'L)*Q3XSMW%5F_
M;EL;'RY<$^Y/#\3!=N&37RP3+4S/3E9VX:Y=^GEU%3&;[J34OG5=[T/'HIN?
M'IR+-Q>:S@\'_NK=?;\W9N3);0B_T.1]?7J0D4&N<;-$$BS^W;E+US0D"&;\
MNI%YL%-)%_?'6^E_&7R'+[>V=Y>A^9NOT_+TP!RPVLWMNDF?POT/;N./(GFS
MT/3#7W:_.9L=L-FZ3Z'=7(8%K>_&__;S!H=ON2 W%^1@]ZAHL/*M3?;L)(9[
M%NDTI-%@<'6X#>-\1T&Y3A&['O?2V<6ZQTK?L\O0WOK.$E0]9^=][U+/?G!-
MS1!Y=FT;QVQ7L[>^GX4N^6[M:O;3RL7Q!CNZL;>-ZX]/I@E6D>SI;&/!Q6B!
M?,:"BGV P&7/ON]J5__^_A3>[%R26Y<NY(L"K]WJ-<LSSF0FLQ?DY3N(\D%>
M\8R\3[;VH0F+!W9E8^I<[-G[;L;^_L&UMR[^XP4-Q4Y#\:(&@+H*O6W8NQC6
M*\ /^<VZ]MWB.;R?@OEE'3=+AT@V*$(2FRA:*"H4<N\Z1#IAN[7_1*AGC47P
M>Q;FS(Y90'%OO+WUC4]^W*'C<8=+[^*=GV&G=;6?P8\%^8%#-C$;'?.#.W#
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M'A]ID[.=5,^Z!C!DWW"AYTYMS/;&\W110T/UM=R"P)M*JH8:--7&TUL%M.Q
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MBR88T/Y*:[>;!(*NC\__ %!+ P04    "  I.&91[%EB>F "  !^!@  &0
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M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RUEMM.XS 0AE_%BK@
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M-?9;HKH.]G:P7TU"O'\4#H%+.J6Q&C!"_]6,H&2"RB]A7XTP[!\+^VJ,X>#
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M%P944S?PO-BM,6F<+#7/;GF6LDY2TL M1Z*K:\R?KX"R[=3QG9<'=V1=2?W
MS=(6KV$)\KZ]Y6KG6I:"U- (PAK$H9PZE_[%;*+C3< #@:W862/M9,78H][<
M%%/'TX* 0BXU U:W#<R 4DVD9/P:.!V;4@-WUR_LU\:[\K+" F:,?B>%K*;.
MQ$$%E+BC\HYMO\#@)])\.:/"7-%VB/4<E'="LGH *P4U:?H[?AKJL /PPP.
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M"/2N1\@CVQ'4;K38VBY>"8TSP2Y+G-H@30">KX70+QLS&/KO0/874$L#!!0
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M)FY&%9V,!-\A8=#:FOFPV;=LG2]6FD)9**%7F>:IR562\$VI)+J#!-B6+G-
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M@CCP!OTJXH,G$)^-]J/*0/S+F</^O6G_616[OY<Q>9)BY/3RBL+N09GVP$A
M@JY@IR@_QM&PJU>/3Y\,N]>E>]"\%"#6MFN4R+8E]</4SK:=Z97MQSKSU_AR
MBGOF9Z:3M<W2O?FZ#;ZA8LU*B7)8:5?>Q4#7EJ@[RWJ@>&5;IR57NA&SGYGN
MQD$8@%Y?<:[V ^.@[>\G?P!02P,$%     @ *3AF45^OO39O P  -Q   !D
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M*@9' KE-(+<,Y T$^F9VH CO"5>Q4GG/2F^[:9^7F/WS<>)="S;SF!^V=B?
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M2W.;,!#'OXJ&R2&92</[E;$]D]CMM(=./7'3'CH]R+ 8301R)1$[W[X28.H
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MO.F3S42R;=UJUDRJQE4/<_5K 5P;J/V,,7F8Z.[5_:S,_@)02P,$%     @
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MYI]02P$"% ,4    "  I.&91!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "DX9E&II*J*[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( "DX9E&97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ *3AF4:<)"I,.!0  /!4  !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( "DX9E$-*,DB+ <  )(>   8              " @5 -  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  I.&91T1F+_+0"  "7"
M&               @(&R%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ *3AF4:NFV?_)!P  \B$  !@              ("!G!<  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "DX9E'-^8;9O0L
M -9-   8              " @9L?  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  I.&91+>OE0?\'  "X(@  &               @(&.
M*P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ *3AF46?(
M6#/#!0  CP\  !@              ("!PS,  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( "DX9E$HAFB7'@0   ()   8
M  " @;PY  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  I
M.&91F>Y0&B8#   U!P  &               @($0/@  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ *3AF4721H"DB!0  MPP  !D
M         ("!;$$  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  I.&91?&X+)P\&  !V#@  &0              @('%1@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "DX9E'(.7<&>0P  $<C
M   9              " @0M-  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ *3AF4<F:-&F6 P  #0@  !D              ("!NUD
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  I.&91XJH%
MSZ,#  "="0  &0              @(&(70  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( "DX9E'K-EGE$P4  -P,   9
M  " @6)A  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M*3AF405/"YH7!   CPD  !D              ("!K&8  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  I.&91:-=0?[\%  !V#P  &0
M            @('Z:@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( "DX9E&<F>]DAP(  *,%   9              " @?!P  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ *3AF4>75R,.K @
MK 4  !D              ("!KG,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  I.&913\CO?&H#  !:"   &0              @(&0
M=@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "DX9E$V
M+J"([ ,  %0)   9              " @3%Z  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ *3AF48@#5RXG!P  TA$  !D
M     ("!5'X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "DX9E&J^]N]( (  .\$   9              "
M@8.3  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ *3AF
M45;8)7?X @  ; H  !D              ("!VI4  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  I.&91?/7YMJ("   &!P  &0
M        @($)F0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( "DX9E'O$H_&L (  $4(   9              " @>*;  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ *3AF44G!J2*% @  $P8
M !D              ("!R9X  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  I.&91S3HC-F0#  #K"P  &0              @(&%H0
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "DX9E%?K[TV
M;P,  #<0   9              " @2"E  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ *3AF4;5^<-#G!0  ?1@  !D
M ("!QJ@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  I
M.&91?88N\V<$  #\#@  &0              @('DK@  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "DX9E$S'A%C< <  !,B   9
M          " @8*S  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#
M%     @ *3AF46TBWL;U @  N @  !D              ("!*;L  'AL+W=O
M<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  I.&91^[2KBAD"   Y
M!   &0              @(%5O@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;%!+ 0(4 Q0    ( "DX9E%5F$,QS@,   (,   9              " @:7
M  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ *3AF43@D
M0^LZ!0  EQ@  !D              ("!JL0  'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6Q02P$"% ,4    "  I.&91%XUJ3>X"   L"   &0
M    @($;R@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M "DX9E&OH6R\0P(  %H+   -              "  4#-  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ *3AF49>*NQS     $P(   L              ( !
MKL\  %]R96QS+RYR96QS4$L! A0#%     @ *3AF4>]XP=JF P  +QP   \
M             ( !E]   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "DX
M9E$I78B@DP$  .(8   :              "  6K4  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "DX9E&(C*DWI0$  "\9   3
M          "  376  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Q #$
*3@T   O8      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>152</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations</Role>
      <ShortName>Business Combinations, Assets Held for Sale and Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CashEquivalentsAndInvestments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables</Role>
      <ShortName>Business Combinations, Assets Held for Sale and Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CoronavirusPandemicCovid19</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations -  Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail</Role>
      <ShortName>Business Combinations, Assets Held for Sale and Discontinued Operations -  Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Management Services Service Line (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail</Role>
      <ShortName>Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Management Services Service Line (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails</Role>
      <ShortName>Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d44327d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="d44327d10q.htm">d44327d10q.htm</File>
    <File>d44327dex104.htm</File>
    <File>d44327dex105.htm</File>
    <File>d44327dex311.htm</File>
    <File>d44327dex312.htm</File>
    <File>d44327dex321.htm</File>
    <File>md-20200930.xsd</File>
    <File>md-20200930_cal.xml</File>
    <File>md-20200930_def.xml</File>
    <File>md-20200930_lab.xml</File>
    <File>md-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d44327d10q.htm": {
   "axisCustom": 2,
   "axisStandard": 20,
   "contextCount": 152,
   "dts": {
    "calculationLink": {
     "local": [
      "md-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "md-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d44327d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "md-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "md-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "md-20200930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 407,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 9
   },
   "keyCustom": 35,
   "keyStandard": 283,
   "memberCustom": 27,
   "memberStandard": 22,
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.mednax.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Fair Value Measurements",
     "role": "http://www.mednax.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Accounts Receivable and Net Revenue",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations",
     "role": "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations",
     "shortName": "Business Combinations, Assets Held for Sale and Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Common and Common Equivalent Shares",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentShares",
     "shortName": "Common and Common Equivalent Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Common Stock Repurchase Programs",
     "role": "http://www.mednax.com/role/CommonStockRepurchasePrograms",
     "shortName": "Common Stock Repurchase Programs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "role": "http://www.mednax.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies",
     "shortName": "Basis of Presentation and New Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Cash Equivalents and Investments (Tables)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations (Tables)",
     "role": "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables",
     "shortName": "Business Combinations, Assets Held for Sale and Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn08_31_2020_CorporateJointVentureMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail",
     "shortName": "Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn08_31_2020_CorporateJointVentureMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
     "shortName": "Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
     "shortName": "Cash Equivalents and Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
     "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
     "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations -  Additional information (Detail)",
     "role": "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
     "shortName": "Business Combinations, Assets Held for Sale and Discontinued Operations -  Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "md:BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020_PediatricSubspecialtyPracticeMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Management Services Service Line (Detail)",
     "role": "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
     "shortName": "Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Management Services Service Line (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020_RadiologyServicesMedicalGroupMemberusgaapDisposalGroupClassificationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Discontinued Operations (Details)",
     "role": "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
     "shortName": "Business Combinations, Assets Held for Sale and Discontinued Operations - Schedule of Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020_RadiologyPartnersIncMemberusgaapDisposalGroupClassificationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2019To09_30_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Income",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-3",
      "lang": null,
      "name": "md:PracticeSalariesAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn09_30_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Equity",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2019To03_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements",
     "shortName": "Basis of Presentation and New Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Coronavirus Pandemic (\"COVID-19\")",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19",
     "shortName": "Coronavirus Pandemic (\"COVID-19\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Cash Equivalents and Investments",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestments",
     "shortName": "Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d44327d10q.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts payable and accrued liabilities excluding accrued income taxes current.",
        "label": "Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts receivable and net revenue disclosure.",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable and Net Revenue"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_AccountsReceivableRetained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts receivable retained.",
        "label": "Accounts Receivable Retained",
        "terseLabel": "Accounts receivable retained"
       }
      }
     },
     "localname": "AccountsReceivableRetained",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued payroll taxes and benefits current.",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "terseLabel": "Accrued payroll taxes and benefits"
       }
      }
     },
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended and restated two thousand eight plan.",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "terseLabel": "Amended and Restated 2008 Plan [Member]"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_BasisOfPresentationAndNewAccountingPronouncementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis of Presentation and New Accounting Pronouncements [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combinations assets held for sale and discontinued operations disclosure.",
        "label": "Business Combinations Assets Held For Sale And Discontinued Operations Disclosure [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureAbstract",
     "nsuri": "http://www.mednax.com/20200930",
     "xbrltype": "stringItemType"
    },
    "md_BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business combinations assets held for sale and discontinued operations disclosure text block.",
        "label": "Business Combinations Assets Held For Sale And Discontinued Operations Disclosure [Text Block]",
        "verboseLabel": "Business Combinations, Assets Held for Sale and Discontinued Operations"
       }
      }
     },
     "localname": "BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CapitalLossCarryForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capital loss carry forward.",
        "label": "Capital Loss Carry Forward",
        "terseLabel": "Capital loss carry forward"
       }
      }
     },
     "localname": "CapitalLossCarryForward",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CashEquivalentsAndInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents And Investments [Line Items]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsLineItems",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CashEquivalentsAndInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents and Investments [Table]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsTable",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CommonStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "terseLabel": "Common Stock [Line Items]"
       }
      }
     },
     "localname": "CommonStockLineItems",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CommonStockRepurchasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entire disclosure of common stock repurchases.",
        "label": "Common Stock Repurchases [Text Block]",
        "terseLabel": "Common Stock Repurchase Programs"
       }
      }
     },
     "localname": "CommonStockRepurchasesTextBlock",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchasePrograms"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CommonStockTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "terseLabel": "Common Stock [Table]"
       }
      }
     },
     "localname": "CommonStockTable",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ContractedManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracted Managed Care [Member]",
        "label": "Contracted Managed Care [Member]",
        "terseLabel": "Contracted Managed Care [Member]"
       }
      }
     },
     "localname": "ContractedManagedCareMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue.",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "terseLabel": "Coronavirus Pandemic (\"COVID-19\")"
       }
      }
     },
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CovidNinenteenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Covid Ninenteen [Member]",
        "label": "Covid Ninenteen [Member]",
        "terseLabel": "COVID-19 [Member]"
       }
      }
     },
     "localname": "CovidNinenteenMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DeferredTaxAssetsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAxis",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DeferredTaxAssetsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetsDomain",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DeferredTaxAssetsGoodwillMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets Goodwill [Member]"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Cost of Salaries and Benefits",
        "label": "Disposal Group Including Discontinued Operation Cost of Salaries and Benefits",
        "verboseLabel": "Cost of service salaries and benefits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Cost of Service Supplies and Other Operating Expenses.",
        "label": "Disposal Group Including Discontinued Operation Cost of Service Supplies and Other Operating Expenses",
        "verboseLabel": "Cost of service supplies and other operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Gain or Loss on Assets Held for Sale.",
        "label": "Disposal Group Including Discontinued Operation Gain or Loss on Assets Held for Sale",
        "negatedLabel": "Loss on sale, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation goodwill impairment.",
        "label": "Disposal Group Including Discontinued Operation Goodwill Impairment",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillImpairment",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation long term professional liabilities current.",
        "label": "Disposal Group Including Discontinued Operation Long Term Professional Liabilities Current",
        "verboseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermProfessionalLiabilitiesCurrent",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation operating and finance leases liabilities current.",
        "label": "Disposal Group Including Discontinued Operation Operating And Finance Leases Liabilities Current",
        "verboseLabel": "Operating and finance leases"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingAndFinanceLeasesLiabilitiesCurrent",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents disposal group, including discontinued operation, operating expenses",
        "label": "Disposal Group Including Discontinued Operation Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets",
        "label": "Disposal Group Including Discontinued Operation Operating Leases Right Of Use Assets Current",
        "verboseLabel": "Operating leases right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeasesRightOfUseAssetsCurrent",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation other income (expense).",
        "label": "Disposal Group Including Discontinued Operation Other Income Expense",
        "terseLabel": "Non-operating (expense) income, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation transformational and restructuring expenses.",
        "label": "Disposal Group Including Discontinued Operation Transformational and Restructuring Expenses",
        "terseLabel": "Transformational and restructuring related expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DivestitureOfMeddataMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestiture of MedData.",
        "label": "Divestiture of MedData [Member]"
       }
      }
     },
     "localname": "DivestitureOfMeddataMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "label": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "terseLabel": "Estimated EBITDA"
       }
      }
     },
     "localname": "EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ExtraordinaryItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Abstract]",
        "label": "Extraordinary Items [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAbstract",
     "nsuri": "http://www.mednax.com/20200930",
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Axis]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAxis",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Domain]"
       }
      }
     },
     "localname": "ExtraordinaryItemsDomain",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount.",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "verboseLabel": "Financial Instruments Measured At Carrying Amount"
       }
      }
     },
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_ForecastForFirstQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For First Quarter Of 2021 [Member]",
        "label": "Forecast For First Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For First Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForFirstQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForFourthQuarterOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Fourth Quarter Of 2020 [Member]",
        "label": "Forecast For Fourth Quarter Of 2020 [Member]",
        "terseLabel": "Forecast For Fourth Quarter Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForFourthQuarterOf2020Member",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondAndThirdQuartersOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "label": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "terseLabel": "Forecast For Second And Third Quarters Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondAndThirdQuartersOf2020Member",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Second Quarter Of 2021 [Member]",
        "label": "Forecast For Second Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For Second Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_HospitalsContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospitals Contracts [Member]",
        "label": "Hospitals Contracts [Member]",
        "terseLabel": "Hospital contract administrative fees [Member]"
       }
      }
     },
     "localname": "HospitalsContractsMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents Income (Loss) from continuing operations, per basic and diluted share",
        "label": "Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]",
        "terseLabel": "(Loss) income from continuing operations:"
       }
      }
     },
     "localname": "IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "md_IncreaseDecreaseInAccruedSalariesAndBonuses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in accrued salaries and bonuses.",
        "label": "Increase Decrease In Accrued Salaries And Bonuses",
        "verboseLabel": "Net decrease in accrued salaries and bonuses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt and capital lease obligations excluding long term line of credit.",
        "label": "Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit",
        "verboseLabel": "Long-term debt and finance lease liabilities, net"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MaximumConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum consideration receivable.",
        "label": "Maximum Consideration Receivable",
        "terseLabel": "Maximum consideration receivable"
       }
      }
     },
     "localname": "MaximumConsiderationReceivable",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MoneyMarketFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of money market funds.",
        "label": "Money Market Funds Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MutualFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mutual funds fair value disclosure.",
        "label": "Mutual Funds Fair Value Disclosure",
        "terseLabel": "Mutual Funds"
       }
      }
     },
     "localname": "MutualFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1996 non-qualified employee stock purchase plan.",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NonqualifiedstockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-qualified\u00a0stock options.",
        "label": "NonQualifiedStock Options [Member]",
        "terseLabel": "Non Qualified Stock Options [Member]"
       }
      }
     },
     "localname": "NonqualifiedstockOptionsMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "North American Partners In Anesthesia [member].",
        "label": "North American Partners In Anesthesia [Member]",
        "terseLabel": "North American Partners In Anesthesia [Member]"
       }
      }
     },
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NumberOfPediatricSubspecialtyPracticesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of other pediatric subspecialty practices acquired.",
        "label": "Number Of Pediatric Subspecialty Practices Acquired",
        "terseLabel": "Number of other pediatric subspecialty practices acquired"
       }
      }
     },
     "localname": "NumberOfPediatricSubspecialtyPracticesAcquired",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "md_PediatricSubspecialtyPracticeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pediatric Subspecialty Practice",
        "label": "Pediatric Subspecialty Practice [Member]",
        "terseLabel": "Pediatric Subspecialty Practice [Member]"
       }
      }
     },
     "localname": "PediatricSubspecialtyPracticeMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Increase Decrease In Salary And Wage.",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "terseLabel": "Decrease In Salary | %"
       }
      }
     },
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfDeferredPaymentOfSocialSecurityTaxes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Deferred Payment Of Social Security Taxes.",
        "label": "Percentage Of Deferred Payment Of Social Security Taxes",
        "terseLabel": "Deferred Payment Of Social Security Taxes | %"
       }
      }
     },
     "localname": "PercentageOfDeferredPaymentOfSocialSecurityTaxes",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of net patient service revenue by type payor.",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "terseLabel": "Percentage of net patient service revenue"
       }
      }
     },
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PracticeSalariesAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Practice salaries and benefits.",
        "label": "Practice Salaries and Benefits",
        "terseLabel": "Practice salaries and benefits"
       }
      }
     },
     "localname": "PracticeSalariesAndBenefits",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.",
        "label": "Practice Supplies And Other Operating Expenses",
        "terseLabel": "Practice supplies and other operating expenses"
       }
      }
     },
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_RadiologyPartnersIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Radiology Partners Inc.",
        "label": "Radiology Partners Inc [Member]",
        "terseLabel": "Radiology Partners Inc [Member]"
       }
      }
     },
     "localname": "RadiologyPartnersIncMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "md_RadiologyServicesMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Radiology Services Medical Group",
        "label": "Radiology Services Medical Group [Member]",
        "terseLabel": "Radiology Services Medical Group [Member]"
       }
      }
     },
     "localname": "RadiologyServicesMedicalGroupMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Retained earnings and accumulated other comprehensive income [Member].",
        "label": "Retained Earnings And Accumulated Other Comprehensive Income [Member]",
        "verboseLabel": "Retained (Deficit) Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "md_RuralAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "terseLabel": "Rural Area [Member]"
       }
      }
     },
     "localname": "RuralAreaMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of financing receivables.",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "terseLabel": "Schedule Of Financing Receivables [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_Seniorunsecurdnotes2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SeniorUnsecurdNotes2023 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2023 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2023Member",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_Seniorunsecurdnotes2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SeniorUnsecurdNotes2027 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2027 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2027Member",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period shares stock swaps.",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "md_StockIssuedDuringPeriodValueStockSwaps": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period value stock swaps.",
        "label": "Stock Issued During Period Value Stock Swaps",
        "terseLabel": "Stock swaps"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockSwaps",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_SupplementaryLeverageRatioRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary Leverage Ratio Required.",
        "label": "Supplementary Leverage Ratio Required",
        "terseLabel": "Leverage ratio"
       }
      }
     },
     "localname": "SupplementaryLeverageRatioRequired",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_TaxYearTwoThousandAndTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax year two thousand and twenty five [Member].",
        "label": "Tax Year Two Thousand and Twenty Five [Member]",
        "terseLabel": "Tax Year Two Thousand and Twenty Five [Member]"
       }
      }
     },
     "localname": "TaxYearTwoThousandAndTwentyFiveMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Two Thousand Twenty Seven [Member]",
        "terseLabel": "2027 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentySevenMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Two Thousand Twenty Three [Member]",
        "terseLabel": "2023 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unnamed Corporate Joint Venture [Member]",
        "label": "Unnamed Corporate Joint Venture One [Member]"
       }
      }
     },
     "localname": "UnnamedCorporateJointVentureOneMember",
     "nsuri": "http://www.mednax.com/20200930",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r226",
      "r229",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r226",
      "r229",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r168",
      "r213",
      "r214",
      "r330",
      "r384",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r168",
      "r213",
      "r214",
      "r330",
      "r384",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r215",
      "r226",
      "r229",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r215",
      "r226",
      "r229",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r207",
      "r227",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r171",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued expenses, total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Gross, Current",
        "terseLabel": "Gross accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r24",
      "r41",
      "r172",
      "r173"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r36",
      "r349",
      "r368"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued salaries and bonuses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r70",
      "r71",
      "r72",
      "r370",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 35.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 33.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r230",
      "r232",
      "r248",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in corporate fixed maturity debt securities classified as other.",
        "label": "Other Corporate Bonds [Member]",
        "verboseLabel": "Corporate Securities [Member]"
       }
      }
     },
     "localname": "AllOtherCorporateBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r232",
      "r241",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r48",
      "r174",
      "r183"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for Doubtful Accounts Receivable, Current",
        "negatedLabel": "Allowance for contractual adjustments and uncollectibles"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r101",
      "r311"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities not included in the diluted net income per common share calculation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r101",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Non-cash charge against goodwill"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r105",
      "r157",
      "r160",
      "r166",
      "r181",
      "r280",
      "r285",
      "r300",
      "r347",
      "r367"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r26",
      "r28",
      "r68",
      "r105",
      "r181",
      "r280",
      "r285",
      "r300"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r22",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r22",
      "r194",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "verboseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r176",
      "r185"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r234",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r225",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r225",
      "r228",
      "r265",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r270",
      "r271",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "positiveLabel": "Business acquisition total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r269",
      "r272",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Business acquisition contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r23",
      "r49",
      "r103"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.",
        "label": "Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r98",
      "r301"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in financing activities\u2014discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by (used in) investing activities\u2014discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net cash provided by operating activities\u2014discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "verboseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r125",
      "r129",
      "r130",
      "r132",
      "r134",
      "r143",
      "r144",
      "r145",
      "r181",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 32.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock; $.01 par value; 200,000 shares authorized; 85,504 and 84,248 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r348",
      "r350",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r59",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "verboseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r106",
      "r255",
      "r259",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Deferred Tax Assets, Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r101",
      "r154"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Net Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r13",
      "r79",
      "r378"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r13",
      "r19",
      "r253",
      "r258",
      "r263"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "negatedLabel": "Income tax (provision) benefit"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r194",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r22",
      "r191",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      },
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Assets held for sale",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r194",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r194",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "verboseLabel": "Loss from operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r191",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r194",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r194",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r14",
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r101",
      "r193",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Preliminary and incremental gain loss on sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r81",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r123",
      "r125",
      "r132",
      "r133",
      "r134",
      "r139",
      "r140",
      "r359",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average common shares:"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r81",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r125",
      "r132",
      "r133",
      "r134",
      "r139",
      "r140",
      "r359",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r135",
      "r137",
      "r138",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Common and Common Equivalent Shares"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r142",
      "r182",
      "r209",
      "r210",
      "r243",
      "r244",
      "r245",
      "r256",
      "r257",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method ownership percentage in joint venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r293",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r216",
      "r217",
      "r222",
      "r224",
      "r293",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r216",
      "r217",
      "r222",
      "r224",
      "r293",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r190",
      "r331"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicDistributionAxis": {
     "auth_ref": [
      "r184",
      "r361",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Axis]"
       }
      }
     },
     "localname": "GeographicDistributionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicDistributionDomain": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Domain]"
       }
      }
     },
     "localname": "GeographicDistributionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r188",
      "r189",
      "r346"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization that is the governing authority of a community.",
        "label": "Government [Member]",
        "terseLabel": "Government [Member]"
       }
      }
     },
     "localname": "GovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]",
        "terseLabel": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]"
       }
      }
     },
     "localname": "HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Health Care Organization Revenue and Expense [Abstract]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueAndExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Net patient service revenue [Member]"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r344",
      "r356",
      "r362",
      "r382"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r105",
      "r112",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r181",
      "r278",
      "r300"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "(Loss) income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r75",
      "r81",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r125",
      "r132",
      "r133",
      "r354",
      "r357",
      "r359",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r75",
      "r81",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r125",
      "r132",
      "r133",
      "r134",
      "r359",
      "r377",
      "r380",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]",
        "terseLabel": "Loss from discontinued operations:"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r19",
      "r22",
      "r264",
      "r378"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Loss from discontinued operations",
        "presentationGuidance": "Net incremental loss on the sale of MedData",
        "totalLabel": "Net loss",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r79",
      "r81",
      "r129",
      "r132",
      "r133",
      "r359",
      "r378",
      "r380",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r129",
      "r132",
      "r133",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r78",
      "r101",
      "r155",
      "r179",
      "r355",
      "r376"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "verboseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r106",
      "r120",
      "r121",
      "r156",
      "r253",
      "r258",
      "r262",
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r64",
      "r353",
      "r375"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "verboseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable / receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r134"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Weighted average number of dilutive common share equivalents"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r76",
      "r153",
      "r309",
      "r311",
      "r360"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r83",
      "r85"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "verboseLabel": "Investment and other income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r345",
      "r364",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letters of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56",
      "r105",
      "r161",
      "r181",
      "r281",
      "r285",
      "r286",
      "r300"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r47",
      "r105",
      "r181",
      "r300",
      "r352",
      "r373"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r105",
      "r181",
      "r281",
      "r285",
      "r286",
      "r300"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r22",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r22",
      "r194",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "verboseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r22",
      "r191",
      "r197"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 28.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "verboseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r37",
      "r350",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Line of credit outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Credit Facility Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "verboseLabel": "Line of credit remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "terseLabel": "Accrued professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r66",
      "r105",
      "r181",
      "r300",
      "r351",
      "r372"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 36.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash used in financing activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash used in investing activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r98",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r73",
      "r74",
      "r80",
      "r102",
      "r105",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r131",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r181",
      "r300",
      "r358",
      "r379"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r211",
      "r279",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "verboseLabel": "Contribution from noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r37",
      "r350",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes Payable Fair Value Disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r157",
      "r159",
      "r162",
      "r165",
      "r167"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 27.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use\u00a0assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r108",
      "r122",
      "r150",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and New Accounting Pronouncements"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized holding gain (loss) on investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments for credit facility amendment and financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r88",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "positiveLabel": "Business acquisition consideration paid in cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition payments, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r234",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 31.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $.01 par value; 1,000 shares authorized; none issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r25",
      "r27",
      "r186",
      "r187"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from issuance of senior notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r92",
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on credit agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Contribution from noncontrolling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Proceeds from maturities or sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "verboseLabel": "Proceeds from sale of business, net of cash sold"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "verboseLabel": "Other revenue [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r22",
      "r73",
      "r74",
      "r97",
      "r105",
      "r112",
      "r120",
      "r121",
      "r157",
      "r159",
      "r162",
      "r165",
      "r167",
      "r181",
      "r278",
      "r282",
      "r283",
      "r288",
      "r289",
      "r300",
      "r362"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r33",
      "r34",
      "r195",
      "r374"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r223",
      "r314",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r223",
      "r314",
      "r317",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r95",
      "r107"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Payments on credit agreement"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r101",
      "r200",
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "verboseLabel": "Transformational and restructuring related expenses"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r210",
      "r246",
      "r371",
      "r391",
      "r393"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 34.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained (deficit) earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r158",
      "r163",
      "r164",
      "r168",
      "r169",
      "r170",
      "r212",
      "r213",
      "r330"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "verboseLabel": "Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r17",
      "r20",
      "r21",
      "r22",
      "r198",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "verboseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r234",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r149",
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Percentage of Net Revenue"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelfPayMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed.",
        "label": "Self-Pay [Member]",
        "terseLabel": "Private-Pay Patients [Member]"
       }
      }
     },
     "localname": "SelfPayMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r231",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Vesting period of options, maximum years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid for Tax Withholding for Share Based Compensation",
        "terseLabel": "Number of shares withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r104",
      "r105",
      "r125",
      "r129",
      "r130",
      "r132",
      "r134",
      "r143",
      "r144",
      "r145",
      "r181",
      "r209",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r63",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r142",
      "r182",
      "r209",
      "r210",
      "r243",
      "r244",
      "r245",
      "r256",
      "r257",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r142",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsScheduleOfManagementServicesServiceLineDetail",
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r39",
      "r40",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r39",
      "r40",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Forfeitures of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross",
        "terseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r39",
      "r40",
      "r209",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Forfeitures of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r210",
      "r233",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Gross",
        "terseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized for repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Company's Common stock repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r39",
      "r40",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchased common stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r39",
      "r40",
      "r209",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchased common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r45",
      "r46",
      "r105",
      "r175",
      "r181",
      "r300"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total MEDNAX, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r105",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r181",
      "r182",
      "r210",
      "r243",
      "r244",
      "r245",
      "r256",
      "r257",
      "r276",
      "r277",
      "r287",
      "r300",
      "r302",
      "r303",
      "r307",
      "r389",
      "r390"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 29.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r308",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r308",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Other Third-Parties [Member]"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r216",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "verboseLabel": "Federal Home Loan Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r216",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "verboseLabel": "Municipal Debt Securities [Member]"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase decrease in valuation allowance deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/BusinessCombinationsAssetsHeldForSaleAndDiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r124",
      "r134"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r123",
      "r134"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r413": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r414": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r415": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r416": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001193125-20-287356-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-287356-xbrl.zip
M4$L#!!0    ( "HX9E%G>^ON]# ! !)S$P .    9#0T,S(W9#$P<2YH=&WL
MO6MSV\JQ+OS]5)W_@%+VRK:K()D >+5LGZ)U65&V+2FBG)V\7UPC8"@B 0$N
M7&0IO_[M&8 D2()W7 9 IU9DB0"!F>YG^C8]W9_^W^O8DEZHZYF._?E$.6N<
M2-36'<.TGS^?!/[PM'LB_;\O__?_?!KY<"/<;'L?Q\;GDY'O3SY^^/#KUZ^S
M,35L\GJF.^,/:D-M-'H:/"2\TS+M?R_<^_KD6F>.^PQW-K0/[/(3\>CT=G;5
M,&=?B-_<_A!>G-VZ\NA?&K]7Z?5Z'_C5V:V>F70C/%3Y\(_OWP;ZB([)J6E[
M/K'UA;&8&\:^?+]!EP;N4?WLV7GY !?@&TKOM*&<:LKT=M-SFJK2V?2"\([Y
M\R<NU8E/C;7?Z7T@KNXZ%OTPOWGZ==T);-]]2QYB=)&S;W&8>N"Z@(=UWXNN
M)GR1ONJCY"^Q*PE?L(FI>\G?X)<8#3N+7_%,/?D+<"'A#9X_<=?<#U?8\[N+
M7PB\TV=")K/O#(GWQ&D=74AXQZNU@:/_^!9#9>"[&Q@)5V?#=OW5$<"'"6\W
M7]<]4F& A45!__'UX=O\=C_Y_OFM'WR7V-[0<<?$!PG!GM0Z;:BG:CN^3C9-
M>GF-PTM/@>X+WYCR8=M[N_.YKE_Z3%"=<(E%B<'^]4W?HE^4QNG?/GT(?X</
MQ]0GDN[8/K6!"#Y]]3^P+YY+^HBX'O4__WB\9K*/O>64_A&8+Y]/+L+;3Q_?
M)O3D WO*A^D[GASC3?+\-XM^/F$OESX9YDOTP7\;IC>QR-M'R79L^M]?/IFO
M']GWJ!O^:AH&M?FO</TV&%/7U"6;C.%1(#L^]L?4-N#__K5%GD_",;_Z#W3X
M^>2^H?R$_Q@0'IU&[Z?6X+^??!D2RZ.?/BP\<OJ&:Y?HC*;1*R(L?[QWZ9#"
M<C8&OJ/_^YZX=^[ 9Q+D[\0*Z#UU!T 8X*+)Y \?LM)J:8V6HBV-J>_=V;&Q
M2(%MAE=^P"\_?PPN?TZH^S-ZFD%U<PR#_7QR<WM]\J5QUE"FPYZ.,Z5QKXQ1
M47]JC'9*+_,Q7CCCL6/O2]A6L83=:="Y4'5U35PZ>L"7A.GIQ(+AF(YQ#9]Y
M.ZZ/OVEK%L?JJZYLD!EO%_ REU@WMD%?_X>^[?B:!OROV]-ZS=[.K[O@*C6:
MV#\I<:]LXQ((O^,;3T\5%83D;DL_-KTYKSE[O+O 9^8-,P-7D-GL)B%3@1&I
MB<CT^!-7.-YMM7I=M==+Y/K0<7S;\2E_]_7MSU:GI;6XZ/]H$6::4OOTQ^#D
MRV5 )=^1B&0YGB<-76?,1V;: 8Q<<@!O7'_ )<>5_!'</'(IE6"R_LB38(*2
M#1IG^C<(6FI( SKQZ?B)NI+6D"4V(QDDMV3:NDL9Z(@EA5.2X ?[V K8UY[
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M2@,Z\6/[[EHCW'CG9TPNJ1Z_I+!+2D]Z]\,F@0'+U'@_WUTK#Z%0.Z!V0.V
MVJ'FVJ&YI!WFYCY3"ZRGU9C.SHH_PI<IUPFW\#SI>WA>]XJG7&[2(,OZ0D*%
M41ZTBJ0PFJ@P4&&@PBA28;0V*HRK/P+3?TM=8:"^* ]81=(7+=07J"]07Q2I
M+]H;]<4%\4;2M>7\FA>DVJ I)%02PHV]_$JB@TH"E00JB2*51(=WW@*N^HZT
MH"V2]J%1YA<]]O++_"[*?)3YF/Y5@O0O%=._1-#0W9,OWXD-:XRIX%E3U$O3
MTP//8W4VF$?6MXGUYIG<LYMK;E#H1EB+@]WS0+W "IV_NPFK<<7J9Z(:+P\J
M15+C2AOU..IQU.,ET.,:ZG$1]'COY,O?6.4J$]QI5DR>J63XP)K^S32ZY7@!
MJX73?W("7_I.W']37WHPO7^CFBX/Z$12TRJJ:533J*;+H*:;J*9%4-,*;ZEF
M^RZL:JZC[UU'IP93RZB$RP,I5,(B*N&$>@2S4HCJ_NHUX3M85:$B^E:<6F8)
M.D*)"CO<+!9BN'O\R]5#O/Q"0KI]B94[5F) WP!]@R)\ ZS$((9OH)Y\^4:?
MB14Z!;Q](GH%)0*34%X!9C^B^D7U6PKUVT?]*X3^U4Z^L-TPZ9KHON.BZBT1
MCE#UHNI%U8NJ%Y-0Q1]U@N9MGGSY88=]H*C+3@82B\;/G0^H'KBF;])PT^R'
MQYO 1&XR*NH2P4XH18VG15!1HZ(N@Z)NHZ(60E&W3KY<O8[,)]-'K5LB# FE
M=7NH=;?FJY1&G6*V2@[J5>ALE?;)E\'-[[?]QQ\/5P-,21%E[.57%%JC!HH"
M?K+NBVO;579W=1H$$E>QD:=!K+CH6-8A$><3&[/NURN]!'3-4K"K:]NI8A_J
M1;VWM0_U3E!=9&]:W:CW6A\Y-J,6S(K9UA2:C87W@9ZU6D"B;B7JQ=WMX.[;
MS67_\>I2^MK_UK^]N)(&?[FZ>ARLHS$2=1M1WYFVY(^<P".VX;U'.AY,QX4B
M]9N(&'_5@:W"5QYQO!7$[-Z*=.E>%QJ97UWNEMUI_<9M!;":DRZWMC;3YM_:
M^FOZC^4F_F'QEVWMN7=RA)*;U2[R^,]_!(Y_OC24\,/%<%*N;UQY;QFZ*2>*
MSFR#/ZO%UL-?6#'=%9>SXIA!M&Q#RTK'KRE8E-68?/ZL.T):;HE62T]$__>S
MZP2V$>>PVFC*DJIUX4>K]7Z;4&5A;!&9VA\,P,0^C'];M/U::7SL8RO_J#I1
M++MUN\.*W.!';!(\:21F-%BL9OO.4?:.=VC-2\3SJ.]]1$D@U*/J1+$2:/#%
MM;G_HM=8X'C=]O5*'&4G490L0G@'#9;LJK-?Z!^!^4*L>+ON8E?VR9?_VOG>
MQ$U%\_6C[=C7+M%Y"5F;C.$!@7?Z3,CD(YM\WS;8/U?SF??]"^*Z;R 4_TZL
M@)Z F6^S1S^PP/Q]W[NS&[V?6N,G<WY.I, VPRL_X)>?/P:7)Y)!=1.HZWT^
M.64A71@IY8D+0T9T__.)^>I_M(.QX?C1G2Q;I2FW%/73A\7Q[D'_I-W( L1&
M)?BKJ#\UY2?S5]+BK]+HR-U.HTC^"F0_"2P/!R/']4_!,!I+IOU"/7\LCC!,
M??7MOZ+Z+\2T6(3XVG'9Z8GYB8E+^N3/_XJ,Q5QD9U>16YUF[41G)="0OJ3M
M,$5:44%;/_.TK^LP6]^37*I34." -5FRJ8\">;H$(P(]S.AS2_T\I:_:[LB*
MVD+Q*SSOTY>U3:TIJ^UV-85ME<3HO4LGQ#0D^CJAMD?1GITNH8@P5R%=\I2;
MBB9K2@?%IK@\SR * *JRT:VFN*R?;7ICZ\Z82CYYI7'[%&5KM,Y"^CPR\LPM
ME'QL4E7N]&HH6_,9=M);LD-'"E+X/]1U#.*-V%2[JJ*>KR#CL"4FL#2NDIR]
M\T?4G2:31MO/*&2C9<2)T^<TR=7K;\AJMX82MB0,S\!T5>2N5BC#T71-,:S*
M\2.-J&4PIDL>0;MU'E;CQ+D;7IK>Q '*_ [(F("Y8@4L"95UN(,AFG9 C5D'
MVCQ%;Z^ER*UFH5YD765OJLA(7T9W6W)/$3$:.RU*LG+R1H24L@/SDO:6]%$2
M?W@T>/(:YN\O'0%(OT#(FK( M9NC\-*H4M2NPQS%L%USL$I;>5FECXY/+'3T
M-]D>N>Y0R6TP-6%::&J*Q^X,$J<T\"L:Z.+C0: MRO'>=<"[\=_XL0%V8F#"
M<F07TK)09D<[S2&E[BUB^WW;N)H2ZY;F(\([7;E5;-9Y7>7WGJS/0)RK<KM3
M46F.<GH7.?V[XQB_3,M"H;RP,J=DR<F&;G8;<KN-X5JQ.)W!!IG<[/3D;@N/
M'J!@WM9JP/:)_6RR.EMAD -MY]7%>VW":J3?S!=JS.D5>L5Y6<]J!R0WGFPH
M _/3E^<JN$[%9KB@_;R:"A9NJ]K/('.)1Q>JWR;2^YB:2*D\D./]U!F>!AZ-
M2W@,;R^E-4TY^XTQ]H%]YV[XPPL7?2[2OM65>ST-I;WXO$]?V+?:<E,IE/=H
MN9?!<K^D0^JRSI'F[.S'DB!'<<Z7])10LRS_?"WWMBKWBO7$ZRK+]V)\!BEP
M;;G=++06"%KMQ8KH\+0("N7-1P=N'5O/,96DW92[*LIC@7F>07&(+HABM*E1
M8&\1V)O.H@@AN,MTJG:/DPGY* )AS][652&DBY L]E';345N=47<1\5S+$)G
MY-=ACL)+I$I1NPYS%,.BKM+IZO <BT@;?-F6V0[MA%P""9K<5%DLH=!3K@7)
MU4)8F$%<0%::+;G74-# $]_ TT!5&4[ 4M5$T%6UF&0)1%&5R%V+28IAY%6Z
M0=ZWF_[7FV\WCS=7 ZE_>RE=_>W'S>,_A8IDYJFMQ'Q4G2@FD+.VSNO:9U]A
M?X>/OT> '8YIYSS+)$^FQ3MB8/L\L1Y5)XJ50+\?&^I1<^]/,B%OA!_HL0V)
MZ+H;4-&J[6<30!@;LS84]R$)^K;1#PGP;2[OKEZCC:;H4JSZ;YXE3;1N5V[5
ML.I^^7B?0=Q):<CMJI8PK9),G9I+$\?E8'.&TM"TB:W3Z-1/S(X20[0*L*U_
M'5*(GZ"8KKVW7"M"R\UF#3/\RI0<M"=&L/(^VL 'RFMGZ9PF2NQMI]X*D=E*
M5V[W\(![&9B?0:)=5U9;>%1&>/&ZT&8J"C,((D3+9/SD''@0UO*IJ\0M-OC0
MEAM:KYJRMGX&;RRVA2U4$A=;C$+"]E'I=.6.HJ+Q6P5T9& =-]IRMRMBKU;,
M410ZG;X.<Q1>)E6*VG68HQBF;'6;J6  =J,9DJ?=V>QV9:U=:. -#<]<G?]6
M4Y&[BHBV)+K_A[C_COU\"AIP#%AX\GG&U]K\A(7*SK65N&/C(R/:(]#L$DC6
MMXT+,C%!/_'=C[LG> 1W\.:I0M/;OP$'[H87+C7,O)I>=9JJK+:Q$&@5\)%%
M>8J.UI!!L%53FE=33F,ZPL$[TCD7BFO"VL)"<67A?P9)NDTL&E=%"3QQG2'U
M/. EL5#\)BR_[\2:\"LZ_>9XW@7?_'BFMO[&-ZZ)]<,VV)Y( $O0R%DHJV 1
M:^WZE=RH%"PRZ) "@JNG8 :9\&(XJ6H]RN =:I?'XH6Y5:[7Y+:&!G IN)]-
M'Y)B>T6B^9N>W U+T:.D75.5/+Z^<HXRJ'*OV-[(=16R>S$^ Y-5E;M*1?-P
MJR0Y1<^P+=/!AT.S+;$R?,UD<R9 R2!$W)8;C4(/+6)B;AE3#.LP1^&E4J6H
M78<YBF';"A,[R#E]%V,'&\V4G K;M)4>MJ\3D=D9! CD-MB7/;0OT;Y$:P#M
M2T242(@2*'9:\X+6SGAL^F/*"M^RXP_Z+"TE9JB6PURM_*/J1+$:.*"Y;<$,
M1L2E(\<"O>'Q 'WG7*)_!*;_]A'7MB"/JA/%!%+^ J_:>W>:Z^?YCO[O<^F_
M/H%6MZ<C/_6H?FJ^GHY, X;Q,?Q':;6T1DO13KZ<L:9L[/XO0"U7>B%60,^E
MS1[Z[(T#]D(N-;Q^X(\<%Z9E[.6T>_S+<;_]YO9Z1\<]Y4&N#R,=,TA%;C22
MPDA+'TCA.R0R&^$A3+CQO"!#!C HL?G] M?"H_8A'%@[PG2HOS)"&!W=@?HF
M'Y8@2JY,F0:+//X[DQZ8.I"#6J\>1K#T.#HINY@[+!#AV/O;.JW#;)WP=2(;
M.ON-,!LK1VTTLK)S5J9W%_B>3VR6FY3;_/8<8L96SO+HNBVYU4@ZE+5,?!:X
M2Y7:0N ]8ZMWA=I-66TF'=A8 _70MN2T=^;$E"6X-J%PZPNUW@2Q/(O?_(TQ
M-T-C<F7]8$,$,7F=_FY_MUEH_5\,:>UBX_4-P_3#P@'Q$2=2?]^-K DQ#1A_
M*'$E/2PZA/)W6C)_1OE[H-.-'15EBBW5G$IR-51-[G6P9&)9,)"^I.YU.W*O
MJM*Z?GY[7]>#<6 1'VQAAY^2U9WQQ*4C"H1YH5&A A3$\]XE4W+Q Y07<6*%
MY]59=9!;ZM\-'\EK3E*YU\.4V%*"(7WQW*EHS8(JR=P'ZA.X8$CO##HT==-_
M+U'BVF GU^ELP;O-BVM*I*N(,K'%=AE2+3WAZL&XX+,M!]95N=%*>W6=?'E?
M-&\$$*0'\3J#FB]*0U8T$<MHX8$#H5.GZS!'X<5.I:A=ASF*85@*X_+G?*#U
M^]7E;?\?L@1^REFX)Y:88EPC@W2SC<(C;!&)KCAI\MD$ QQVV@JZ]X)R/(N^
M!LU>5^[U"JWRBX[\+I*4U=N!1[B.!=>?XX/>K!"/4*SF\8\ !+O4\\MU.BS[
M^LXFL!76^$U$GISJ>=<PQ:%,2;([H**&&;(8CA#:L:K#'(47<Y6B=AWF*(9Y
M7-=P!$8;MOB>L\J?]X[+OM#W?==\"GSR9-%'9]$3R=6&[39:<J.!/6FJA))Z
M1370G!5:,==ACL(+ITI1NPYS%,.<+4DYKY8@Y;Q6:LWR\VF+MK$(%O+)E__*
MT*R)E1KMVT9!&V^:W%2;<E>MGV$K'',SZ%P@*\V6W&L4NJ^*UNAN>E4#O6HX
M 7@P0BC66DRR!$*J2N2NQ23WEHWP@\4M5NW#B$HZ91&,)6QM-U;C=%34-81,
M,/SX[S-Z[6W;K7D>.\-GZ@FFX(A*1&>'L8C]!B^ ]_K,'G3A8ULR8>;/+MB*
M$^+ZDC.4_!'UJ'3AV-P#X<>YKDV;V+H)-PU\^( 7B3V3%GFTG$L0(U9W5U,Z
M:6KS)Z2 I.S8O\>4LC3[M22NK,Q] ;?,85D>./LLYHD]4;" F"=F_2)O'K<#
M^"-',WOCEVGX(S;HQF_GTE0>:&RPL:T'I:7)TO3'^_.3#^O8K6AG:I=]>6&@
M9^U.PEBCC\_YUW]%;WX".Y -DT@CEYEX?P+C$!8"DP$,XJSE-L/PIP\DF@H_
MAOY%V@*0D\4[HDEWSUJF'>UP1/<S7W V4C<<$PE\9\E9Y!^=;'WM_G[K C&F
M8N9 N$:/X23=+HJR!/<LT?3V(DGZA&0T#:#A:[.IJ9V?S1.DZO;"WW>W@[MO
M-Y?]QZM+:? (_WR_NGT<2'?7C-!WWZ_6DAIINXVV[TP;]*D3>,0V/%FBKSJ=
M^-*$NF&>M 3JE;Q'^AY.WQ\V"0SPGHVM5(R_2SW:( D?<;Q%(C&[EJLEG5K6
MA!ALQ^WS2>.$_QT]F/^]H+KY"R*-$MKIX2=1ST:N<\^E!:6\-R\B^Q^>99&)
M!Q]/?YM=6ICW23B7I A$[+*QI#O;[=^F887$ZPJ,?+U+,__:+K_CH^>_<Z\H
M@6&[&+_=+7%Z:2<W/L+Z?+F=M?;* 5EP\O)]Y>J+86FPLI.?3]HGVP81K9WP
MSWABSMRI7KQEROC8FHRN1&XD]],6XJ<S<W6=Z$[/]=RH"Q[!^J;2=[AOY$E7
MMC&OP,Q_/KD?$F1TOD,<@$*FXR?JADS5&O)*Z*'R>$8D;X7)+?R#0#X 5>50
M-%MBB'F\:,-25'$IQNYF6[,90EL *" (=@"!TD,0U!X$* D0!,5*@F/LFY0.
M<&R>;)@8MQI0K&VCRUOJ2RY]H79 %X.%NP/G8)-NMW2IG6X^I#86G_2UZXS9
M!AB[Z7]-?W01>/ \ZLX2_ON>1^$_8[708*/SLZ'PW+A')_T\N6:[(;>U-<>8
M=V/,T9E4J?*_@IQ7>G/.IYA$UVK*/45#SHO(>27+-:_(FM*1-75-^B3R7@C>
M9[/J%<9W66GUBN7].@LNGCV;$D!$,#$6+,%2G4S9PT*KVC1+(<RJ1?*:3!.1
MA<A"9%6$Y#69IB@!.@R][<G>NPEUB<^.(-#7";7![?@H6 @N7QM>U&<AU9!J
M2+5LGH4;1KMJ+4T0K77/PU(ZE3QB$7=:2N&)VG1H^E[I%-B^3]P]\#@V/DYI
M-8A(U;>-KQ&A<MU+TAH]N9?8,KOR4>72(2";Z++64&1M73$Y1( 8",AT;ZD'
M,D!IK^FSA0@0"@'9R(!NMR&WNP7+  Q B&C*!9.)-37EPFZUSDIP DV[Q$4=
MD0X6->]5.@OJ7$5DR]704U6YV5S3LQ9EO,!PR$;B QQ:W5HFDY05#IF:@.VV
MW&S5,J.PY'#(1CIT5# '"W8(,/Y7-J/Q=W!=6($L9BH28VS:IN<S$+]0M!37
M9Q]&5(.%WU^@6;3P<S4200UH30P%E0H)V6B MB:K70P+EP,)V6:>]YJRVD&A
M4"HH9)2(WFW)FE)=NQ MOCTMODLZ<0$<A..6FWUCU@3G/_P#M/56%G.<7O [
MD)LU#(*E'2-;K@9?1U9ZZ/:7#PT9&7URLX';@"5"0Z:&G]J0.\V"SYPA' Z
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M<UN:G;->UH5]<">DS-&0NLP3(XJ(+<16=6A>EWDBMA!;0F!+K)T0@:-+=<L
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MH16;WH++6CBO,^"Q@54).@[49)HED#15(WE-IHG(0F0ALBI"\II,$Y&%R!(
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M[9]:0SP+=9<CEUU9;6)ZH$ (*B6',;A>-D,TH;_I,P@N[&^*-H P\A:Y@%Q
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MG09VK2DGBD0J6+@!9*U&0^XBR,H)LO1:%S4[/5EK"YHWA)LF"5ZN!EZNX00
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M&ST!!=?& ^R(YPK@.:/T54WN-4J0O8K5$2NGCUU'I]2(0JJ S\ -#ZDZP%1
MKC!Z&AV.G;,AICR]!I8.@(??0ZZ^L4)QCF51_AWO;EB8]F[(W78)W.JB$84@
MSP7D&>7^M&6U*:")B@=1*ZO*XZ[UQ&6)NOX;[_!"P;B=L"6 7G89O1)>/>X^
M8NB]16P?A-S5E*<YI^O*W49//*F&CG<-(9Z1+]X$ZU0M&<31%Z^" E_PQ9GW
MS33Y4[19M+B_[3D6[FV7T$T!CV2Z^]<?#DW+)#[K[P6W&0'+8J.%=+!N=$OF
MJ2#.*XWSE#3[?RB\#J0E(Q.OO5,ND.-)'#QR@$<.RGWD )=%B9" Q,"3.")'
MFH4K#!%XU)!,._$HCJ!ECC%,MWN8;LVQ^ILIM_.N<[QCTUFE@Q%JA+Z T,^X
MK8^FR1VU;-#'R'65#()XI:AWD77P/M$\$+0:,H;\CJH.FR ?!:B&K,D-$4T"
M#' +A?8M%D$6<,_8(% ;<J=7@A;4HO;YPZAWI2):2 R,>B,2D!@8]<:H=U91
M;XQK5RJX5U ,NR4K(M9EP!AVO6">L7O::LHMM2J9UMBT)WL[O-H-.9 8V+0'
MD8#$P*8]9=R*%;5*\M"TB:V+4B6Y!!M.^&Z$06U9L6N59(Q4BGR0]*OCNLXO
MN-63'%O276J8OD2>74JQ"(0HL9O=C]-]8Z?H[H87G(VYYLVTU([<*D,@LFC@
M()93Q')&91U8*6^Y6S8THT]6 7T\+7<BE#8N@0TN3.[? YUVF;@;HCK&?@3U
M0G-6"KD#DR@?GM$U+K4J7JBQ9'I>0&R=UUGRJ&TZ+@S+KU06CZ .6.*P<G!
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M'( [')J6R=_Q%!D6\&9WXKA3K+LP/6=(.9YA2L3S')@;OR@O7HI_3P9Q/N:
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M&3R3$#1*$):,@#M ;*G *G0-Z8\ Y [H.EB6H:@% 3 BH6)ZH_R4;&#'6BG
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M:%M, &<KS48BHHC)*&6L2&6K6=)YJ6ZX: RQR;/+@77PQ(_)=0%0BYUGF'[
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M^G^C_AXQ,$^309Q$&%2CBN<;S_N6]WFSM 9N\UVG="7#:IIV^_+(G2T-^@Z
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M21S.>*/I3R(T3S])EN?^_=4]#'?'?$8VW=5DP@+W1Z/3:74ZC=:/QC(?^FZ
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M;< $R)[@1 0AJKU85Y7,.\*IF_>);"!I$*W5W"'%!SBJ2((5,.(8,W:LQ@%
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M BNT89>=_;O!B+F)#\KR.ER ^-MV#* $1N)Q-G.B;:8C-U-I\4)UY:2&D24
MS"A\0CWO->EA8<+A:_S-.VNASJ%/M+FU5B2&V(%:M"F_%Y,4_%Z(LY42X*)[
M! &@C:=]/,OV+YJS4UOFGBR\390C=0L$R,;^S\(75/?;AC3ZM[>)]>QM52!
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M!=Z^)2[!JPG@SDT?_=%8E@4P9UDN:SRV(RLS[S:BOJ^ZX3GK5VA<7G9WSS9
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MJ?8 3MM#NA.41 WJ"AY+K$HPP%)*^;?UF>\!?X ]%2YLLCT<6-RC!U"%5:0
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MG< 1^:HI\T,O<$*<EMC8%3#<*97?&FJ&]K7BAJKZ'C)$P2'@N9NL3&V1'^O
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M<&,X#T,:#O(WVR<I7424H3Q2XPO=22HCU#8*/8U)G :QW#74]^ [!A,[>=2
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M%IIQ32JHR0EQ.H$7S56WV^IED0KF,)=?-!Y([%E\EMR"7)S95B\;\/B3512
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MY@8+DYT0M6H>H:A4.C6DB5DPE-*JDT2^F.C!*?K "$9CQ4&C@BFF2O8DO?6
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M%DCL*+L$!8.'.^?(@_FL=PE'@9Y0P_G9)R<&SQ*!.>%3<)"DF_*7#FARC<1
M]1J&T5@;I%EZIRQS.8&RSL+IH[<4XHC]?V5!K,Q>1PX%*9"4"W.ZDS'%U]VU
M^& 2T=+A*RCA@0 8QT:K<<67\<2  Z_AU0F;Q#/O%M?GC:\"X'UBR6F69K'B
MT<?TZNZ#@;-F.(\D<:>["TG<:C<&&TCB\_PU:_<+X2@5%]$[A!N*4;"),V$2
M;#AAEK:.*[(E\.D2'4O,M#SEQU?>_)(EL?\=O OB+PY+X-W4[L@H\F(*BTW@
M.E"$!)RA #PL?N3,0SZ*+5V#:P/^\N,Y>T!J'2QM\*]*L@'AX HF=G"DA$6
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M^/,(6Y$%::Y>0%$U)* ,H2W7K5S"=H" U+D^Q1)1^$J2YOH=%"0(^>0>55H
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M(&=Z!-8 UB5KEUK53@BNT2%O<>,K<>!29K]S73YF<5E\1 $=+(=(R'"9 @O
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MWWIX'7UK%X7TUO/K2O_]V6B=YHI*?V#,UZ-H<@M_O$IGX4__'U!+ P04
M"  J.&91;P..Q?->  "XK@$ $    &0T-#,R-V1E>#$P-"YH=&WM?7MSVTAV
M[_^LXG= 3;(IJ0)S+/DYMM=U95LSHUL>VU?V[&1O*I4""5#$& 08 )3,?/I[
M7MU]N@&0E%]:YSJUE;%($/TZ?=[G=Y[\^NZWET^?_'IZ\N+I>/3DW=F[EZ=/
M3__MUM'MR=TG/_*?\/F/\D#TY-GK%W^/GOWR_/7+U^=__>&/7\_>G?Z 7T3C
M$3SW/"O;K'[ZY,79WZ*W[_[^\O2O/USE:;MX]'!R+R]_B)(BORC_^D.1S5OZ
MU9,WYK%E4E_DY:VV6CVZO6H?1_+WM&K;:LD?S:NRO=7D_YT].G)_SY-E7FP>
MO<N761.]RJZB\VJ9P$@G+\]^>?77'^K\8@%#/7GV]/3#(I_F;80KBY[\^.SI
MDQ_?X-+Z9G!T_!FG,*,]X3G\]N;EZ[__=OKJ773RR_GI*?WK8^?29A_:6WF9
MPNL?W?W+]>:&DWGWZ]G;J&]&.*'HH%WD3?0O_W1T]\'C)[\_/;FHLVP)0SWY
M\?>G^.G#QX<1/+!,TBQ*RC2B169IE)=M%4TW]-DT:Z^RK 2B>?K;Z8M7)_\6
MO3T]_]O9\].W<73VZOD$!XJC9#SZN:CJ/$VB656OJCII\ZJ,#NS8I\M546VR
M6@T=T_N?3Z+?DGH6G>>S15*G3?<WF9XNO/1MMFJSY32K_Z6<-JO'QP_BZ/CV
M\6U>P7R>S=K\$M;31-4\?/:A/ H;D[E].;4_>I&T>K1)M.5,C^]^&?HZ/WU^
M]N[DY=L;HZD_?CT]/SUY2P<+?](\S/$AN:SJK(%W%QN@EXOD@NA%-M,\AG_=
M?]Q$S]9-7F9-P_N)9Y)F<_@DQ7/$G>?[C%L.?\E_^*A.\*_Q: $$V5:/Z7!Q
M,_JYS5?9B\AN0IHU.6Q"!+<DH\_,5YE<F1)6V4;SNEK:;\R6S&#$.I^N\7[0
M&\Q;MQ+;%UO@J]=_Q-$[7.7/K\]/>9UPG##+)D\SN<9PD?#"+-?M.BG@N\NL
M3,JVH<4"-2SS!M[;9+#BJFX7$9Y97O+UAD^B"GY<1Q=5E=)'ETFQ3J9%Y@\2
MCT<X1IW-LGS5TH/->C[/9WE6SC8XA:L%L(@HJ3,: -G3['U97159"C2H3@=_
M:L_#/(JL#^EO7A5%==4\N@EB.IK(O) '3S[+_?[INM,XFAQ%3\Z>NGG0=KW+
MZN63'\^>3MPNZHT;I/3>;::GFZP&?FK?!D2$IPL\;DED,Q[!X:<Y7X*0<HAH
MDM(QZ+,2G@3*XVD:]@STLX05S/+R0K@]#N$S<YHE7KF\7.-S].9HE=4Y$"/]
M NGBX,XA,YU-EM1-'*W+ IA6U%15"7/'2><EO"S%87B*R1P^=1.?1._P<_HT
MIFED;H-A&+-/S,_6<';PXT52%%&RAG.%"S"#/S9 _24<%4ZR6<]F, =<!TPB
M.CA2,Y3Y-S#/-B_T_&#ODAD(X#0I9WPH5[G,+M*;2-N2E!LW/ ^=%(W,:XI7
M<9[5J [ <<+"?9'IEO>&)H/',I%SN0&B/D:B?@%,-6OT?C--GVPCCM8>7)2N
M:Z019D/+)"_QK\Y*8T?UO%5,ZDDS'IU^R&9K>OW?<MC_-R C\M0G 69/K$F!
M E7.)L GHS[=2287K8#CP2OT5_IU3EWBEW84+))"KV=M9;6@(Z4P??KR@6:J
M\<AL0O1\D6?SZ&<@2+B90&ZOD8<C!^C= A8A60TDOT2:7\ LZ!#A3<CI9^L&
M";3>(!'2;E0-<0W%>JH"K@+>:]1D-TBY"5R<BY(IUSY'^] "Z="K\+_ L$BL
M54T+AUCF\([,GF#EYLU3'8^ZFJD1ZF_7L(;+O*EJ3U>MZ?W/*M!K\3TO0&F
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M5WK"N^)!_1X\/TKTL=1+Y[!?0,9:==9F5C"'31SFKM*C+FTU[G%<^DZ.1&/
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M)!O[U2HF+\L8C(V*D]G8FS/X"/$;4[LH=(ENYYI_88O)07?!W"M)0G%*)27
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M[E[>+[G.H=O[!=?:>WF_PAV"U\S^LY;S[+M (L#@/RC)KVMH76M*7(1&AHF
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M!%.0:WJX55GL51DI!N$7!^C"Q(^DQKX*!/>9\5D1P?*"<@S'?GU:>4&T\EQ
M<U\#%Z^;1;X:C\ZD>X(8_V?M@"7$^^&5?^YG6&EX9GB/ZO4)LL2/_2%( /\5
M4R&TO8%'?W%]>TBJKM;3(I\5FUM@;Z*H)%^;R%!N_@(;^#[#'K<<N?AO,^OQ
MZ)^/>'@0Z(44&Z,1I!MV;IW9'$_63NW>YYN:8D'!'!\'J&A;YZ<8&;:BX(G"
MS3ZZS7PL01_K):$CWB+87R</:VZ87'IPJ=0(&)D&MO<ENL)[T5#,"'0@H)U*
M.G& V36M&%-75];%FAG;3B6.+Z#K@5R%7'K(-9/D(Q7I+*H!W:*>R7Z[G21.
M;AU_MWB^6.K%LYM*O?CY]?EOF'9Q?OKR].3MZ4U- QC^+Z>O3L]/7MJ9P*2>
MOSPY^^VMI.!_W+P^21(=3;KU  =A3D3F-8-'$;+(ETU6S-G8K.F?Z )!:X$_
MBGC V!1!L^E9X3^3%/&X&L:J-K QZ-KS<&-Z06@"+!D#'$,UV=D'F'YYX4!O
MC )A^GM2TSQ?@=DN,^]2H\%__Y=_^NG^@Y\>_P<K%-A,5N1V7_)6'*4&(IQT
M/RF1E!Z/#TRI)".\HI[CU1V'/39L6U>RP^H,+401 "U8W3S.]NC:,VYVU^HV
MHGT3]XZ8')P"&&U&)<SJBCK<HMJ'M *;W0N\U:6@VGL]6*7CD1^>LT9J*G(D
M[T('N>,FB&X$L^50AG2H6M+,4/ 278F/HS&MVPGD&-2I.D/G MJ@Z".^R+A/
MI< ])ZMDQD$#+WO(CZIU>M?3#C$<0I[IC"&'6"VI4(CC*_7W,T&+F5LP982'
MQB\JT\TE%W06TU,AS>#2IA@(2=JF8KAEXP+18 !D45#QO0S#N5QH1^B?7BVX
M<1?&DDIV3? _K=D1]W0/8=P=F15'1VF!'BQX0[U_"&1*X H(M"'$D@[=^*HX
M'V>L LX6],=,&M>-=%CGYAG$*JB!1O@>UIB*E,L70!'PD?-5=8$.]- F<@*#
MU55Y,5\7CN)C76J/K7,+AV*>+2OY/$7^1OYT7'B: 3>TJ..(=XU$[P"W!87K
MSVK*W\O' 5)(4;%2ZR8ZZ0T(AHTZLA*Q<<F:TVTTD#WBFZ69"K*4JBZS35^O
MO]FBJAHB!^;*;&L24S*8CG()\-?/B300AU\&;H8'[L1QS"S"0)AMNNH1'K6L
M #;TPB.$*&#.\ ;'D4Y>G)[H&VK[WMLY<DU\F]B>)S0*_(PX;_2S /<CE/^Z
MM?'7)3H );F"KAJG21)C;@)*-2?.+7/PPEZ0,U5C4Y2IY5L.THS0VP3,;54D
MB)GVAV";T04U@;<+/A4/98O/QW5/12^!BO<X< W"_6DTU_(WG;:BQV6;($J<
M,[R5^T\1ZIP#7=U-1O!^X.Z\@FV$Y5E"L&ESBG'"G(E >9T&LL<(K OZ-EJO
M5+<"14&X()@XI5+BK</@+\V2.!F2HGB5;?9 X!@]$M PLP^PF^RIX2OOI=%X
M^S+8.,/D/:DQNETT=FQ4C[OV0'=#$%&D.XTXJ\]T&6;8M8W%:;&T2)J)!<=+
MUZI+SR?J6-F :E752M[T^('"^\)71*.G>Y@ZAJKMR5&[NI#M$D*4::5)1X3^
M*VZ5*DTHMQX".M,$4R,.VU&@UKXL;:Z*F5KG6O&<1,6QL1NG[7@94^+VU_H5
M:3J]&M9!?JGF(QLRU\=L=QSDF%&NI.LXM5D0+4L^@A$D-+.J0#*B&I*7#A/K
M8R8YU*H(M0/GB>#A8$&7W:/F_L.D]-&)DE<2,>U,"I?:/GR#.B+*)K)$XAKY
M$8\4$>U@C@A0$'Z?=_>T>Z9P-[CC Q+W+0IK5::QD;&1&.C?' 7WN\ C48(B
M!VE:X\[$%*YW1S'3Y3_VJ>@ #"7Q*:OC5MH2G_AXM.5MR!9!C^=F-B#:S)FK
MN> JJ/$J&X(8W+IT@HR_QYW26V472ILM#N<>#MI)1/2=T@;;4W.!R.VO)D.<
MA6Z[P;%/$?#8GHGU85LG<'I^]O:$-8=OU\_U['MD_W.Z4(Z5=F.=&&%,F_-@
MVFA.C?!,"R#.D?*M1V:U>-T*9)UH )+AP9B<>//6I F*><6]5;<84K:OJB1)
M,[.R/Q_03XR*,RC78FE1 ]*1FKWK!$UOY83869(6AGYQ4#ZY7YUQ4SOT/4Q4
M13A@]B53(R;.],RIW38AOB)#-=MA]B*.W&X)=*)MJ6>'<*P66R)11C[OS+:C
M"(T0G>=%^VB=,G[7),V/M +'6E]TD(Q'UAYY8V?K^4AZ&BLI*D.)R@DE).+8
MK)(M2Z(WJH%]A?M5(/YJ9DUG^R+D;MB#E17]RZK EN=U;FR M$-6(E"='; U
M%#]4R?!)U^W.'DJS@BT+56:#*]E]U+LF>T(#CD>L8P= H@(>*H2;1,9U@-XG
M'AQU.=M\D,YN79(6R%.[J"J4G#E"XAKP:KZD':CI.G9$;B27(W8A];Y.=]0\
MIZ.1N2"/N>$N*8-[YZ$CAV*GTDA->B^2<C(X@<>J/U@E%^A#OEPO>UO,D1[E
MY].9$D!1]]!AX?S(:*>P40<GBC"5G19BHK9EJC6@P+E&HH@+9\)VMG"]*-6(
M&@:ZD@GUD 'C#-H@LS=.US]0DF]K3#67R8N,5XU$,U&)I=9> R.K@0E/"^J(
MJCD;2UK:RM]+<LU1:ZU&ER80J1J_.%6 4['!U[^T=Y6,%+_R%H\5"DN^(I[/
MJB-0P9Q' W-7?RNXOV6[N06[+<VMQJ.#8Y,XD8*>0OT$&$A^JRGG97FB'K^#
M?_*4KS^_R)N>0;/>WT&2)360;JW=@T532>6+]KD$EX3,DH:RCP\>Z/UQM19.
M00BR1C*:7+-K:N)+D:@&7L++ZGT&G >7QW>)6:91XEV#AFZCP\M*[&;%#;\^
M;=_;ZH;=N1^[>O]Y?6X'3&%T26/][7BTM2.@<M&;L'Z"9=D$["L-1J>432%W
M#]EE;<(?)D9"K]V6,_-%=OG^MEU6R;;(%\ 227>JKUUV0IBZ27J9-UGH$FX6
MC!T_Y#,79JR<J>3QD>L@WECK@V6Y8)7H8>^S5*&024S>#B(&\^X<UJUY#GY)
M,\/NK9$K$)(W$/- 5Q,IB1Q=Y?X7B.K.V?#BE?S*9_M 6F[L\F2VR7N3SS4>
MB0L]0XV406D=E^I80YSXK)"RAX>2#MOA*PP_4EP'T^)L+T3%@NQMZ>&DG/Q&
M]\A.JLNR/@$6EPQD,:))6__A^DBY=V\**)=< /_P'?&^ #B5.K]/0R?[RAA%
MQHW_]?\_%PT?W_Z(*5  H@=4B%UAWZ9';T?FVI,?G[U^\7?X\-=WO[U\^O\
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M[-EBD4Y1=\[7XGE6>F\]5XAW&W1@4+;@(]BN_>AMV>"=0N/8J5MH[)R7Y)/
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M0"15W3N&:59K^35]COZP%9IB(KUH"C-0'<7B".ZA7.%)4E49)OA<D&"1FUG
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M#(V!53P:O*ZS3Y@N03OWX/&C/>"D_C9=:;F^K\I[ITAN:K-VTBDD"V*T@\?
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M_-%'^YBYK,43L._.<7@4O4PK+!N(7J&EFDE9[)W463_BY-G3%/%%4BYO:CO
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M'.96!P!,R@A1+%KN_6[.BE,>P?8+E,= ^?;Q?\GV",2N9/##P(A01C(Y86_
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MQ7M0DLO-YKD[-=/!_&WQSET?!Y#TQ=$.A:]\2[#.5:)P+!;F8OV3&\&''.X
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M(NXLPJM_(&ES)M+FF,7)X?V#QS:+P@@*(?*N\U!\/0QC09GID^PBRT$T:ZF
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MRF FEBV\2L2')57&J#&9.3T]ZA^ZAZ6!I 0>N/MB;S?;Z[ W!PPA(HRC$PX
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MX2IN_@XHLJOS($-.ZQ5;ZRW&_]E\80>[\SV3]OV5+?R4+M$;##E'+Q/LOYG
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MY\J"-/$'/MHW/_?S2TE3?QI 8_9%X7=02P,$%     @ *CAF46>9!@\T$
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M$Z0TD-;ZJ$\RF[KX/%Z@+)+6_/SG)6!F'%:4L"^BL\F=)[JZ#;->-%.O@=W
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MI#^ZI78YA>9,BFALA<%+0"8W0?1*ZO%8(%.+S7//BQ)*\1%Z$,W!,(#GH?\
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MG&'H(:X)^CF 7,%4ABESY?V'?Z\,'-2IW@X ]61Q,CW$(UW(XL2+$TSEO)P
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M!$_"F#Z[^#[.1:67JQ).,G[%30J-KG7KC06@0#9*=^]');_E<M+@2<:=V(^
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MR. (X!=]^0-I!P9L?S^UM#!ZP1F0)&-;:1NBS]&'64NN(?IZ02CH]F@([9K
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M)AQ -,LE,&V!54Q8&,-NH:'>C[_O<#8>1DUVYF,2R*=7&$XED_3" =X]AA.
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MEY,&3S(YZOT(*!5]VKND3*IS5ZLC51 Q2[#R$8K_7A?3<[[IB5L6M=(P[3!
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M95CR!_\[6"<HA^E%4N;8@E1XWW_8';($[_?/X0:MA6<)-IT]*H>1+$/$M9U
MVPM\S?4#3<=OPBC-/(F^3AOF 6SZA]0,<Z0-%<4<9B$WYU:;\L";\7F;\##I
MB1:WSSY?G%^?_@L]L_^6K16#37A<>W#SO7>0]S%;7:.Q,>RP[?%PPKS"/B9+
M"":1XVM8WVP>DA?5!MR6DM]D=$LI!2GJW9K!8J!'--K4]:\)F6_HK7MR4(9I
M!:NI[U3D@KW8<B0RNR81.-%]"G@%Z>]3D.OQR!/EV VN7Z]R[%7 2GF6.6KJ
M\Y!RS.>D98A$Y8N\QM_,R %T2R[0T:->J &_2,*OUX-$"61&)X02O(3TM+HD
MK%N68\K#XZ$X'FP#E7#U@: >W<0Q,5$_/O>QH1Y.(Z=YBHY&AWF78A=RMFCL
M3<W[.BGK8 )^2#*2]17NT5+?DH5U_.<8,OUF88X5"W[=PRS!0]\W_*4/=;J$
MXMY'\+R/"?+TV5-OZ]*'06:(*=;BO_IAI%LNB+^!"R".RSW[2MQ:^!J(6L?_
M(]T$T2N^.T4(<N)_FY0W)?8J:YC2(Z9;6-*T)+,D 'GO,'D!"FG4J0*X(\ P
M95W9>2C G0'M'69]G256Q<3J3D8C.>S7H4UQ_J^#6A#MH1Q4I]TYLYG6C'N%
MT18!]VHM81U WR."I!IS(1J=&"4'!%=O:Q&2[;:$6ZP*>F$"*;I,,10*+M.*
M@(K-$F)LE+KM$5*A.ZY-E#ELUH\U[\<Z'#Z?1P,9+=R/\1(0ZC=]FJ -WH^Z
MA03],?]FR.?Z1 )_(RF.=:"0"Q%4$02 TFJ# $VA,CTG[(M,"03+![781HQ2
M1"/<(#D0+J9MDAW^U-FB\6R6COFRV"_I.@;3(@-O?:0]RV^<)FB,E2"FFZ=P
M&F.ZY3 #5E@-T6X\5)T":X;4A9=I13S7#HP%:+0A_/Y##QX3^(?:A;#D.+I.
M[<S>*9#V\ AZ.=>2RKY=4\7U9)^@T0S[$#&:,?<'ES;!O_5F#/ B[^(1, J^
MAXCI;IETOO625]H-HZT6_)/$Y:RHPCYCH</)$. ZD(1#^(>D0FL+>#?M V*[
MY5@/[!6@;6,!M8QQ(9,AT7R$"1V4CP 1#L?G*#O42H=6VB,@EGNN3=#<M(X%
MSW+F)8R&Q/0 'SI4#\ 1V#[32Q\DQP,O? >RF;1W2S1T0MMSA83&=G[5W'OB
MR 2OUC-7V#]#M'TB\= $*VFRA>2&$XW0TUU55#Z0$5*-5A,=3/UI8SO\IVST
MKP^[1UB2)"QJ'6S.M:PI>=1(>RFE,&U( $:#W#!L0C W?)&0I18R(Y6<+^UB
M[)O<+7$X6:U-R;O):JP++;S*?B1W39Z3C(06XCH.G*B:0P,T42^#FZ 19[J-
MG"6=\.9'*N%,X[/,GG".Z3&6-.AVUMDT2<W.FS P:L4S-"]JK?,='B=WQR^Q
M_*SZ[@&ST^605Q_@IB@A]_#:Q0OVQ8H2,YV4KU<UW%76]UT7_:KW,/U2HR<)
M];,"#H#@%?2?[*^ 5."1?G3P5F%4]V/##%S6#]RZ'[AB-'#\ZYKA#U$654[Q
M0<RBFAG*N+$KJ9]A_52D5_DSYH@<-57&9DK:/YC!D4MD8#J:PA:L-^"ZAW(O
MILK6"(+RKL88\2@.!()5D:&49I,EFPW*$/XQ(H76 %*MFAHT^E8R; DNV*O5
M'V .-\J:?=(>WA5)Q+5$=7!3T+0%7S>M'9;D^X&QG=,K%^F#R5["6@2\GI$7
M)9X1>5 BO!I((2,&OA0O/J'.5K*&#R7$!RV]0GO(Y1@/K$4+Z*5@K$>P,:=0
MS*E?U IG?XQ6X=3[1&F[&C#%N89J8RQH[16M(F['.&A;-;L:6K\NG*=BR3,M
MDDV/IL)7I%/ 8PQE*3;\P1EO)KI"'HP-O?E5]/$(;17G@OIL?;F2UEMOFB]0
M^==DCV[#/BM+E1?Y22]%8[*#.MQ:\ PAKT5.@+)$#0<FA_Z*/B'*$ DXEY<?
M:AL'/[*?QGX+]Z!'\EK,2&L*R0#C#^_G<%_"-:)1)OQS!FG%L#P]W9'B87\5
MOD7)B6[6W:,6&,HS.EOFNJU UY'Z$'S7,+KA0"@J2;*D)(9NG ]9?"J_C0(-
M[8"-]O@S"1_Q3K],,L)'ND,Y(J:)O"RC]P"U/3T: KT40X@U/9C.'_5QOV6W
MT?YYDB3'DL3@'QH";*@MANB:^/KZ;?,>ZGV2)27"2W*>-B$OT6&%KH.?U]+5
M/(]ON36O^[;-*3[:#GZQ/9WYBF?^4<*\#S2;889[;]P78 S>$7<Y]M;/?:N4
M[[#?9XP?FHTZ<I0UJJCO[EDQ#>21JVG3&>#>38[U>-\63FWGB%:UHO4QNCA"
M&%.P*%)QKT"T4?@)L_;P!+G"9-CO/N3T$1.C200IPBYNG;V"9% Z'G< ^Z?7
M"F$'. ?M<^3VYL2-TWL'L3MQ6->'$G-_]I246Z&Q43?W^N:9D-_QFV!<,]"T
M"[7U,^3YH4SR:E.4NZ1Y();@JSP2I(3L^9D8O%D5<L8OFLEA$S#&:1/;#!O3
M-(IEAHG<&YE2&K&/8ZG3HD$;M0R(W#XMQP2[?.L0Z#WB5H[?HWRQP"!6LMPP
M2C/:^D3.*$ \!H84QF-4^'0WGF%^@&VZ)W%^_HSJI[-#56.>RJ["^&F%]:R"
MJ?J)O4G4O#HK4Z0=^S*42I^#3>B +Y@0:"GQI?I;8HL\MF?XBJL+L4GEC9)1
M"NOF3$;LV N:#->8[F@X?HYLJ0]&=3/#T:M.II<R^ <WHWK.S#S5U,-H-L.(
MN%5=>%,C?/;J4NIH?R'C;3RR=2R'\+D2DR=\[<@$,SA:^0S,B/B!GV@-R:1;
M'M;C1#JRX4GYX2FXX<G9\-0N?2W;O.9E973_."+NU$9M/QY02MXI7$X^@E]L
MX4M:ZB_):#$W@)%+PK#D$2<R>Y]A>I[420RW$R?)1V2*9Y$R,[?JI<?,UGK,
M"X:U4>AET,YG_N^ 0Q%.CNW^T';?)LN\O6B4_FO O0CE\\^0X ;ER- 43>72
M:Q*R"*FCQ&,13">>83-"F<)GO(4E+3APFJ=\H1-%AK$;LG[.O%W(+W'0^K59
M?/6>E"2CE.E144-[^2JKNJ/R)4;$=*\6)"':I19PI^IQJ8#!:?LBJD"B@(W+
M6 '!SD4(@Q7 /X+'3C?21C>JX>L>,076VL'1O<MB32FJ4-A0RNDQKM[\+?-H
MRZ1-YA21@Y?DG8A-^_"1$)B1Z2!OF.9JX3&MV/1P(.D\33QR/Z+618W8$903
MGHS321HI FE<L5KJ+K"7J.F;U(K8@/UF(Q0CD<6+G8[Q](ASLY5I'J(O-F:1
MZ1AW0M$,OC;$&_06:1C]GQ)^=*_\<5G9(?-V'I 5S<ALGTSR<&8L(B]JWI!%
MMK>9@/PY)Q51[7>TK$[:^5A2C5?S[7=#SG4_PCW4W&&+;C<U20MFVH"P.ZSN
MI;N;#7TC\:G(4NRXLJ*.!ALCP_X>-=M4HB$8^X<+2;5VKN??MA5*XWC0T&K&
MAMBTFJX *'P@!\XF<&L:AL!5RZ,<0+_0)H&VE//Y#(+FHYF7PO9HV@/@DRG*
M6;';%SDY=#I]0:J4#TV_$.B52""I9=RWP]8/MPR-:<?<!T&Z"D-2X*L Y/%)
MN&,NSHM=@E2EL"3M?3[Q)N%8AQCP"VL:ZK$VUVQ[?8Y-A9+1LVLJB/A#]FF:
M(G:U^C9!Z55^ENQ1G62?(7DE18%P33^/2-=),(1.WQZ0#B<H!TT7\ OK% C[
M'@3QJ0U&R!IJA1&L_&G'&7T5B>X8M!HA:.M1"T2<#@'#VK ]7F"L.V/7)Z*E
M:!BB6 J%B>FD=[#&BP-,VZ<Z2=FS]?JP.]#*%[1X"UE(2O@$\PH]-V_#2!$[
MFZ*?)-*94H^O##-RH'N]EM12XB@V=96.:+;)=8MIBR;^N. P?'T.-VB-ZF_Z
M 0FI9(Y@SJ6*1H-Q@RS1I2:Y>Y"'EG_DL,YJ-*V/L(Z.L1ZH^E*W]?N$):"O
M69D$&KC&(:(+/*^*N!-I!FB[T &%^0P'B2&,,"$-'(P X7-/]>^'YC6HAT+B
MT=)CC\>D@BG1:ZR U#C<D;=^*U3#>U@^HS6\A24JTCNX+K;L0L[/2790Q8F7
M_[37G=WBXSC>4W6?)->_!ELLT&^Q5NP\\H1^&O#?7H'NZZ#Y/&#?!QP#H;:8
MWD>4>L'-,*TY@C$\*.1+4<>[7#]:ZG'1IJ_I7E75 ::JY?JHF<^%^IB_$4CI
MGU> -7!_NYO.$EZ:REJ[0*L9_9!DY#YF8WT6N(=..;W(M3?LY_'IU7<00'/D
M-0APZ=/CQ2:2??R<5H-D6LV8HF4BT9ID2I!FIU^2,KTLR@W$1D"I:C.(>O6@
M9\@N7&L:)0:,7+/TMD DBW-+LXDL4:HKT-$-Y9@['(?F;X<2TI=8RU[DBO1?
M-<^\A_7HYV)^[/G/!7PD&D__^V&X\D]5=1FU6'1<*NT4Y9;[Y$U6(:<9$>JY
M\5@TH7&JS0"Q(3GD*2P!W.VSXA7"YF_%GHD_^/4>R_:$OP/VF"R-#0E^'[V9
M4"N*E7U0:TG4AN%CJ2Z_,IUDW":BE=NMG:!4WXQID(T!H4+\;]'J3]4=J]\S
MYHGLPT5-#G@S20,@:\[0O%%[<*0?#HS"D7),/-!3?Y;\\?Y+LI>\<&+<V<\Q
MG;DLDS25MJ$4O-=LF2M91?X:4FOLD<8=GX6 F<%)V=Q):;REE,&-Q3N:*6J,
M'YVV8(=?0NEH5$^QAR'^K+T+8$8UO!=@*+V->:$DM<$ M]L$NQ*6;L="$Q&(
M<$FW@;SAJFZ#]SA4WE4H0$DL$@5W$@AH]/K-Q@'L1L)+&"!6V^!D]V^@&#%;
M@HE[?SW%J&W"E)V_UC#$M_&?, *+[/O?E@&8LMTWU0>WNWWVU6F;_5'?H'O]
ML23FJLDT,\9]OJE4E8CIL-M[";3TN_LE<35]<V\Z$\*]_3/%5R1;^SO8^E:"
MZ(5N(==T]KUFZV01SQ'72QSS"[KAMI6)ER;*6+D1X(3+I!':XE ?75:L0=](
ME$>91:G2'=HQ1M612233G%@U1IG0:0PPC\^C2NZ,_)27,,G07V'ZIR(C[Q9]
M3%!.BO;<Y/=PC?FNR9/@):KPGW@Q#)Z&6NZ3/A]J76[<1J^]RN^;L8I:>$GL
M2*_ Z7.",E('Y&13E"?W28;WLSU7H&$+$+ZZYTP8/T-CD6RP2QSN+4R/0\R-
MSU,S/ELZ/AD='VQT$-X0-[G8JI>KO#Y@N[#JCE[!75AO/3Y))'QK[XH\=87-
M,BE+=G]XK%"*DO*5%6!H(R8*LS:'J,_'CN;(/GJU1_QF'7WNCM)CQ?YZBFVM
ML)9FJ$)]3D>!ODA+GH,B\3(J<"X>E["O&\T&_>@II-F(#U+([RRIGBZSXDME
M5[]/T"U,V3X1_\IJ?:0#H#WBJ]$GG0Q%:3[I3'BL^(%9.,U3\C^"[&?L99&J
M4_594I:O6!FH-]^]^2DN<JF G1OR/NN*N!F/D64ER"4'$O0'CC)V3FO0$F]/
M;?HW5B558T/>V%IZA-;D!]A3)@/T"+<H)Q?[B15@O 8MC.)0:4:U5!QJC%\S
M,F"Y3SQI1#K^!=>2>='M<GL.V?\[&2]>UD\8*? .V\V+S08JUSG?C'@V35['
M6*2B*X$%X[+*.BT>_NZH0W,2UOG67[?\?,/;OI8G0)@"C*LP+Y,&'_GN 6,Z
M6FD[6N1^_EIF-T,;2/_F0&1*_=L"KP\2$Z9OR^(9I3#]\/I3!3''ERC'6Q/,
MX^FZ1L\L:*'?($PAYO=I8WM916I$K5%+!CR^@J\)):Q)WX".&.BI!7\YR(G@
M5.@-W3C1;?VFDS3IN@=] &@ZE 7/&D_$<8R**WJMS8D2BPE'J="2,7"@W"OQ
M6X;!GC]W/R#4*3BP,1!J/?B;W_SA^_?O_RA^0O=MF 25DDPW#RH-\6<J;I-7
M>E9S693]>>O-AJNXJ3 ')IT]JKR1+$,4MYW IBBYA  :#N0*IH9*!9@D4]^2
MWDZ))1W '&M#K3('FG_-N=ETRGU65+5J^91W": E KZEND%N>'3&G;8.K0\V
MW!/-QMNK%-5@DZQ11L[5$ORGE,;]R=ZV7[G6(N%"*(D,5C+5D&'*HT*4Q1K"
ME+Y6U9Y?&:\D^KX^5<1 DA':FCYL \1?'%AF&;'9X\V7!W'R1+.<F.)MI#*F
M8 NM._<P1T7YJ<BW#[#<G<-'58#%G$1P31+*9:Y0K#L@_4\P_G> 4(A)LR;(
MQRM8Q>3+BSILPK,M*,WT3([(,.KV">40KYYGU$$PU*]!GT *->1<C3#:FJY'
MM'UX?=&Q_Z$HR^(+(M76\7+3.'#)MH0TNR$6Q1#"1Z4)0NR$@?YGE!<E]H;I
M'83F"4=##1!W#:0($CG4^B!)R0MT9W6".-IL.A1#-ITIWE0JHP*;/\VY@_MN
MKV6Z:"CZ>-05%>>"V!&WZU]LT;#;]=L(T <MXEHTM/ 9:H 6.X&@WWAN35WU
M3^38^N8Q0UOMZ9$5E5#JH95.HS#=IJ1].XZ2 !R-*)3(6DQ>K5BX#(*,BE;(
M10NF7V8856J<&4#]IL 9'"M-2J&=0==S@MJ<$1!F+=B<YOK*EC5[\L_Q:!@=
MY]+3W.__F/(#$<=QKA/U$&5XS=:-&/,^G.1X1)K/X29W(_8DC:D:_#92+N:G
M5T2C?5?T0JRC=$DEL?#:J);54BL[8F\@7=).\&&Z).HDC3M=T@#*A@IK@.,8
M%==-NJ0QX2@5VDVZI$BYWT*ZY+P!.5J=15K_YM(E+95DNGF(*UWRH3A=_WI
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MO2Q*\E)46U%VE*K92Z4^<W+_%3^V:('1&1W!MF?4_#>:73\@7P'X,_2I-FK
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MHGN8HZ(\Y!4Y)$[SHH85;O);U;4L31=/<2X-WZ.P!&W_4]/^NFT?[L+6- %
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M=[:7XMPSFN58$4!:#A1_?MB?8)+53V=)"6^3&I$JEHPA;::DKJ-'KTHKPQ!
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MLISAH6Q@ ".$=$1Y<;*$G$_86%_5<*<ZEG%!/*:<-Y.Q&*6A&"0]:W*>"7E
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MF)[3!Y49(\R3DR8(*O-"IE+TJ<"3I187(F&D */5Z,NJV7^ME!F.@4J.NAN
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MF2R?<%?V+_P#.0#XI_\/4$L#!!0    ( "HX9E$$DKW\N$   *__ P 3
M;60M,C R,# Y,S!?<')E+GAM;.U]ZW/C.)+G]XNX_Z&N]W-U27Y[8F<W5'Y4
M^\YE:VW7].Y=7#!H$9)P39%J/ESV7-S_?GA0$B7A24)*4+,1,]UN&P#QRTP
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MDPF/I#6#?G;4'7[)YB]FW9'?K'O)R#[-]C,CWFTVY^"/N\,\*0 Q]X[]Y-Z
M0(DHG-LXG$A8MM8F..WU^B=]__DDGK68.2=^,F<A:D2WPVET0Y2^L- =7&MM
M^6%P[C^SU+,7,^W4;Z;=DJMK&/\'"K-;\IM<P[:-UDQ>3SMTE,GF+V;=61=8
MQV71G'FU]AQ^APXS.0(Q \_]9. -N4861)N:8(H\*1["F6R_%#7E&\Z%_VQ3
M3E[,L0N?.79%Z)+1:W"$WO\'^E"R;*,M%]23KO!,-GLQTR[]9-I5F65K>[Y:
M-9$UY^!/_6>=%H#DKMWSDWV5)')0_/*"DPEUPY>>=*HN_.+3F5U3 T+"2D_M
M)AS275(@BAV_(2*68850R4IQ%TZ%RZZP4@-"PDI/[2B5=*X,QMSJ_U@6-.:.
MQANJUZ:B(Z/(>6?8:@1%PEQ/S2S/U$6(0.L?O;[@(I:=E)O-N"AW0+F13ES"
M)D\-+B]92(7L^6/VFL82'JVUX3@[H,*(9RWACJ>6E860W;R/IF$R08K;G:@I
M1]V!YQSEY"4L\]2BPC?T6QRCAY*&KBN/L%4SOLOW_&>5=.(2-GEM-Z&.!!G1
MBAFA653N%?7:R,B!'*G-*,J>G"8=>#&PP2+AK]=6EI?P_2ZBGA9CS/,P&*Q)
M21].AP[8I\U02+CIJ?F%8QI$$2%[7OWK'B>HK^2DH#W'WP$SM1Z!Y,G<:PM,
M!>2*_/B8O:0_$Q/^K5IS[!W09W3SE_#.:Y-+A8:=#X_9,$O?,,^+HV7@1A=.
MA0[<((Q 2%CIM<FE@C1,\R*,_R>>:[4=40=.@<X80940)$STU+1"-Y1!AD(%
MV^I-.,H.N$0()RUAC:?F%)KO*QY.TT1]^]MLQM%VP.HEG;B$39[:55:7V.R*
M;.N3-%._P*ZUY,_.G;$MB^<NX9?71I7G61C'BS@;);_66G)#4F=NX^*Y2_CE
MM77E9H:R"4XFW[+T9S&]2F?S,%&O,V$/3H/.F,;4&"1\]-J*\CQ%<6S"OGI#
MCK@#6H=BZA)FM3*2?-F,<-E%U(LV+Z:5V"RD9ASFKPQ9F7^>A.'\"PTK^H+B
M(E_\A@4:U62H^G6P3'A8BZ4GFCCS)5>$S=AT#XZ.;9=#>UP\P-, P7K#X A(
MU;,FZ/IR4:!Q%'M3H"Q']TWV-E?,K%PJC'FZT3XX C)L*'BC8J)H^HZ"<2!Y
M21.UT)C3C7PM+%?'!SF<69H.!6^-^@?'0*9(/0O%+#='Y2BB!W0YOX4XIK'7
M5>Q]]<:,:0CY:['Z+[GO6,.1@F,@HUA3L6B"SU%4$5'17E,X$1&ELS&0!T6W
MX!C(,-"8^3HPCD*1(+>"88;F(5ZD7M S6-@^. &Z@C;EK!R%HQ E2);R%! O
MX3NJ2:Z"I<+VP=G%2>^B8VQ5(W$4O 2[+S\64W)UK]-%P=GMQ@%4L&Y3EDH@
M. IK@K]3L:Q&\S0/XV]96LZ)!,<E]<T4YCHR.'\;#TH.M-/^!?#EV_J$;@_7
M4:P5L+9FN"%L+"0@EZUVW*[/WE6H59$680RF@:5$-HL/FMJH(%=0>OV<4P,4
M43:5BIB\6W#LQ2YO8&G1HG 5@06YTW]+T^@GCD4Q!)M-@F,OUJ0!Y]9F["JX
M"I)+MSC!!;K';S2Q6A$F$TR3TS%RJ%>BNF-P#.12:<U1 QRNXJP@^5QI LGD
M'H4Y>L*3:?$X_I%SI"IE6M6/J!/'_>.NV+?-H+B*UH)5C:ZKJ2[OAB9+6MXI
M..V='OMA[C!@M $.5U%?H$MZ=4E\2).1S;UXU3XX]N+R8[)\I=-W%0\&R4R+
MNYP%RUN,&IST+L\NNZ)1NP#J*EX-WKRBO0L'G3FT:_-U%6\&>>V]Q^$KCMGC
MV2+)[S2-"9"<ER8U\#(P'2(X GZ,;NE38H735?0:Y-JM 3;W.9%W"HZ ?.T:
M,5 K R)TKB+>FG%],XWV+ JD2=YK0&[>J].I^E/M^49NRG0V=G *?*1K6+HN
M!VYANPJR [;74/=-=H5=4.!#;P)7=>-77^##PDHLK%"YBL?SQWICP7=U1TXC
M?XX)<\X;XG(5Q@>JTEL<$]H^ 51&UE;<5L-Q%1#HB>[G^&V\Y<C\Q;B+6X0K
MX*X"&6$-PMLDM+I4!%#I95V)0!V'JU#'9H8$P;7A/DTF+RB;4>]:YHX]QW1D
M>K0]OL9XPDM^+;7<1?-[G- R262Z6')G<#!P<.(/YVVOD0XIX"K<$MB/3JPV
MF3T?Z/HRK>O$GWM$4Z.#.5!7L9N0FL?W,)ZS!++D'I72:H6L@C9*1A],ZPKC
M'TE$CTER!T>1D: T'#$X ;9).Q"=-M!=Q9:"OF)MOKS6:&KY]KS>,SB ?<4$
MHB3,:D\638?OTG5LQH_3PD[!B3^WC\9'BAJ=A.N=,DPVO6X924?[P?DK+[";
MH=L7D;:4D$B=M6'4FXNMF0 %)\#1F&ZE@,&1L-+>S@GX--[H,5Q%O>ZS68-.
MPO5.&3Z'BYDRK+HH?$'K *IZCB&3Q)R5 9&PM%-^B;7:%=JL"AM- ZA2PZV8
M*40AX:2UD1$XQ&I9GWL88G)SJ>QG-<2J5RAMYP"J,&<K?AOBDDA M_P)1Z-R
M5L8T<12[P]"$6!F:HB3';XA?9*FA@UQ?'\?D1JM^DK09B=O8.BD=#8%*Q,7:
MF B[83RA(L0)BF["+"%WD;Q&C6LTQB/A2X5YYP"J-&4KD3#$)9& 3ED M^EC
MI;T'4&E46_%7@D.2$J=3<;K?<9)FBSIS*%?:_3>:!N=GQ\='P$%#C?@I12+A
M:*<,==L465J.AK0<)&%/463XM2RHO^5+2BU':5*0>9.I3 SDP,T'.,V!G54=
M[0:M\$MDSMY_T>.PAQ;A#L$I\ [CUIPGQRB1@_8V/B\2T X9K:>HP"."[@"S
MT2[SC8,9UPB)'S,VUXB9*88H8[5%C>UML@&",^!W%6,&F!CCE"@/(*OM.EI>
M7790%E.B\?Q]M:2UPK#9,3@#]BQV*@1"= >0!E>$\B[/2VO&\TX!5&'>'3*]
MANP DM[6C)(-]G^#W@%4Z5]'(F *T5%^6T]DP6+;5_0*H$H)N^>]$)JC3+>P
M%MDMD-K]7M(C@"K>L2MNUV =0 +<+7B/99$784+M#C;,KG4+SL"M[6XYOHG-
M47+<+;;O^4J])%/^..8O3/N^0?.O+N=A<&F6] B6)<_W^FCUAI(2W1+YHR[;
M=!Z_XV)Z5>8%F6.V--_19"3D?Y'ZI;/!: %4-483;LC>M)JA/( ;]#) I,JD
M;E+O1]HG@"H^W9SU:BR@MV1!<-VP"LAX#N,PXQ;6KRA!8RS,DZ3N$%P /T^J
M2;_.+@,HH!=<%:_*^3SF\V4^%%NP-9S3=0\N@1\-FO+1"-@!7%6_$2G-PIAF
M>XEF.,&4. 5^0Q5.Q4:KZ1E I[2SX;P-I@.HRG*-R%R)BD\QD)]CQ%A#0,_H
ML^G?V>\5G#?I'D"'@#1AOS&P [C%/B%"CG)4E!FAT16YM$V4<1VBYM2C[JC?
MP66N!',8=5P,SG%IV^"TUSLYZY "ID?BJJ +H&O'$MS*M=6$J:O6P3FPD:G%
M!6@#A:.J*I#LO$O>R"Y$Z<"QJ:.V!:V#<^ 5:L].&0I7=59@]]R%0YE>==YH
M&4 70FO"R6T$K6NI7'(N)FA";:U@7%SL--3BQMW"OJ-BFD8KZ55MO$;]@PM@
MK:D)QTUQN:K6 KN:'](D73]]].M:VB>X +X-V?-;C<59I1;0$[@NT3R%3$G0
M+D/Y\Z]HG&:HE@WQYIV0C8#%29A]W!%:YM9.VSO\:G#1.0OWKJGAJL@,O)P2
M[-4"K S+6AG;ZA% UU]L*A]B)*U+RZSK&R_@-755R\!QZ,AN/DA3>1Y!5T/8
MQ2;4BAB'4#5GG43"Q#<FL<DVPW#Z=?".VP"BJXHXP"HS*HQL4VOM& V..W<!
M%F. K9PC>.?E<XP56]L095_#'(\&272-XY(Z.5$/+H6GA8MA.<6 '9K-N>X4
M\B&4T-$?F0MJZ#S?+4?B5 12,9R*05-=1$P.5Q5ZH$VH!NCK5&TK6/6Q."V!
M_ -]$2TA05S5\_%)N,2:&:,LS_7(LCXJE#?[@Q-F(IR+G7OZ R+2(10QLKF"
M-#NF+<;DE/7B&K=W86I_0Q23TE6U)?_WXQH=&AW[5J,R^D(7W^ZRJ J)Z:IJ
M%*RP+C**+4)5#8YY69?@O'./OTHHAU&W:1,B6S46W&7M@W/@%Q8EH\QXNP+B
MJGR37XRM-BD+UE8]@G-@>Y4#YM:A'$:E):'XLI@->ER1VW29&<6-68T3G'?.
MG\,>WR$47?H=X<F4"/R "&DX00_E[!5EC^.M(&7=;F\U3G ._ 1JSVNQS-BC
M/H3:2A+4=>76,.3?<J3@ MA*LV.Y4>+>64$FP!0!5<Y%N"1[#4M]&/0/+D_W
MOS*7,WNACA<F$%C#X!(\U[$I1<7K20#G *+[EZ@X'6CZ]C2A"V?PCE7N \I^
MP:4ON7-6O-(P50KC -+@;6"[3F<A5H66"ML'E[YDOY*R2J)S2]$<5L*[[X@>
M\ JV;K4-^CU@.ZN<-V)>2B <0 H 2945+5.5_0AU@*V<M@PV@ ,:^B_P[MHJ
M=Y%$!D51I(QM.2*A$;!5Q)3E3H ZR@$ :SU;GFSD$H18,(6)XK5L'%SZDK?.
M6-M:G_NN\M+ME87=*#/1[_F2PGA=!&3RX@ZTH^0#<Y3AE-H7L@)*U,S2FJXE
M_>SW?$E;;,3VK:D[2C4 S[QFWOG]GB]W+Q/V">;N*K= A,8X80KBMQ)'M+ &
M2$RR8),AB#,4YBQ#Y'/YFN,(A]E'M6D12>9SE?.[\:"T<LX%?-TI&_EHC[5U
ME@,O]#Z9@OLC(92(:5[NW\C91VCTC6C)=#$])L]H5&:\=$Z&<UK^G*5/&K*-
MS2#V:U>?9(F;3KITR.R<$JXR,("KM?P@KF-E]0(6CU,HHE0D)-1EK+,?C!P>
MOAB2C=75!@"=Y7'P3U*X*N=*5%2C$5+Z<@UN(2MZA,Z2*?@G+(J%\BU3Z\L-
M1R0D]>55<C<;3 UEZTP-_@J.:M4TE!SMD$&_WR6ENQW,0\B>H%H\+!<I'A55
M::S!SS"+;M-LC'!!O6T:;CR:40EINW2M;XVT=7X%+U+3*1>2@@YJ8UWC00EI
M#T!%-@;J++>#J]<_Y9',2O'\#.>2!/YF?0GP+MCL+?' YE\P9V1U0#;CY&9G
M KT+)A);0*[2'L#Z7_R?LLJ?^9)*O! 8^M=-->D)_5GBG&Q1SRA[PR/$*?6$
M1NF$FZJ9_"M=.';[:<(D7XK5FAP1^R&'JVP*X!KM$YJ7V6A*:;&UZ>HT#E5?
M0J;.V5/T>%IG%O!'!Y6 Y5MT0\[SSH14G;.*& !J';#O#^^[X&ER!.QZ".)I
M<B0/Q;:VT')OA9L$3-*:.)H< 7L?MG T.9*'6UH;286\ PR"N@KSZ6V<_LP!
MXZ"6<[ +?]KJ1CAU N#V@0HZDV&6OF'"D:\?/\A1<Y<LBZ,,1@5^XX_#>GCV
M@P5]Z/2<>I9(W8$:83V X"J">8P+C:O7JE'0AZXPWY178LYO(G,42N6#$QA$
M*N:3WN79*?"=S*V -(+?-FK+"RU^S<A!+13)",=HS7/R)75WWNSB<V3/!S9F
MNA7&W='H ,+3]E&LM'\,?'?8G02()<Z<*HYBWF#=7>NP'L>W."%'-RW]F>9%
ME4QOE);JNEZF0Q"J 9N\]RU+=I0Y@-*Y]CZ%$J>Z8^#7U7U+BHH.!Q")=UU-
MU+Y@DZ8GH1"POK/_\\F (*Z*^@**# L%H!9=0CK3*H/2/H0JP)?X?8N)AA1M
M8_>\N*\MHI.N$?]WC5C5D[19RGG#00BY@;VZG%_TK9"[BA<$3@"_@7DPXCH8
M69,(OVFR9YET#_H>),JV8JRI>,BP'DQYXPV\PPS-0QPM3MQJ R6*.]M<!WF.
M=/6.&PQ(2 J?!'LGXF..OG64GJ<"M3R4RXPRHH$$"4<@1(-/NKL3D5' ;1V?
MYZF,+#;98?A!=UB>?2<KR0QQ^(IC=KHW.J%4 Q*2PA=(WNF9I4=_"#%\0OP4
M;:U*=$4)6QD2CT)(!U\Y>5>"HX)\"(%[VZ 7B^+C-LVNXA#/J)FR^F%Y@:T.
M[B?"[NS-3HX:C$_(#5\V>2<2UI@8AQ#X)SGKEY1M>MI)1R&D [Z][U1)DD-V
M54$94EK,#1^BXHU.?+Y$ P>GO=[).;!;MENCD"."P)9[=I3&UXP.8@\9A<RU
M&I<7#P.^[KD5.3?T<!6[Z(,CFSE]G6QMG(; >CS4-K8$[RQ@$G#+DL"^2]Y0
M[LH?6C$8T5M\B5%RXP^MQ7H($8OD7KL([!S]6>(,?2USG* \1]S/DQ*F^HLJ
MY,1FF*!_ZJ?6I&6X6'SLL1]&S.,6;DX_]CL;4:EU"_IGP,]G.Q:-+:R'$0))
MR#5"*&).X\]AC+Z'!<W+^$%M&FD<HQ%3UQ['AA)B/QHA)O##F6/!:4J"PR@K
MO+5NF)F#$(6H<,7', Z3@E""AH7.:3N;W48]$B&BG]<K5QN0"?S6(9=>[DED
MM2P.YL%XC&-,YD:PDV9126F*M"^R#4<D1 5^7]OMWF1%AL,HGFQ.4#<F2<.!
M"8G]# !J*&DNJ.&JG+-OQD@!$9P8(XW'Y;:3@Y(W-_0XA +1YG1ULIEQVOD9
M:KWSO6L)WEF5:/^,D,OP)Q=&2,5@A".^Y,AR8X348MU9@6@@5?V>*I*$=F3>
MRM@@:9^@?^)G2+Z6E7IU6P!4PO].&:&?T+RZISZ.3?DO[4/(XJ=YN2'_-4 E
M_.^:+;DFY(O:0H_C9Y3@-+M/D\D+RF;7Z-5T0U -$?1/_;0Q.]@?]+@EXM*I
MRB;#Y7I8CZHV, -N=B%$\=-NW%08E#@ES#<W#GNQ5ZQMB)6 5SYT]]0I[O$U
MQA/MW==B%$(\/PUX+DX4$^@2N>FP07BU4=8*F%L?+K6^A%!^FD*<GBI;@"62
MT2EOY#K4[SA)Z3L;2\E091\U% M15T(D/XT:#J1"CE<B%)UR.EX<I+=IMDID
M;+Q;:#L30OD93MY2[] AEHB&N6W4BY/$G'9NGG\,!R8D/BC+APMJ2 2N4S95
M0R(X>?XQ'I=9K0_K)NV&'I+<@ITRR)K3U<EFQFEW4!?Q!N E@F-OR07>JNC_
MJ4?16Q@CEC!D44.,.<(FT?HO:BUY@8CM&+<J[?_-.]$JD@EZ(B?_S7B,E$]'
M^YU(T#_KZ+,3!)TD@FY?AQM8T*DSYCI!!F319]D'P<XJW"PIT>AH;CL\(79'
M S+<H9>(FK6YFU>/('BRPF>!:RM10?^\HS4-+.!)9,)--9@]5!3Y&N8X?QP/
MZPQ*H@?TLTIW0BOD9&E"?ASQ8B/[KC!2FT<:XY%A0G1I)Z(@'1]?7.Q_R3UF
MDS"I,OBNRKB0_Q!P8.$!>XWR48;GB[S16Z!>"+N_QFKST4Z_RZD)?# 8,%N\
MS/=#&D>%3@0^RGLI.$06?_B&LS(?AJ3G#(^NZ"6D?VF^#PBJL=Z\$_X02I +
M3/;!RC@I%K6R?7!V<7IY>6JSG@7S$<%\_-O=]0/A>8%00K6".,W+#*F67+.!
M. (@R[X9;=>73TN8NRK\LX_5L*$0)%$]!FWO>6^6GZ8>&57D3?'QC$8TNLOL
MH#0?A.UGEP"5N6I3O$NJ27X/LS\0J]6W-5VBMJ&L"''RDH54H>?Q(F8+>->?
MY#0$?MIMP'+Q\;ES*G7ZY+P-<<;N"=]12.&![!'+2:S(;+(KJ+HQ[O3Z^]\'
M1),R6<S*?AP-<)2F$;G%:] ,7(>/W.U,T>QZ6CRA-Y24:-\+:DE;@U6TU38X
M7Z9];ZJH:LAAK*?:CT,F#VR5EM!S2SEMBJW#JV1Q.[U*9Z]$CV<V2WZ^_H;B
MZ#;-:&CMHD[0MNFXC42V^_2*&>H+H.NO!.=GQQ?G9RU7HZM9:1:K\\]P]$ ^
M0[ODYM9>L#O2=5HYE>:RKI+$[EU1K2:2+V82QB9ZJJ)7<'X*H*.:Y BWNXHV
M')' !U9JM;P1*[2M\';X!.?.C2PC#_UA967B1>SWO1YOPBPA=W3Z*,\F8+ 8
M95V"\PN E;@Y&Y.U)NU#( "O)C5QQ4M) Z?#BX7Y -\E(S(B?D,T\1#=9MAO
MAY6[,/OEOE?-:F-BWLK+ZHM/**8.QBQXBK'BE=9G7+@Y&ZRM=@,3?EO=._=,
MC*_U.9NLTY8C$W( WV1=L%.\YIV0IL,[0RU&8!4Z,,S221;.]KX=M#06V3VV
M"%\U!<10KC!])S(MX/<+":4$;Y0&0#HNZI@_OS"UD;DAH(0Z(>Q;T!53,3+P
M-!HGN.CU]G^J&4W1Y!"S&XB !?9H;\ ;\1'5!'B'EZFU@]W"D^@@'.T _ 5T
MI/W@_S19H[9#<<S0]:'U+!$OS,9H.[PZE1X]+\R ]0_@UW/2 UBG=%ZUZ;R%
M.*;TKFSRC/9&ET&+83A6\")PUJR1W/6:(._TLX70IP9FE>[,LP9@)3Z/IB@J
M8_0X7DZ/OY$1V:R9W2NB1X_)$Y6ZC)P23+DQ7JI.O\.HU0<.,#%BIWCU[H88
MNSJ*FYH@JA#5,+Y+"%5*MF 7D%;Q-(,9U3JT<M1J/$XBX$M4 WEQ UJ2#;8;
MV[[&H0?F &AIW#L&L%VLMIP%11_2 N7W*7\_68:3K^ALMZM;CTK( +P@)9S1
M;=D-D8+NSLY>=<+))$,\I=OCN+X&#=]N]/T)M8#?6ZWDP@*3HWT84@(6JX"F
MCDW9&VRVP(WS/[Y^T'_>$HJEF<WN83$:H21P!L5&NX8U0DFVH2Z85=JYW=D>
MZ(?CE7I\>=KO0V@&BT!Y1GK5<EUK2)TA+X^!W@-W27_)2A:#=W2JQT#;^0+4
M51SF9(]B#Z:#=ZQ**"+MPVD";&"3L$G#4RD41T<V$'OKL*[368@3U9OD5F-.
M!>#LDGH>25X:Y7 <G:U 3"4[USS-P_A;EI9SAA*/\8BS1;UR-3TY?7Q)]&.R
M?DT!2?*T=$GQ5D#5KFQM7T:H$V!SJBDSK45A Z-8&,PSD+NVDCZ%$4[C=/(Q
M#+,B(:/>):/O:/:*,K'>*6]/()[T>L#[M3DCMDR=!LC$S-M3DG !\Q[2K)@.
M9B@C$)/5M =$,2VF*,>ABI.&G3G!@&TB+=AJ"U/,XT[E_%Z>8N0VC5A:%1.%
M>MF8[W6^Y(&TTJ2W,8C9:5W#$.J&M#3[KJV 7),SD/PYG:$E5;Z&,2U[\#Q%
MB+[Y#Z((<WI8IC, F V_%@-;ZA7BI;/6[Y]08H&WSA/N:7 HS(/;+D)$09TM
M3$(=&_A6V ]+" 'LTZ_EDNF#G"WH+KLNJB-&81:IV[A1T.7Y.\*3:8&B =F%
MPPEZ**F&^CBN4==N75J,1Z #+T@U4W2KT1IJAY>AM7__2H6X2\9I-N,7*%2$
M.#X$E_\SJ]RZHJ<[6X+*WJP:C\5PG)_ KD #,F]=LUO"]>HA*\^*FB"3_]H4
M8O*KVI;#?:B_HV*:UESXMW^+T$,X0Q(K>=LA.24!WT/;\7]=GIP1PZL'-".Q
MDL&2FMGUG3@U@%Y&G;%R6T(,44.]MPG.EQ])0N9'M.9LGI([/_KO*4Z*OQ$*
MT*#Y!*FLM49=.68@$[P%2[9.#SMTCA[4@&QZ53X$:HK^>,G")"?G*K7^?/VH
M_T7SF&H^"#55'?>!O-9<'PPMX#MZ>/- :+0OKMN-.16 U<H&3--S?P.?HQ<Z
M*(\9T?XG/14,>G&Z %_H%>R2.,\8 '+T3.?B5!?L<*J'-TT/OO,!O;ZYWJ]-
ML7;[E4ZLU3[^I"_-4SP?HHRZ7H<3E7>K\1B<9D!^4J;\%*]K>XR.'K-@;.2R
M\C5.K'"[KFQSUH-(M-_4&9S-%TB],:.DQG%A'897UC!@MVY&$V -1L(F#4^E
M4+RR2NW=K9M1P1<_?2F/))JI'(Y'9B;!=B1>?=*V#%7?%]][U:K30X"R%ADQ
M1KJ %*TY,K@;@H;>!OS9P %EFA'FK20J&BTEE]!:<BJ#K*@E1P2GFVLIO<4;
M)0I0=^?F3R@ON*!O#7=)A FX,HP53V["MHP 1[XX':IV/ST$*#N)0_;]CHLI
MLR%18R&Y)[ZD-TF!%7;0!J-P>@%YN>NY:,!U0WQ>65K,7D3?T:BDR=8?QV,\
M0IET4Y8WYNB!WD#:<$OPZ*D&N"N#R:Z=*1:;W?,(D;,+IRHO"5%;3@#@!P[C
M+5L-07+[[WF\1A<X?B3Y'(WP&*-(N3M+VW,B %WW]:P1L%*+1,+.W5MS1#G1
MT@R-PKR@^0G0*$VB01*]3'$6_5L99G31/XYI%Y7>:S4$)P*HZXF./5LJ<3.
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MT%XEWG<<4\(PPB55:WPFB%%XE>U^!Q$F#"=@A/,VQ25<V9@O5'YZ6P7[7IW
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M\K48E_$V= /NVXQ#J =\^MH*@SVZMO;]2RX;"9K0XHE0TB':3IML!:MNA#K
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M_US.YS%'R:SI6Y1U)6^&G^,D!KJA>"B$MF3[AXNK^T;69A;23'F#:(833%E
M$VI7E'$4/J+^"*<^T)O(;H5VA\2"#JP#\.DGP$:8"P:ASHQ<>_'?=0]U;C[
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M-#,R-V1E>#$P-"YH=&U02P$"% ,4    "  J.&91@=Z#-G%?  "VL $ $
M            @ %!D $ 9#0T,S(W9&5X,3 U+FAT;5!+ 0(4 Q0    ( "HX
M9E'8%O;L] <  )(M   0              "  >#O 0!D-#0S,C=D97@S,3$N
M:'1M4$L! A0#%     @ *CAF48;Q:QGO!P  FRT  !               ( !
M O@! &0T-#,R-V1E>#,Q,BYH=&U02P$"% ,4    "  J.&915WE'Z3P$  !8
M$   $               @ $?  ( 9#0T,S(W9&5X,S(Q+FAT;5!+ 0(4 Q0
M   ( "HX9E%GF08/-!    ZD   /              "  8D$ @!M9"TR,#(P
M,#DS,"YX<V102P$"% ,4    "  J.&91QT\K@8,0  !/ @$ $P
M    @ 'J% ( ;60M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( "HX9E&I
MO)?#R2<  -A* @ 3              "  9XE @!M9"TR,#(P,#DS,%]D968N
M>&UL4$L! A0#%     @ *CAF4:()\@,O70  $U0% !,              ( !
MF$T" &UD+3(P,C P.3,P7VQA8BYX;6Q02P$"% ,4    "  J.&91!)*]_+A
M  "O_P, $P              @ 'XJ@( ;60M,C R,# Y,S!?<')E+GAM;%!+
4!08     "P + +,"  #AZP(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
